EP2785828B1 - Human-derived bacteria that induce proliferation or accumulation of regulatory t cells - Google Patents

Human-derived bacteria that induce proliferation or accumulation of regulatory t cells Download PDF

Info

Publication number
EP2785828B1
EP2785828B1 EP12854485.5A EP12854485A EP2785828B1 EP 2785828 B1 EP2785828 B1 EP 2785828B1 EP 12854485 A EP12854485 A EP 12854485A EP 2785828 B1 EP2785828 B1 EP 2785828B1
Authority
EP
European Patent Office
Prior art keywords
clostridium
cells
mice
bacteria
regulatory
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP12854485.5A
Other languages
German (de)
French (fr)
Other versions
EP2785828A4 (en
EP2785828A1 (en
Inventor
Kenya Honda
Koji Atarashi
Takeshi Tanoue
Masahira Hattori
Hidetoshi Morita
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
School Corp Azabu Veterinary Medicine Educational Institution
University of Tokyo NUC
School Corp Azabu Veterinary Medicine Educational Inst
Original Assignee
School Corp Azabu Veterinary Medicine Educational Institution
University of Tokyo NUC
School Corp Azabu Veterinary Medicine Educational Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48535050&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP2785828(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by School Corp Azabu Veterinary Medicine Educational Institution, University of Tokyo NUC, School Corp Azabu Veterinary Medicine Educational Inst filed Critical School Corp Azabu Veterinary Medicine Educational Institution
Priority to EP21198256.6A priority Critical patent/EP3978598B1/en
Priority to EP19178787.8A priority patent/EP3569690B1/en
Publication of EP2785828A1 publication Critical patent/EP2785828A1/en
Publication of EP2785828A4 publication Critical patent/EP2785828A4/en
Application granted granted Critical
Publication of EP2785828B1 publication Critical patent/EP2785828B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/145—Clostridium
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the subject matter described herein relates to a composition which induces proliferation and/or accumulation of regulatory T cells.
  • NPL Non-Patent Literature 1 to 7).
  • NPL Document 3 Abnormality in the regulation of crosstalk between commensal bacteria and the immune system (intestinal dysbiosis) may lead to overly robust immune response to environmental antigens and inflammatory bowel disease (IBD) may result (NPL 8 to 10) .
  • Treg cells regulatory T cells
  • NPL 15 specific species of murine bacterial commensals that can strongly stimulate Tregs
  • NPL 16 the human intestinal tract harbors more than a thousand bacterial species, many of which have not yet been cultured
  • CD4 + T cells are regulatory T cells that have been identified as a cell subset that suppresses immunity.
  • a transcription factor, Foxp3 is expressed in CD4 + T cells, which are known to play an important role in maintaining immunological homeostasis (NPL 8, 9, 17, and 18).
  • Foxp3-expressing cells are present in large numbers in the colon and only Treg cells present locally in the colon constantly express IL-10, an immunosuppressive cytokine, at a high level (NPL 19). Animals having CD4 + Foxp3 + cells from which IL-10 is specifically removed develop inflammatory bowel disease (NPL 20).
  • ATARASHI ET AL "Induction of Colonic Regulatory T Cells by Extra Clostridium Species", SCIENCE, (20110121), vol. 331, no. 6015, doi:10.1126/science.1198469, ISSN 0036-8075, pages 337 - 341 and ATARASHI ET AL, "Induction of Colonic Regulatory T Cells by Extra Clostridium Species - Supporting Online Material", SCIENCE, (20101223), vol. 331, no. 6015, oi:10.1126/science.1198469, ISSN 0036-8075, pages 337 - 341 , describe the induction of regulatory Foxp3+ T-cells by clostridia, in particular of clusters IV and XIVa.
  • ATARASHI and HONDA "Microbiota in autoimmunity and tolerance", CURRENT OPINION IN IMMUNOLOGY, vol. 23, no. 6, doi:10.1016/J.COI.2011.11.002, ISSN 0952-7915, (20111122), pages 761 - 768, (20111116 ), review the role of microbiota in autoimmunity and tolerance and reference the effects shown in ATARASHI ET AL (above).
  • EP1955706 discloses a synergistic composition containing an interferon and a natural bile pigment, useful for treating autoimmune diseases, allergy and cancer, by inducing regulatory T cells.
  • ITOH and MITSUOKA "Characterization of clostridia isolated from faeces of limited flora mice and their effect on caecal size when associated with germ-free mice.”
  • LABORATORY ANIMALS APR 1985 vol. 19, no. 2, April 1985 (1985-04) pages 111-118 discloses the characterization of 115 strains of clostridia accumulated from 3 separate isolations from the faeces of 1 limited flora (LF) mouse produced by inoculation of germ-free mice with chloroform-treated faeces of conventional mice, and the effect on caecal size when associated with germ-free mice was studied.
  • LF limited flora
  • the present invention provides compositions which induce proliferation and/or accumulation of regulatory T cells as defined in the claims appended hereto.
  • Other aspects of the invention are defined in the claims appended hereto.
  • the present compositions and methods have been made in view of the above-described problems in the art. Described herein are methods of identifying and culturing intestinal commensal bacteria, isolated from humans, which induce, preferably strongly induce, the proliferation, accumulation, or proliferation and accumulation of regulatory T cells.
  • compositions also referred to as bacterial compositions, that (1) comprise (a) one or more of the identified intestinal commensal (human-derived) bacteria; (b) a culture supernatant of one or more of the bacteria; (c) one or more physiologically active substance derived from one or more of the bacteria or from one or more of the culture supernatant; (d) or a combination of any two or three of (a)-(c) and (2) induce the proliferation and/or accumulation of regulatory T cells (Treg cells).
  • Treg cells regulatory T cells
  • composition which comprises (a) one or more of the identified intestinal commensal (human-derived) bacteria; (b) a culture supernatant of one or more of the bacteria; or (c) one or more physiologically active substance derived from the bacteria or from the culture supernatant, wherein the composition induces proliferation and/or accumulation of regulatory T cells.
  • the composition comprises one or more of the identified intestinal commensal (human-derived) bacteria.
  • the composition comprises a culture supernatant of one or more of the bacteria.
  • the composition comprises one or more physiologically active substance derived from the bacteria or from the culture supernatant.
  • the one or more bacteria or one or more physiologically active substance derived from the bacteria is three or more.
  • the one or more bacteria or one or more physiologically active substance derived from the bacteria is five or more. In some cases, the one or more bacteria or one or more physiologically active substance derived from the bacteria is seventeen or more. In some cases, the one or more bacteria or one or more physiologically active substance derived from the bacteria is twenty-three or more. In some cases, the one or more bacteria or one or more physiologically active substance derived from the bacteria is 23. In specific cases, the bacterial compositions induce, and preferably strongly induce, proliferation, accumulation, or proliferation and accumulation of regulatory T cells that produce an immunosuppressive cytokine, such as IL-10, in the colon (e.g., the human colon) at high levels.
  • an immunosuppressive cytokine such as IL-10
  • Bacterial compositions comprise, as an active component, at least one organism and/or at least one substance selected from the group consisting of: Clostridium saccharogumia, Clostridium ramosum JCM1298, Clostridium ramosum, Flavonifractor plautii, Pseudoflavonifractor capillosus ATCC 29799, Clostridium hathewayi, Clostridium saccharolyticum WM1, Bacteroides sp.
  • MANG Clostridium saccharolyticum, Clostridium scindens, Lachnospiraceae bacterium 5_1_57FAA, Lachnospiraceae bacterium 6_1_63FAA, Clostridium sp. 14616, Clostridium bolteae ATCC BAA-613, cf. Clostridium sp.
  • MLG055 Erysipelotrichaceae bacterium 2_2_44A, Clostridium indolis, Anaerostipes caccae, Clostridium bolteae, Lachnospiraceae bacterium DJF_VP30, Lachnospiraceae bacterium 3_1_57FAA_CT1, Anaerotruncus colihominis, Anaerotruncus colihominis DSM 17241, Ruminococcus sp.
  • bacterial compositions comprise, as an active component, at least one organism or at least one substance selected from the group consisting of: Clostridium saccharogumia, Clostridium ramosum JCM1298, Clostridium ramosum, Flavonifractor plautii, Pseudoflavonifractor capillosus ATCC 29799, Clostridium hathewayi, Clostridium saccharolyticum WM1, Bacteroides sp.
  • MANG Clostridium saccharolyticum, Clostridium scindens, Lachnospiraceae bacterium 5_1_57FAA, Lachnospiraceae bacterium 6_1_63FAA, Clostridium sp. 14616, Clostridium bolteae ATCC BAA-613, cf. Clostridium sp.
  • MLG055 Erysipelotrichaceae bacterium 2_2_44A, Clostridium indolis, Anaerostipes caccae, Clostridium bolteae, Lachnospiraceae bacterium DJF_VP30, Lachnospiraceae bacterium 3_1_57FAA_CT1, Anaerotruncus colihominis, Anaerotruncus colihominis DSM 17241, Ruminococcus sp.
  • a bacterial composition comprises at least one organism selected from the group consisting of: Clostridium saccharogumia, Clostridium ramosum JCM1298, Clostridium ramosum, Flavonifractor plautii, Pseudoflavonifractor capillosus ATCC 29799, Clostridium hathewayi, Clostridium saccharolyticum WM1, Bacteroides sp. MANG, Clostridium saccharolyticum, Clostridium scindens, Lachnospiraceae bacterium 5_1_57FAA, Lachnospiraceae bacterium 6_1_63FAA, Clostridium sp.
  • Clostridium bolteae ATCC BAA-613 Clostridium bolteae ATCC BAA-613, cf. Clostridium sp. MLG055, Erysipelotrichaceae bacterium 2_2_44A, Clostridium indolis, Anaerostipes caccae, Clostridium bolteae, Lachnospiraceae bacterium DJF_VP30, Lachnospiraceae bacterium 3_1_57FAA_CT1, Anaerotruncus colihominis, Anaerotruncus colihominis DSM 17241, Ruminococcus sp.
  • a bacterial composition comprises a culture supernatant of at least one (a, one or more) of the bacteria described/listed herein. In some cases, a bacterial composition comprises a physiologically active substance derived from (a, one or more) bacteria described/listed herein. In some cases, the one or more bacteria or one or more physiologically active substance derived from the bacteria is three or more. In some cases, the one or more bacteria or one or more physiologically active substance derived from the bacteria is five or more. In some cases, the one or more bacteria or one or more physiologically active substance derived from the bacteria is 17 or more.
  • Bacterial compositions can comprise any bacteria (Clostridia or other bacteria) that contain DNA comprising a nucleotide sequence having sufficient homology with sequences provided herein and that exhibit substantially the same effect on regulatory T cells as that exerted by any one of the following: Clostridium saccharogumia, Clostridium ramosum JCM1298, Clostridium ramosum, Flavonifractor plautii, Pseudoflavonifractor capillosus ATCC 29799, Clostridium hathewayi, Clostridium saccharolyticum WM1, Bacteroides sp.
  • MANG Clostridium saccharolyticum, Clostridium scindens, Lachnospiraceae bacterium 5_1_57FAA, Lachnospiraceae bacterium 6_1_63FAA, Clostridium sp. 14616, Clostridium bolteae ATCC BAA-613, cf. Clostridium sp.
  • MLG055 Erysipelotrichaceae bacterium 2_2_44A, Clostridium indolis, Anaerostipes caccae, Clostridium bolteae, Lachnospiraceae bacterium DJF_VP30, Lachnospiraceae bacterium 3_1_57FAA_CT1, Anaerotruncus colihominis, Anaerotruncus colihominis DSM 17241, Ruminococcus sp.
  • bacteria present in bacterial compositions have at least 90% (90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) homology with sequences provided herein, such as, but not limited to, the nucleotide sequences designated OTU herein and listed, for example, at the pages following the last Example.
  • such bacteria contain DNA comprising a nucleotide sequence that has at least 90% (90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) homology with one or more DNA sequence designated herein as follows: OTU136; OTU46; OTU221; OTU9; OTU296; OTU21; OTU166; OTU73; OTU174; OTU14; OTU55; OTU337; OTU314; OTU195; OTU306; OTU87; OTU86; OTU152; OTU253; OTU259; OTU281; OTU288; OTU334; OTU359; OTU362; or OTU367.
  • bacteria contain DNA comprising a nucleotide sequence that has at least 90% (90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) homology with DNA of one or more of the following: Clostridium saccharogumia, Clostridium ramosum JCM1298, Clostridium ramosum, Flavonifractor plautii, Pseudoflavonifractor capillosus ATCC 29799, Clostridium hathewayi, Clostridium saccharolyticum WM1, Bacteroides sp.
  • MANG Clostridium saccharolyticum, Clostridium scindens, Lachnospiraceae bacterium 5_1_57FAA, Lachnospiraceae bacterium 6_1_63FAA, Clostridium sp. 14616, Clostridium bolteae ATCC BAA-613, cf. Clostridium sp.
  • MLG055 Erysipelotrichaceae bacterium 2_2_44A, Clostridium indolis, Anaerostipes caccae, Clostridium bolteae, Lachnospiraceae bacterium DJF_VP30, Lachnospiraceae bacterium 3_1_57FAA_CT1, Anaerotruncus colihominis, Anaerotruncus colihominis DSM 17241, Ruminococcus sp.
  • bacterial compositions comprise bacteria (such as human-derived bacteria) that contain DNA comprising a nucleotide sequence having at least 97%, 98% or 99% homology with sequences provided herein, such as, but not limited to, the nucleotide sequences designated OTU herein and listed, for example, at the pages following the last Example.
  • the bacteria in bacterial compositions contain DNA comprising a nucleotide sequence that has at least 97%, 98% or 99% homology with one or more DNA sequence designated herein as follows: OTU136; OTU46; OTU221; OTU9; OTU296; OTU21; OTU166; OTU73; OTU174; OTU14; OTU55; OTU337; OTU314; OTU195; OTU306; OTU87; OTU86; OTU152; OTU253; OTU259; OTU281; OTU288; OTU334; OTU359; OTU362; or OTU367.
  • the bacteria contain DNA comprising a nucleotide sequence that has at least 97%, 98% or 99% homology with DNA of one or more of the following: Clostridium saccharogumia, Clostridium ramosum JCM1298, Clostridium ramosum, Flavonifractor plautii, Pseudoflavonifractor capillosus ATCC 29799, Clostridium hathewayi, Clostridium saccharolyticum WM1, Bacteroides sp.
  • MANG Clostridium saccharolyticum, Clostridium scindens, Lachnospiraceae bacterium 5_1_57FAA, Lachnospiraceae bacterium 6_1_63FAA, Clostridium sp. 14616, Clostridium bolteae ATCC BAA-613, cf. Clostridium sp.
  • MLG055 Erysipelotrichaceae bacterium 2_2_44A, Clostridium indolis, Anaerostipes caccae, Clostridium bolteae, Lachnospiraceae bacterium DJF_VP30, Lachnospiraceae bacterium 3_1_57FAA_CT1, Anaerotruncus colihominis, Anaerotruncus colihominis DSM 17241, Ruminococcus sp.
  • compositions that comprise, as an active component, (a) one or more of certain species of bacteria that belong to the Clostridia class or bacteria that contain DNA comprising a nucleotide sequence having at least 90% homology with sequences provided herein, in spore form or in vegetative form; (b) a culture supernatant of one or more such bacteria; (c) one or more physiologically active substance derived from (a) or (b); or (d) a combination of any two or three of (a), (b) and (c) and induce the proliferation and/or accumulation of regulatory T cells (Treg cells) suppress immune functions.
  • Treg cells regulatory T cells
  • compositions that induces proliferation, accumulation or both proliferation and accumulation of regulatory T cells
  • the composition comprising, as an active component, at least one organism and/or at least one substance selected from the group consisting of: Clostridium saccharogumia, Clostridium ramosum JCM1298, Clostridium ramosum, Flavonifractor plautii, Pseudoflavonifractor capillosus ATCC 29799, Clostridium hathewayi, Clostridium saccharolyticum WM1, Bacteroides sp.
  • MANG Clostridium saccharolyticum, Clostridium scindens, Lachnospiraceae bacterium 5_1_57FAA, Lachnospiraceae bacterium 6_1_63FAA, Clostridium sp. 14616, Clostridium bolteae ATCC BAA-613, cf. Clostridium sp.
  • MLG055 Erysipelotrichaceae bacterium 2_2_44A, Clostridium indolis, Anaerostipes caccae, Clostridium bolteae, Lachnospiraceae bacterium DJF_VP30, Lachnospiraceae bacterium 3_1_57FAA_CT1, Anaerotruncus colihominis, Anaerotruncus colihominis DSM 17241, Ruminococcus sp.
  • the active component is one or more of Clostridium saccharogumia, Clostridium ramosum JCM1298, Clostridium ramosum, Flavonifractor plautii, Pseudoflavonifractor capillosus ATCC 29799, Clostridium hathewayi, Clostridium saccharolyticum WM1, Bacteroides sp. MANG, Clostridium saccharolyticum, Clostridium scindens, Lachnospiraceae bacterium 5_1_57FAA, Lachnospiraceae bacterium 6_1_63FAA, Clostridium sp.
  • Clostridium bolteae ATCC BAA-613 Clostridium bolteae ATCC BAA-613, cf. Clostridium sp. MLG055, Erysipelotrichaceae bacterium 2_2_44A, Clostridium indolis, Anaerostipes caccae, Clostridium bolteae, Lachnospiraceae bacterium DJF_VP30, Lachnospiraceae bacterium 3_1_57FAA_CT1, Anaerotruncus colihominis, Anaerotruncus colihominis DSM 17241, Ruminococcus sp.
  • the active component is a culture supernatant of one or more of the bacteria described/listed herein. In some cases, the active component is one or more physiologically active substances derived from a bacterium described/listed herein. In some cases, the one or more bacteria or one or more physiologically active substance derived from the bacteria is three or more. In some cases, the one or more bacteria or one or more physiologically active substance derived from the bacteria is five or more. In some cases, the one or more bacteria or one or more physiologically active substance derived from the bacteria is 17 or more. In some cases, the one or more bacteria or one or more physiologically active substance derived from the bacteria is 23 or more. In some cases, the one or more bacteria or one or more physiologically active substance derived from the bacteria is 23.
  • a bacterial composition as described herein comprises at least one of the following: one bacteria as described herein; at least one culture supernatant obtained from culture in which one (or more) of the bacteria was present (grown or maintained) or a fraction of such a supernatant; one or more physiologically active substance derived from one or more bacteria (such as from the bacteria named herein) or a combination of any two or three of the foregoing.
  • the term composition/bacterial composition refers to all such combinations.
  • the bacteria in the composition can be, for example, Clostridium saccharogumia, Clostridium ramosum JCM1298, Clostridium ramosum, Flavonifractor plautii, Pseudoflavonifractor capillosus ATCC 29799, Clostridium hathewayi, Clostridium saccharolyticum WM1, Bacteroides sp. MANG, Clostridium saccharolyticum, Clostridium scindens, Lachnospiraceae bacterium 5_1_57FAA, Lachnospiraceae bacterium 6_1_63FAA, Clostridium sp.
  • Clostridium bolteae ATCC BAA-613 Clostridium bolteae ATCC BAA-613, cf. Clostridium sp. MLG055, Erysipelotrichaceae bacterium 2_2_44A, Clostridium indolis, Anaerostipes caccae, Clostridium bolteae, Lachnospiraceae bacterium DJF_VP30, Lachnospiraceae bacterium 3_1_57FAA_CT1, Anaerotruncus colihominis, Anaerotruncus colihominis DSM 17241, Ruminococcus sp.
  • 90% homology e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% homology
  • the bacteria contain DNA comprising a nucleotide sequence that has at least 97% , at least 98% or at least 99% homology with one or more DNA sequence designated herein as follows: OTU136; OTU46; OTU221; OTU9; OTU296; OTU21; OTU166; OTU73; OTU174; OTU14; OTU55; OTU337; OTU314; OTU195; OTU306; OTU87; OTU86; OTU152; OTU253; OTU259; OTU281; OTU288; OTU334; OTU359; OTU362; or OTU367.
  • the bacteria contain DNA comprising a nucleotide sequence that has at least 97% (97%, 98%, 99%, 100%) homology with DNA of one or more of the following: Clostridium saccharogumia, Clostridium ramosum JCM1298, Clostridium ramosum, Flavonifractor plautii, Pseudoflavonifractor capillosus ATCC 29799, Clostridium hathewayi, Clostridium saccharolyticum WM1, Bacteroides sp.
  • MANG Clostridium saccharolyticum, Clostridium scindens, Lachnospiraceae bacterium 5_1_57FAA, Lachnospiraceae bacterium 6_1_63FAA, Clostridium sp. 14616, Clostridium bolteae ATCC BAA-613, cf. Clostridium sp.
  • MLG055 Erysipelotrichaceae bacterium 2_2_44A, Clostridium indolis, Anaerostipes caccae, Clostridium bolteae, Lachnospiraceae bacterium DJF_VP30, Lachnospiraceae bacterium 3_1_57FAA_CT1, Anaerotruncus colihominis, Anaerotruncus colihominis DSM 17241, Ruminococcus sp.
  • the composition induces regulatory T cells that are transcription factor Foxp3-positive regulatory T cells or IL-10-producing regulatory T cells. In another case, the composition has an immunosuppressive effect.
  • a pharmaceutical composition that induces proliferation, accumulation or both proliferation and/or accumulation of regulatory T cells and suppresses immune function.
  • the pharmaceutical composition comprises a bacterial composition described herein and a pharmaceutically acceptable component, such as a carrier, a solvent or a diluent.
  • a pharmaceutical composition comprises (a) (1) one or more species of bacteria belonging to the Clostridia class, as described herein, in spore form or in vegetative form, (2) a culture supernatant of such bacteria, (3) a physiologically active substance derived therefrom or (4) a combination of any two or three of (1), (2) and (3) and (b) a pharmaceutically acceptable component, such as carrier, a solvent or a diluent.
  • (a) above is at least one organism or substance selected from the group consisting of: Clostridium saccharogumia, Clostridium ramosum JCM1298, Clostridium ramosum, Flavonifractor plautii, Pseudoflavonifractor capillosus ATCC 29799, Clostridium hathewayi, Clostridium saccharolyticum WM1, Bacteroides sp. MANG, Clostridium saccharolyticum, Clostridium scindens, Lachnospiraceae bacterium 5_1_57FAA, Lachnospiraceae bacterium 6_1_63FAA, Clostridium sp.
  • Clostridium bolteae ATCC BAA-613 Clostridium bolteae ATCC BAA-613, cf. Clostridium sp. MLG055, Erysipelotrichaceae bacterium 2_2_44A, Clostridium indolis, Anaerostipes caccae, Clostridium bolteae, Lachnospiraceae bacterium DJF_VP30, Lachnospiraceae bacterium 3_1_57FAA_CT1, Anaerotruncus colihominis, Anaerotruncus colihominis DSM 17241, Ruminococcus sp.
  • (a) above is at least one organism selected from the group consisting of: Clostridium saccharogumia, Clostridium ramosum JCM1298, Clostridium ramosum, Flavonifractor plautii, Pseudoflavonifractor capillosus ATCC 29799, Clostridium hathewayi, Clostridium saccharolyticum WM1, Bacteroides sp. MANG, Clostridium saccharolyticum, Clostridium scindens, Lachnospiraceae bacterium 5_1_57FAA, Lachnospiraceae bacterium 6_1_63FAA, Clostridium sp.
  • Clostridium bolteae ATCC BAA-613 Clostridium bolteae ATCC BAA-613, cf. Clostridium sp. MLG055, Erysipelotrichaceae bacterium 2_2_44A, Clostridium indolis, Anaerostipes caccae, Clostridium bolteae, Lachnospiraceae bacterium DJF_VP30, Lachnospiraceae bacterium 3_1_57FAA_CT1, Anaerotruncus colihominis, Anaerotruncus colihominis DSM 17241, Ruminococcus sp.
  • (1) above is a culture supernatant of one or more of the bacteria. In some cases, (1) above is a physiologically active substance derived from one or more of the bacteria. In some cases, the at least one organism or substances is three or more. In some cases, the at least one organism or substances is five or more. In some cases, the at least one organism or substances is 17 or more. In some cases, the at least one organism or substances is 23 or more. In some cases, the at least one organism or substances is 23.
  • bacteria such as human-derived bacteria
  • DNA comprising at least 90% homology (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% homology) with sequences provided herein, such as, but not limited to, the nucleotide sequences designated OTU herein and listed, for example, at the pages following the last Example.
  • the bacteria contain DNA comprising a nucleotide sequence that has at least 97% , at least 98% or at least 99% homology with one or more DNA sequence designated herein as follows: OTU136; OTU46; OTU221; OTU9; OTU296; OTU21; OTU166; OTU73; OTU174; OTU14; OTU55; OTU337; OTU314; OTU195; OTU306; OTU87; OTU86; OTU152; OTU253; OTU259; OTU281; OTU288; OTU334; OTU359; OTU362; or OTU367.
  • the bacteria in the pharmaceutical composition contain DNA comprising a nucleotide sequence that has at least 97% (97%, 98%, 99%, 100%) homology with DNA of one or more of the following: Clostridium saccharogumia, Clostridium ramosum JCM1298, Clostridium ramosum, Flavonifractor plautii, Pseudoflavonifractor capillosus ATCC 29799, Clostridium hathewayi, Clostridium saccharolyticum WM1, Bacteroides sp.
  • MANG Clostridium saccharolyticum, Clostridium scindens, Lachnospiraceae bacterium 5_1_57FAA, Lachnospiraceae bacterium 6_1_63FAA, Clostridium sp. 14616, Clostridium bolteae ATCC BAA-613, cf. Clostridium sp.
  • MLG055 Erysipelotrichaceae bacterium 2_2_44A, Clostridium indolis, Anaerostipes caccae, Clostridium bolteae, Lachnospiraceae bacterium DJF_VP30, Lachnospiraceae bacterium 3_1_57FAA_CT1, Anaerotruncus colihominis, Anaerotruncus colihominis DSM 17241, Ruminococcus sp.
  • the pharmaceutical composition described herein induces the proliferation and/or accumulation of regulatory T cells (Treg cells) and suppresses immune function.
  • Also described is a method of inducing proliferation, accumulation or both proliferation and accumulation of regulatory T cells in an individual e.g., an individual in need thereof, such as an individual in need of induction of proliferation and/or accumulation of regulatory T cells.
  • the method comprises administering to the individual a bacterial composition described herein or a pharmaceutical composition comprising a bacterial composition described herein.
  • Clostridium bolteae ATCC BAA-613 Clostridium bolteae ATCC BAA-613, cf. Clostridium sp. MLG055, Erysipelotrichaceae bacterium 2_2_44A, Clostridium indolis, Anaerostipes caccae, Clostridium bolteae, Lachnospiraceae bacterium DJF_VP30, Lachnospiraceae bacterium 3_1_57FAA_CT1, Anaerotruncus colihominis, Anaerotruncus colihominis DSM 17241, Ruminococcus sp.
  • compositions described may be administered to an individual in need of treatment, reduction in the severity of or prevention of a disease or condition such as an autoimmune disease, an inflammatory disease, an allergic disease, and an infectious disease.
  • administration of the bacterial composition may be in combination with, or preceded by, a course of one or more antibiotics.
  • administration of the bacterial composition may be in combination with administration of at least one prebiotic substance that preferentially favors the growth of the species in the bacterial composition over the growth of other human commensal bacterial species.
  • the prebiotic substance(s) is, for example, a nondigestible oligosaccharide.
  • the one or more prebiotic substance(s) is selected from the group consisting of almond skin, inulin, oligofructose, raffinose, lactulose, pectin, hemicellulose, amylopectin, acetyl-Co A, biotin, beet molasses, yeast extracts, and resistant starch.
  • a composition that comprises the bacterial composition and at least one prebiotic substance.
  • the bacterial composition may be administered in combination with a substance selected from the group consisting of corticosteroids, mesalazine, mesalamine, sulfasalazine, sulfasalazine derivatives, immunosuppressive drugs, cyclosporin A, mercaptopurine, azathiopurine, prednisone, methotrexate, antihistamines, glucocorticoids, epinephrine, theophylline, cromolyn sodium, anti-leukotrienes, anti-cholinergic drugs for rhinitis, anti-cholinergic decongestants, mast-cell stabilizers, monoclonal anti-IgE antibodies, vaccines, anti-TNF inhibitors such as infliximab, adalimumab, certolizumab pegol, golimumab, or etanercept, and combinations thereof.
  • compositions that comprises the bacterial composition and at least one substance selected from the group consisting of corticosteroids, mesalazine, mesalamine, sulfasalazine, sulfasalazine derivatives, immunosuppressive drugs, cyclosporin A, mercaptopurine, azathiopurine, prednisone, methotrexate, antihistamines, glucocorticoids, epinephrine, theophylline, cromolyn sodium, anti-leukotrienes, anti-cholinergic drugs for rhinitis, anti-cholinergic decongestants, mast-cell stabilizers, monoclonal anti-IgE antibodies, vaccines, anti-TNF inhibitors such as infliximab, adalimumab, certolizumab pegol, golimumab, or etanercept, and combinations thereof.
  • corticosteroids such as infliximab
  • the bacterial composition can be used as an adjuvant to improve the efficacy of a vaccine formulation.
  • the bacterial composition can be used as an adjuvant to a vaccine for the prophylaxis or treatment of an autoimmune disease or an allergic disease.
  • a method for prophylaxis or treatment is described, the method comprising administering the bacterial composition and adminstering a vaccine.
  • Assessment of the extent of induction of proliferation or accumulation of regulatory T cells that results from administration of a composition described herein can be carried out by a variety of approaches, such as by measurement of the number of Foxp3-expressing Tregs in a patient sample (such as a biopsy or a blood sample), promotion of IL-10 expression, promotion of CTLA4 expression, promotion of IDO expression, suppression of IL-4 expression, or colonization of an individual with the bacterial composition.
  • the results of such assessments are used as an index of the induction of proliferation or accumulation of regulatory T cells in the individual.
  • administration of a composition described herein causes induction of the regulatory T cells that are transcription factor Foxp3-positive regulatory T cells or IL-10-producing regulatory T cells.
  • composition described herein can be administered by a variety of routes and in one case, is administered orally to an individual in need thereof, such as a patient in need thereof.
  • the composition may be administered in a number of oral forms, such as in spore-form (in a dry powder or dissolved in a liquid formulation), in enteric capsules, in sachets, or in a food matrix, such as yogurt, or a drink.
  • the method comprises (a) obtaining a (at least one, one or more) sample, such as a fecal sample or a colonic biopsy, from a patient before he or she is treated with a bacterial composition described herein; (b) measuring or determining the percentage or absolute counts in the sample of at least one bacterial species selected from the group consisting of: Clostridium saccharogumia, Clostridium ramosum JCM1298, Clostridium ramosum, Flavonifractor plautii, Pseudoflavonifractor capillosus ATCC 29799, Clostridium hathewayi, Clostridium saccharolyticum WM1, Bacteroides sp.
  • a sample such as a fecal sample or a colonic biopsy
  • MANG Clostridium saccharolyticum, Clostridium scindens, Lachnospiraceae bacterium 5_1_57FAA, Lachnospiraceae bacterium 6_1_63FAA, Clostridium sp. 14616, Clostridium bolteae ATCC BAA-613, cf. Clostridium sp.
  • MLG055 Erysipelotrichaceae bacterium 2_2_44A, Clostridium indolis, Anaerostipes caccae, Clostridium bolteae, Lachnospiraceae bacterium DJF_VP30, Lachnospiraceae bacterium 3_1_57FAA_CT1, Anaerotruncus colihominis, Anaerotruncus colihominis DSM 17241, Ruminococcus sp.
  • the method further comprises (d) administering the bacterial composition to the patient if the percentage or count in the sample obtained from the patient is lower than the baseline value.
  • the method may further comprise measuring in a patient's sample (e.g., a fecal sample or a colonic biopsy) the percentages or absolute counts of other commensal species that belong to Clostridium Clusters IV and XIVa, but are not present in the bacterial composition, wherein a value of the percentage or absolute count (measurement) lower than baseline further indicates that the subject may respond favorably to administration of the bacterial compositions.
  • the method further comprises administering the bacterial composition to the patient if the value of the percentage or absolute count (measurement) is lower than baseline.
  • the patient being assessed suffers from inflammatory bowel disease or a C. difficile infection.
  • Also described is a method of monitoring a subject's response to treatment with the bacterial compositions of the invention comprising: (a) obtaining a (at least one) sample, such as a fecal sample or a colonic biopsy from a patient before treatment with a bacterial composition described herein; (b) obtaining, a (at least one) corresponding sample from the patient after treatment with a bacterial composition described herein; and (c) comparing the percentage or absolute counts of at least one bacterial species selected from the group consisting of: Clostridium saccharogumia, Clostridium ramosum JCM1298, Clostridium ramosum, Flavonifractor plautii, Pseudoflavonifractor capillosus ATCC 29799, Clostridium hathewayi, Clostridium saccharolyticum WM1, Bacteroides sp.
  • a sample such as a fecal sample or a colonic biopsy from a patient before treatment with
  • MANG Clostridium saccharolyticum, Clostridium scindens, Lachnospiraceae bacterium 5_1_57FAA, Lachnospiraceae bacterium 6_1_63FAA, Clostridium sp. 14616, Clostridium bolteae ATCC BAA-613, cf. Clostridium sp.
  • MLG055 Erysipelotrichaceae bacterium 2_2_44A, Clostridium indolis, Anaerostipes caccae, Clostridium bolteae, Lachnospiraceae bacterium DJF_VP30, Lachnospiraceae bacterium 3_1_57FAA_CT1, Anaerotruncus colihominis, Anaerotruncus colihominis DSM 17241, Ruminococcus sp.
  • the method further comprises (d) further administering the bacterial composition to the patient or ceasing adminstration of the bacterial composition to the patient based on the comparison in (c).
  • the method may further comprise measuring in the subject's samples the percentages or absolute counts of other commensal species that belong to Clostridium Clusters IV and XIVa, but are not present in the bacterial composition, wherein a higher value after treatment than before treatment indicates that the subject has responded favorably to treatment.
  • compositions described herein which contain, as an active component, selected bacteria belonging to the Clostridia class or other bacteria, as described herein; a culture supernatant of such bacteria; a physiologically active substance derived from such bacteria; or a combination of two or three of the foregoing are excellent at inducing the proliferation or accumulation of regulatory T cells (Treg cells).
  • Immunity in an individual can be suppressed through administration of the subject composition, such as through ingestion of the bacterial composition in a food or beverage or as a dietary supplement or through administration of a pharmaceutical composition comprising the bacterial composition.
  • the subject composition can be used, for example, to prevent or treat autoimmune diseases, allergic diseases, infectious diseases, as well as to suppress immunological rejection in organ transplantation or the like.
  • a food or beverage such as a health food
  • healthy individuals can ingest the composition easily and routinely. As a result, it is possible to induce the proliferation and/or accumulation of regulatory T cells and thereby to improve immune functions.
  • composition described herein provides for a natural, long-lasting, patient-friendly, and benign treatment alternative for immune-mediated conditions.
  • inflammatory bowel disease is currently managed with synthetic drugs that may have severe side effects (such as corticosteroids, TNF inhibitors), cannot be administered orally (such as TNF inhibitors), have inconvenient dosing involving several pills a day (such as mesalazine or sulfasalazine) or have limited efficacy and short-lived effects (such as currently marketed probiotics, e.g. Lactobacillus GG, Lactobacillus acidophilus, Bifidobacterium longum, etc).
  • synthetic drugs that may have severe side effects (such as corticosteroids, TNF inhibitors), cannot be administered orally (such as TNF inhibitors), have inconvenient dosing involving several pills a day (such as mesalazine or sulfasalazine) or have limited efficacy and short-lived effects (such as
  • compositions that induces proliferation, accumulation of regulatory T cells or both proliferation and accumulation of regulatory T cells.
  • the composition comprises, as an active ingredient, one or more of the following: a (at least one, one or more) organism selected from the group consisting of: Clostridium saccharogumia, Clostridium ramosum JCM1298, Clostridium ramosum, Flavonifractor plautii, Pseudoflavonifractor capillosus ATCC 29799, Clostridium hathewayi, Clostridium saccharolyticum WM1, Bacteroides sp.
  • MANG Clostridium saccharolyticum, Clostridium scindens, Lachnospiraceae bacterium 5_1_57FAA, Lachnospiraceae bacterium 6_1_63FAA, Clostridium sp. 14616, Clostridium bolteae ATCC BAA-613, cf. Clostridium sp.
  • MLG055 Erysipelotrichaceae bacterium 2_2_44A, Clostridium indolis, Anaerostipes caccae, Clostridium bolteae, Lachnospiraceae bacterium DJF_VP30, Lachnospiraceae bacterium 3_1_57FAA_CT1, Anaerotruncus colihominis, Anaerotruncus colihominis DSM 17241, Ruminococcus sp.
  • Bacteria described herein were isolated from human fecal samples using the methods outlined in Examples 19 to 28.
  • regulatory T cells refers to T cells that suppress an abnormal or excessive immune response and play a role in immune tolerance.
  • the regulatory T cells are typically transcription factor Foxp3-positive CD4-positive T cells.
  • the regulatory T cells described herein also include transcription factor Foxp3-negative regulatory T cells that are IL-10-producing CD4-positive T cells.
  • inces proliferation or accumulation of regulatory T cells refers to an effect of inducing the differentiation of immature T cells into regulatory T cells, which differentiation leads to the proliferation and/or the accumulation of regulatory T cells. Further, the meaning of "induces proliferation or accumulation of regulatory T cells” includes in-vivo effects, in vitro effects, and ex vivo effects.
  • the effect of inducing proliferation or accumulation of regulatory T cells can be evaluated, for example, as follows. Specifically, the aforementioned bacteria belonging to the Clostridia class, a culture supernatant of the bacteria or supernatant component(s), or a physiologically active substance derived from the bacteria is orally administered to an experimental animal, such as a germ-free mouse, then CD4-positive cells in the colon are isolated, and the ratio of regulatory T cells contained in the CD4-positive cells is measured by flow cytometry (refer to Example 7).
  • the regulatory T cells whose proliferation or accumulation is induced by the composition of the present invention are preferably transcription factor Foxp3-positive regulatory T cells or IL-10-producing regulatory T cells.
  • human-derived bacteria means bacterial species that have been isolated from a fecal sample or from a gastrointestinal biopsy obtained from a human individual or whose ancestors were isolated from a fecal sample or from a gastrointestinal biopsy obtained from a human (e.g., are progeny of bacteria obtained from a fecal sample or a gastrointestinal biopsy).
  • the bacterial species may have been previously isolated from a fecal sample or from a gastrointestinal biopsy obtained from a human and cultured for a sufficient time to generate progeny. The progeny can then be further cultured or frozen.
  • the human-derived bacteria are naturally occurring commensals that populate the gastrointestinal tract of human individuals, preferably healthy human individuals.
  • Clostridia class refers to a class of Gram+, obligate anaerobic bacteria belonging to the Firmicutes phylum that have the ability to form spores. It is important to note that while currently most bacteria in this class are included in the Clostridiales order, this categorization is still partly based on old methods and is likely to be redefined in the future based on new advances in sequencing technologies that are enabling sequencing of the full genomes of bacteria in this class.
  • Table 2 provides a summary of the categorization of 17 abundant species belonging to the Clostridia class which have been identified by the inventors as strong Treg-inducers and cultured in vitro. All of these species fall, under current categorization rules, in the Clostridiaceae family, and belong to clusters IV, XIVa, XVI, and XVIII.
  • the composition described herein may include one strain alone (only one strain) of any of the aforementioned bacterial species, but two or more strains of the bacteria can be used together. For example, one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen or seventeen of the strains listed in Table 2 or Table 4, in any combination, can be used together to affect regulatory T cells. In some cases, the 23, 17, 5, or 3 species mixes listed in Table 4 can be used together (and administered in one or several compositions) to affect regulatory T cells.
  • strain 1 (OTU136, closest species: Clostridium saccharogumia, Clostridium ramosum JCM1298), strain 3 (OTU221, closest species: Flavonifractor plautii, Pseudoflavonifractor capillosus ATTC 29799), strain 4 (OTU9, closest species: Clostridium hathewayi, Clostridium saccharolyticum WM1), strain 5 (OTU296, closest species: Clostridium scindens, Lachnospiraceae bacterium 5_1_57FAA), strain 6 (OTU21, closest species: Blautia coccoides, Lachnospiraceae bacterium 6_1_63FAA), strain 7 (OUT 166, closest species: Clostridium sp., Clostridium bolteae ATCC BAA-613), strain 8 (OTU73, closest species: cf.
  • OTU136 closest species: Clostridium saccharogumia, Clo
  • strain 15 Lachnospiraceae bacterium 2_1_46FAA
  • strain 16 (OTU306, closest species: Clostridium symbiosum, Clostridium symbiosum WAL-14163)
  • strain 18 (OTU46, closest species: Clostridium ramosum, Clostridium ramosum)
  • strain 21 (OTU87, closest species: Eubacterium contortum, Clostridium sp.
  • strain 23 (OTU152, closest species: Lachnospiraceae bacterium DJF_VP30, Lachnospiraceae bacterium 3_1_57FAA_CT1)
  • strain 24 (OTU253, closest species: Oscillospiraceae bacterium NML 061048, Oscillibacter valericigenes)
  • strain 25 (OTU259, closest species: Eubacterium contortum, Clostridium sp.
  • strain 26 (OTU281, closest species: Clostridium scindens, Lachnospiraceae bacterium 5_1_57FAA), strain 27 (OTU288, closest species: Lachnospiraceae bacteriumA4, Lachnospiraceae bacterium 3_1_57FAA_CT1), strain 28 (OTU344, closest species: Clostridium sp. 316002/08, Clostridiales bacterium 1_7_47FAA), and strain 29 (OTU359, closest species: Lachnospiraceae bacteriumA4, Lachnospiraceae bacterium 3_1_57FAA_CT1) as described in Table 4.
  • strain 1 (OTU136, closest species: Clostridium saccharogumia, Clostridium ramosum JCM1298), strain 3 (OTU221, closest species: Flavonifractor plautii, Pseudoflavonifractor capillosus ATTC 29799), strain 4 (OTU9, closest species: Clostridium hathewayi, Clostridium saccharolyticum WM1), strain 6 (OTU21, closest species: Blautia coccoides, Lachnospiraceae bacterium 6_1_63FAA), strain 7 (OUT 166, closest species: Clostridium sp., Clostridium bolteae ATCC BAA-613), strain 8 (OTU73, closest species: cf.
  • strain 3 (OTU221, closest species: Flavonifractor plautii, Pseudoflavonifractor capillosus ATTC 29799)
  • strain 4 (OTU9, closest species: Clo
  • strain 15 Lachnospiraceae bacterium 2_1_46FAA
  • strain 16 (OTU306, closest species: Clostridium symbiosum, Clostridium symbiosum WAL-14163)
  • strain 18 (OTU46, closest species: Clostridium ramosum, Clostridium ramosum)
  • strain 21 (OTU87, closest species: Eubacterium contortum, Clostridium sp.
  • strain 26 (OTU281, closest species: Clostridium scindens, Lachnospiraceae bacterium 5_1_57FAA), strain 27 (OTU288, closest species: Lachnospiraceae bacteriumA4, Lachnospiraceae bacterium 3_1_57FAA_CT1), strain 28 (OTU344, closest species: Clostridium sp. 316002/08, Clostridiales bacterium 1_7_47FAA), and strain 29 (OTU359, closest species: Lachnospiraceae bacteriumA4, Lachnospiraceae bacterium 3_1_57FAA_CT1) as described in Table 4.
  • strain 1 (OTU136, closest species: Clostridium saccharogumia, Clostridium ramosum JCM1298), strain 4 (OTU9, closest species: Clostridium hathewayi, Clostridium saccharolyticum WM1), strain 16 (OTU306, closest species: Clostridium symbiosum, Clostridium symbiosum WAL-14163), strain 27 (OTU288, closest species: Lachnospiraceae bacteriumA4, Lachnospiraceae bacterium 3_1_57FAA_CT1), and strain 29 (OTU359, closest species: Lachnospiraceae bacteriumA4, Lachnospiraceae bacterium 3_1_57FAA_CT1) as described in Table 4.
  • strain 1 (OTU136, closest species: Clostridium saccharogumia, Clostridium ramosum JCM1298)
  • strain 4 (OTU9, closest species: Clostridium hathewayi, Clo
  • strain 6 (OTU21, closest species: Blautia coccoides, Lachnospiraceae bacterium 6_1_63FAA), strain 8 (OTU73, closest species: cf. Clostridium sp. MLG055, Erysipelotrichaceae bacterium 2_2_44A), strain 13 (OTU337, closest species: Anaerotruncus colihominis, Anaerotruncus colihominis DSM 17241), strain 14 (OTU314, closest species: Ruminococcus sp.
  • strain 3 (OTU221, closest species: Flavonifractor plautii, Pseudoflavonifractor capillosus ATTC 29799)
  • strain 7 (OUT 166, closest species: Clostridium sp., Clostridium bolteae ATCC BAA-613)
  • strain 9 (OTU174, closest species: Clostridium indolis, Anaerostipes caccae DSM 14662), strain 15 (OTU195, closest species: Clostridium lavalense, Clostridium asparagiforme DSM 15981), and strain 28 (OTU344, closest species: Clostridium sp.
  • strain 1 (OTU136, closest species: Clostridium saccharogumia, Clostridium ramosum JCM1298)
  • strain 2 (OTU46, closest species: Flavonifractor plautii, Pseudoflavonifractor capillosus ATCC 29799)
  • strain 3 (OTU221, closest species: Flavonifractor plautii, Pseudoflavonifractor capillosus ATTC 29799) as described in Table 4.
  • Clostridium cluster XIVa or the cluster IV can bring about an excellent effect on regulatory T cells.
  • Clostridium ramosum, Clostridium saccharogumia (belonging to cluster XVIII) and cf. Clostridium sp. MLG055 (belonging to cluster XVI) can also be used.
  • the number and ratio of strains used can vary widely.
  • the number and ratio to be used can be determined based on a variety of factors (e.g., the desired effect, such as induction or inhibition of proliferation or accumulation of regulatory T cells; the disease or condition to be treated, prevented or reduced in severity; the age or gender of the recipient; the typical amounts of the strains in healthy humans).
  • the strains can be present in a single composition, in which case they can be consumed or ingested together (in a single composition), or can be present in more than one composition (e.g., each can be in a separate composition), in which case they can be consumed individually or the compositions can be combined and the resulting combination (combined compositions) consumed or ingested.
  • any number or combination of the strains that proves effective e.g., any number from one to 22, such as 1 to 20, 1 to 15, 1 to 10, 1 to 5, 1 to 3, 1 to 2, and any number therebetween or one to 23, such as 1 to 23, 3 to 23, 5 to 23, 1 to 20, 1 to 17, 3 to 17, 5 to 17, 1 to 15, 1 to 10, 1 to 5, 3 to 5, 1 to 3, 1 to 2, and any number therebetween) can be administered.
  • a combination of some or all of the 22 or 23 (e.g., the 23 strains in Exampe 32 and Table 4) strains described in the present disclosure is used.
  • at least one, two or more, three, three or more, four, four or more, five, five or more, six, six or more or any other number of the 22 or 23 described strains, including 22 or 23 strains can be used.
  • the specific combinations of 3, 5, 17, or 23 strains described in Table 4 can be used (the composition comprises combinations of 3, 5, 17 or 23 strains described in Table 4). They can be used in combination with one another and in combination with strains not described in the cited reference.
  • Cells of bacteria belonging to the Clostridia class can be used in spore form or in vegetative form.
  • the bacteria may be preferably in the form of spore.
  • the bacteria may alternatively be produced (and later administered) in the form of vegetative cells.
  • the term the "physiologically active substance derived from bacteria belonging to the Clostridia class" of the present disclosure includes substances contained in the bacteria, secretion products of the bacteria, and metabolites of the bacteria. Such a physiologically active substance can be identified by purifying an active component from the bacteria, a culture supernatant thereof, or intestinal tract contents in the intestinal tract of a mouse in which only bacteria belonging to the Clostridia class are colonized by an already known purification method.
  • Chloroform treatment of a fecal sample obtained from a human is a method that isolates the bacteria in the fecal sample that have the ability to form spores, and is not particularly limited, as long as the spore-forming fraction is obtained by treating feces of a human with chloroform (for example, 3% chloroform), and has the effect of inducing proliferation or accumulation of regulatory T cells, including mammalian regulatory T cells such as murine regulatory T cells and human regulatory T cells.
  • culture supernatant of the bacteria in the composition of the present disclosure includes such substances, secretion products, and metabolites.
  • the culture supernatant is not particularly limited, as long as the culture supernatant has the effect of inducing proliferation or accumulation of regulatory T cells.
  • Examples of the culture supernatant include a protein fraction of the culture supernatant, a polysaccharide fraction of the culture supernatant, a lipid fraction of the culture supernatant, and a low-molecular weight metabolite fraction of the culture supernatant.
  • the bacterial composition may be administered in the form of a pharmaceutical composition, a dietary supplement, or a food or beverage (which may also be an animal feed), or may be used as a reagent for an animal model experiment.
  • the pharmaceutical composition, the dietary supplement, the food or beverage, and the reagent induce proliferation or accumulation of regulatory T cells.
  • An example presented herein revealed that regulatory T cells (Treg cells) induced by bacteria or the like belonging to the Clostridia class suppressed the proliferation of effector T-cells.
  • the composition of the present disclosure can be used suitably as a composition having an immunosuppressive effect.
  • the immunosuppressive effect can be evaluated, for example, as follows.
  • Regulatory T cells isolated from an experimental animal, such as a mouse, to which the composition of the present disclosure is orally administered are caused to act on effector T-cells (CD4 + CD25 - cells) isolated from the spleen, and the proliferation ability thereof is measured by using the intake amount of [3H]-thymidine as an index (refer to Example 14).
  • the bacterial composition described herein can be used, for example, as a pharmaceutical composition for preventing or treating (reducing, partially or completely, the adverse effects of) an autoimmune disease.
  • an autoimmune disease such as chronic inflammatory bowel disease, systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, or Hashimoto's disease; an allergic disease, such as a food allergy, pollenosis, or asthma; an infectious disease, such as an infection with Clostridium difficile; an inflammatory disease such as a TNF-mediated inflammatory disease (e.g., an inflammatory disease of the gastrointestinal tract, such as pouchitis, a cardiovascular inflammatory condition, such as atherosclerosis, or an inflammatory lung disease, such as chronic obstructive pulmonary disease); a pharmaceutical composition for suppressing rejection in organ transplantation or other situations in which tissue rejection might occur; a supplement, food, or beverage for improving immune functions; or a reagent for suppressing the proliferation or function of effector T-cells.
  • target diseases for which the composition is useful for treatment include autoimmune diseases, allergic diseases, infectious diseases, and rejection in organ transplantations, such as inflammatory bowel disease (IBD), ulcerative colitis, Crohn's disease, sprue, autoimmune arthritis, rheumatoid arthritis, Type I diabetes, multiple sclerosis, graft vs.
  • IBD inflammatory bowel disease
  • target diseases for which the composition is useful for treatment include colon cancer, cystic fibrosis, celiac disease, Type 2 diabetes, and autism-related immunopathologies. These diseases are characterized by a reduction of Clostridium Clusters IV and XIV in the gastrointestinal microbiota.
  • compositions described herein can also be used as a pharmaceutical composition for preventing or treating infectious diseases in an individual whose resistance to the infectious diseases is impaired, for example because of damage due to excessive inflammation caused by the immunity or due to an alteration of the patient's microbiome.
  • infectious pathogens that impair maintenance or recovery of homeostasis of a host, and which eventually bring about such immunopathological tissue damage include Salmonella, Shigella, Clostridium difficile, Mycobacterium (which cause the disease tuberculosis), protozoa (which cause malaria), filarial nematodes (which cause the disease filariasis), Schistosoma (which cause schistosomiasis), Toxoplasma (which cause the disease toxoplasmosis), Leishmania (which cause the disease leishmaniasis), HCV and HBV (which cause the disease hepatitis C and hepatitis B), and herpes simplex viruses (which cause the disease herpes).
  • compositions can be formulated from the bacterial compositions described by drug formulation methods known to those of skill in the art.
  • the composition can be used orally or parenterally in the form of capsules, tablets, pills, sachets, liquids, powders, granules, fine granules, film-coated preparations, pellets, troches, sublingual preparations, chewables, buccal preparations, pastes, syrups, suspensions, elixirs, emulsions, liniments, ointments, plasters, cataplasms, transdermal absorption systems, lotions, inhalations, aerosols, injections, suppositories, and the like.
  • the bacterial compositions can be used in appropriate combination with carriers that are pharmacologically acceptable or acceptable for ingestion, such as in a food or beverage, including one or more of the following: sterile water, physiological saline, vegetable oil, solvent, a base material, an emulsifier, a suspending agent, a surfactant, a stabilizer, a flavoring agent, an aromatic, an excipient, a vehicle, a preservative, a binder, a diluent, a tonicity adjusting agent, a soothing agent, a bulking agent, a disintegrating agent, a buffer agent, a coating agent, a lubricant, a colorant, a sweetener, a thickening agent, a flavor corrigent, a solubilizer, and other additives.
  • carriers that are pharmacologically acceptable or acceptable for ingestion, such as in a food or beverage, including one or more of the following: sterile water, physiological saline, vegetable oil,
  • a pharmaceutical preparation or formulation and particularly a pharmaceutical preparation for oral administration comprises an additional component that enables efficient delivery of the bacterial composition of the present disclosure to the colon, in order to more efficiently induce proliferation or accumulation of regulatory T cells in the colon.
  • a variety of pharmaceutical preparations that enable the delivery of the bacterial composition to the colon can be used. Examples thereof include pH sensitive compositions, more specifically, buffered sachet formulations or enteric polymers that release their contents when the pH becomes alkaline after the enteric polymers pass through the stomach.
  • the pH sensitive composition is preferably a polymer whose pH threshold of the decomposition of the composition is between about 6.8 and about 7.5.
  • Such a numeric value range is a range in which the pH shifts toward the alkaline side at a distal portion of the stomach, and hence is a suitable range for use in the delivery to the colon.
  • a pharmaceutical preparation useful for delivery of the bacterial composition to the colon is one that ensures the delivery to the colon by delaying the release of the contents (e.g., the bacterial composition) by approximately 3 to 5 hours, which corresponds to the small intestinal transit time.
  • a hydrogel is used as a shell. The hydrogel is hydrated and swells upon contact with gastrointestinal fluid, with the result that the contents are effectively released (released predominantly in the colon). Delayed release dosage units include drug-containing compositions having a material which coats or selectively coats a drug or active ingredient to be administered.
  • Examples of such a selective coating material include in vivo degradable polymers, gradually hydrolyzable polymers, gradually water-soluble polymers, and/or enzyme degradable polymers.
  • a wide variety of coating materials for efficiently delaying the release is available and includes, for example, cellulose-based polymers such as hydroxypropyl cellulose, acrylic acid polymers and copolymers such as methacrylic acid polymers and copolymers, and vinyl polymers and copolymers such as polyvinylpyrrolidone.
  • composition enabling the delivery to the colon further include bioadhesive compositions which specifically adhere to the colonic mucosal membrane (for example, a polymer described in the specification of US Patent No. 6.368.586 ) and compositions into which a protease inhibitor is incorporated for protecting particularly a biopharmaceutical preparation in the gastrointestinal tracts from decomposition due to an activity of a protease.
  • bioadhesive compositions which specifically adhere to the colonic mucosal membrane
  • compositions into which a protease inhibitor is incorporated for protecting particularly a biopharmaceutical preparation in the gastrointestinal tracts from decomposition due to an activity of a protease.
  • An example of a system enabling the delivery to the colon is a system of delivering a composition to the colon by pressure change in such a way that the contents are released by utilizing pressure change caused by generation of gas in bacterial fermentation at a distal portion of the stomach.
  • a system is not particularly limited, and a more specific example thereof is a capsule which has contents dispersed in a suppository base and which is coated with a hydrophobic polymer (for example, ethyl cellulose).
  • Another example of the system enabling the delivery to the colon is a system of delivering a composition to the colon, the system being specifically decomposed by an enzyme (for example, a carbohydrate hydrolase or a carbohydrate reductase) present in the colon.
  • an enzyme for example, a carbohydrate hydrolase or a carbohydrate reductase
  • Such a system is not particularly limited, and more specific examples thereof include systems which use food components such as non-starch polysaccharides, amylose, xanthan gum, and azopolymers.
  • the bacterial composition When used as a pharmaceutical preparation, the bacterial composition may be used in combination with an already known pharmaceutical composition for use in immunosuppression.
  • the pharmaceutical preparation can comprise both the bacterial composition and the already known pharmaceutical composition.
  • a known pharmaceutical composition is not particularly limited, and may be at least one therapeutic composition selected from the group consisting of corticosteroids, mesalazine, mesalamine, sulfasalazine, sulfasalazine derivatives, immunosuppressive drugs, cyclosporin A, mercaptopurine, azathiopurine, prednisone, methotrexate, antihistamines, glucocorticoids, epinephrine, theophylline, cromolyn sodium, anti-leukotrienes, anti-cholinergic drugs for rhinitis, anti-cholinergic decongestants, mast-cell stabilizers, monoclonal anti-IgE antibodies, vaccines (preferably vaccines used
  • the bacterial composition can also be used as an adjuvant to improve the efficacy of a vaccine formulation such as a vaccine for the prophylaxis or treatment of an autoimmune disease or an allergic disease.
  • the bacterial composition can be used as a food or beverage, such as a health food or beverage, a food or beverage for infants, a food or beverage for pregnant women, athletes, senior citizens or other specified group, a functional food, a beverage, a food or beverage for specified health use, a dietary supplement, a food or beverage for patients, or an animal feed.
  • a food or beverage such as a health food or beverage, a food or beverage for infants, a food or beverage for pregnant women, athletes, senior citizens or other specified group, a functional food, a beverage, a food or beverage for specified health use, a dietary supplement, a food or beverage for patients, or an animal feed.
  • the foods and beverages include various beverages such as juices, refreshing beverages, tea beverages, drink preparations, jelly beverages, and functional beverages; alcoholic beverages such as beers; carbohydrate-containing foods such as rice food products, noodles, breads, and pastas; paste products such as fish hams, sausages, paste products of seafood; retort pouch products such as curries, food dressed with a thick starchy sauces, and Chinese soups; soups; dairy products such as milk, dairy beverages, ice creams, cheeses, and yogurts; fermented products such as fermented soybean pastes, yogurts, fermented beverages, and pickles; bean products; various confectionery products such as Western confectionery products including biscuits, cookies, and the like, Japanese confectionery products including steamed bean-jam buns, soft adzuki-bean jellies, and the like, candies, chewing gums, gummies, cold desserts including jellies, cream caramels, and frozen desserts; instant foods such as instant soups and instant soy-bean soups;
  • the examples also include health foods and beverages prepared in the forms of powders, granules, tablets, capsules, liquids, pastes, and jellies.
  • the composition of the present disclosure can be used for animals, including humans.
  • the animals, other than humans, are not particularly limited, and the composition can be used for various livestock, poultry, pets, experimental animals, and the like.
  • Specific examples of the animals include pigs, cattle, horses, sheep, goats, chickens, wild ducks, ostriches, domestic ducks, dogs, cats, rabbits, hamsters, mice, rats, monkeys, and the like, but the animals are not limited thereto.
  • the bacterial composition is capable of conditioning absorption of nutrients and improving feed efficiency. From such a viewpoint, the bacterial composition can be used for promoting body weight gain, or for a high efficiency animal feed.
  • Diseases and conditions that would benefit from body weight gain include, e.g., starvation, cancer, AIDS, gastrointestinal disorders (e.g., celiac disease, peptic ulcer, inflammatory bowel disease (Crohns' disease and ulcerative colitis), pancreatitis, gastritis, diarrhea), hyperthyroidism, infection, renal disease, cardiac disease, pulmonary disease, connective tissue disease, weight loss caused by medications, anorexia, Addison's disease, dementia, depression, hypercalcemia, Parkinson's disease and tuberculosis.
  • gastrointestinal disorders e.g., celiac disease, peptic ulcer, inflammatory bowel disease (Crohns' disease and ulcerative colitis), pancreatitis, gastritis, diarrhea
  • hyperthyroidism infection
  • renal disease cardiac disease
  • pulmonary disease connective tissue disease
  • weight loss caused by medications exia, Addison's disease, dementia, depression, hypercalcemia, Parkinson's disease and tuberculosis.
  • the addition of the bacterial composition to an antibiotic-free animal feed makes it possible to increase the body weight of an animal that ingests the animal feed to a level equal to or higher than that achieved by animal ingesting antibiotic-containing animal feeds, and also makes it possible to reduce pathogenic bacteria in the stomach to a level equal to those in animals consuming typical antibiotic-containing animal feeds.
  • the bacterial composition can be used as a component of an animal feed that does not need the addition of antibiotics.
  • the present bacterial composition in spore form can be pelletized, sprayed, or easily mixed with an animal feed and can also be added to drinking water.
  • Animal feed comprising the bacterial composition can be fed to a wide variety of types of animals and animals of a varying ages and can be fed at regular intervals or for a certain period (for example, at birth, during weaning, or when the animal is relocated or shipped).
  • the bacterial composition can be used to promote weight gain and enhance energy absorption in humans and nonhumans (e.g., farm or other food animals).
  • the bacterial active components of the bacterial composition can be manufactured using fermentation techniques well known in the art.
  • the active ingredients are manufactured using anaerobic fermentors, which can support the rapid growth of bacterial species belonging to the Clostridia class.
  • the anaerobic fermentors may be, for example, stirred tank reactors or disposable wave bioreactors.
  • Culture media such as BL media and EG media, or similar versions of these media devoid of animal components can be used to support the growth of the bacterial species.
  • the bacterial product can be purified and concentrated from the fermentation broth by traditional techniques, such as centrifugation and filtration, and can optionally be dried and lyophilized by techniques well known in the art.
  • a food or beverage comprising a bacterial composition described herein can be manufactured by manufacturing techniques well known in the technical field.
  • One or more components for example, a nutrient which are effective for the improvement of an immune function by an immunosuppressive effect may be added to the food or beverage.
  • the food or beverage may be combined with another component or another functional food exhibiting a function other than the function of the improvement of an immune function to thereby serve as a multi-functional food or beverage.
  • the bacterial composition can be incorporated into foods requiring a processing step which may destroy ordinary probiotic strains.
  • most commercially usable probiotic strains cannot be incorporated into foods that need to be processed, for example, by heat treatment, long term storage, freezing, mechanical stress, or high-pressure treatment (for example, extrusion forming or roll forming).
  • the bacterial composition described herein can be easily incorporated into such processed foods.
  • the bacterial composition in the form of spores can survive even in a dried food, and can remain living even after being ingested.
  • the bacterial composition can withstand low-temperature sterilization processes, typically processes carried out at a temperature from about 70 °C to about 100 °C, both inclusive.
  • the bacterial composition can be incorporated into dairy products that require a pasteurization step.
  • the bacterial composition can withstand long-term storage of many years; high-temperature processing such as baking and boiling; low-temperature processing such as freezing and cold storage; and high-pressure treatments such as extrusion forming and roll forming.
  • the amount of the bacterial composition to be administered or ingested can be determined empirically, taking into consideration such factors as the age, body weight, gender, symptoms, health conditions, of an individual who will receive it, as well as the kind of bacterial composition (a pharmaceutical product, a food or beverage) to be administered or ingested.
  • the amount per administration or ingestion is generally 0.01 mg/kg body weight to 100 mg/kg body weight, and, in specific cases, 1 mg/kg body weight to 10 mg/kg body weight.
  • a method for suppressing the immunity (reducing the immune response) of a subject the method being characterized in that the bacteria belonging to the Clostridia class or the physiologically active substance derived from the bacteria is administered to or ingested by the subject as described above.
  • the bacterial composition may be administered to an individual once, or it may be administered more than once. If the composition is administered more than once, it can be administered on a regular basis (for example, once a day, once every two days, once a week, once every two weeks, once a month, once every 6 months, or once a year) or on an as needed or irregular basis.
  • the appropriate frequency of administration (which may depend on host genetics, age, gender, and health or disease status of the subject, among other factors) may be determined empirically.
  • a patient can be administered one dose of the composition, and the levels of the bacterial strains of the composition in fecal samples obtained from the patient can be measured at different times (for example after 1 day, after 2 days, after 1 week, after 2 weeks, after 1 month). When the levels of the bacteria fall to, for example, one half of their maximum value, a second dose can be administered, and so on.
  • a product comprising the bacterial composition (a pharmaceutical product, a food or beverage, or a reagent) or a manual thereof may be accompanied by document or statement explaining that the product can be used to suppress the immunity (including a statement that the product has an immunosuppressive effect and a statement that the product has an effect of suppressing the proliferation or function of effector T-cells).
  • the "provision to the product or the manual thereof with the note” means that the document or statement is provided to a main body, a container, a package, or the like of the product, or the note is provided to a manual, a package insert, a leaflet, or other printed matters, which disclose information on the product.
  • administration of the bacterial composition to an individual makes it possible to induce proliferation or accumulation of regulatory T cells in the individual.
  • This provides a method of inducing proliferation or accumulation of regulatory T cells in an individual, the method comprising: administering, to the individual, at least one substance selected from the group consisting of: (a) Clostridium saccharogumia, Clostridium ramosum JCM1298, Clostridium ramosum, Flavonifractor plautii, Pseudoflavonifractor capillosus ATCC 29799, Clostridium hathewayi, Clostridium saccharolyticum WM1, Bacteroides sp.
  • MANG Clostridium saccharolyticum, Clostridium scindens, Lachnospiraceae bacterium 5_1_57FAA, Lachnospiraceae bacterium 6_1_63FAA, Clostridium sp. 14616, Clostridium bolteae ATCC BAA-613, cf. Clostridium sp.
  • MLG055 Erysipelotrichaceae bacterium 2_2_44A, Clostridium indolis, Anaerostipes caccae, Clostridium bolteae, Lachnospiraceae bacterium DJF_VP30, Lachnospiraceae bacterium 3_1_57FAA_CT1, Anaerotruncus colihominis, Anaerotruncus colihominis DSM 17241, Ruminococcus sp.
  • the bacterial composition is administered (provided) to the individual in sufficient quantity to produce the desired effect of inducing proliferation, accumulation or both proliferation and accumulation of regulatory T cells. It may be administered to an individual in need of treatment, reduction in the severity of or prevention of at least one disease selected from an autoimmune disease, an inflammatory disease, an allergic disease, and an infectious disease.
  • the "individual” or “subject” may be in a healthy state or a diseased state.
  • the method may further comprise the optional step of administering at least one (a, one or more) antibiotic preceding, or in combination with, the bacterial composition.
  • the antibiotic administered can be, for example, one which facilitates recolonization of the gut by Gram-positive bacteria of the Clostridia class, such as an antibiotic that reduces Gram-negative bacteria.
  • antibiotics examples include aminoglycoside antibiotics (amikacin, gentamicin, kanamycin, neomycin, netilmicin, tobramycin, and paromomycin), cephalosporin antibiotics (cefaclor, cefamandole, cefoxitin, cefprozil, cefuroxime, cefixime, cefdinir, cefditoren, cefoperazone, cefotaxime, ceftazidime, ceftibuten, ceftizoxime, ceftriaxone, and cefoxotin), sulfonamides, ampicillin, and streptomycin.
  • aminoglycoside antibiotics amikacin, gentamicin, kanamycin, neomycin, netilmicin, tobramycin, and paromomycin
  • cephalosporin antibiotics cefaclor, cefamandole, cefoxitin, cefprozil, cefuroxime, cefix
  • a prebiotic composition such as almond skin, inulin, oligofructose, raffinose, lactulose, pectin, hemicellulose (such as xyloglucan and alpha-glucans), amylopectin, and resistant starch which are not decomposed in the upper gastrointestinal tract and promote the growth of intestinal microbes in the intestinal tract, as well as growth factors such as acetyl-Co A, biotin, beet molasses, and yeast extracts, preferentially contributes to the proliferation of the bacterial species in the composition belonging to the Clostridia class.
  • a method of inducing proliferation and/or accumulation of regulatory T cells in an individual can comprise administering, to the individual, at least one substance selected from the above in combination with the bacterial composition.
  • a composition comprising the bacterial composition and a prebiotic [00] composition.
  • a therapeutic composition may be administered to an individual together with at least one substance selected from the group consisting of the bacterial composition, an antibiotic, and a prebiotic composition or growth factor.
  • a therapeutic composition can be, for example, one therapeutic composition selected from the group consisting of corticosteroids, mesalazine, mesalamine, sulfasalazine, sulfasalazine derivatives, immunosuppressive drugs, cyclosporin A, mercaptopurine, azathiopurine, prednisone, methotrexate, antihistamines, glucocorticoids, epinephrine, theophylline, cromolyn sodium, anti-leukotrienes, anti-cholinergic drugs for rhinitis, anti-cholinergic decongestants, mast-cell stabilizers, monoclonal anti-IgE antibodies, vaccines (preferably, vaccines used for vaccination where the amount of an allergen is gradually increased), anti-TNF inhibitors such as infliximab, adalimumab, certolizumab pegol, golimumab, or etanercept, and combinations
  • the therapeutic composition with at least one substance selected from the group consisting of the bacterial composition, the "antibiotic”, and the "prebiotic composition or growth factor".
  • the "one substance” and the therapeutic composition are administered orally or parenterally to an individual simultaneously or sequentially/individually at any appropriate time.
  • Whether administration of the bacterial composition induces the proliferation and/or accumulation of regulatory T cells can be determined by using, as an index, increase or reinforcement of at least one of the following: the number of regulatory T cells, the ratio of regulatory T cells in the T cell group of the colon, a function of regulatory T cells, or expression of a marker of regulatory T cells.
  • a specific approach is measurement counts or percentage of Foxp3-expressing Tregs in a patient sample, such as a biopsy or a blood sample, promotion (enhancement) of IL-10 expression, promotion (enhancement) of CTLA4 expression, promotion (enhancement) of IDO expression, suppression of IL-4 expression, or colonization of an individual with the bacterial composition administered as the index of the induction of proliferation or accumulation of regulatory T cells.
  • Methods for detecting such expression include northern blotting, RT-PCR, and dot blotting for detection of gene expression at the transcription level; ELISA, radioimmunoassays, immunoblotting, immunoprecipitation, and flow cytometry for detection of gene expression at the translation level.
  • Samples that may be used for measuring such an index include tissues and fluids obtained from an individual, such as blood, obtained in a biopsy, and a fecal sample.
  • an amount e.g. count
  • Clostridium saccharogumia Clostridium ramosum JCM1298, Clostridium ramosum, Flavonifractor plautii, Pseudoflavonifractor capillosus ATCC 29799, Clostridium hathewayi, Clostridium saccharolyticum WM1, Bacteroides sp.
  • MANG Clostridium saccharolyticum, Clostridium scindens, Lachnospiraceae bacterium 5_1_57FAA, Lachnospiraceae bacterium 6_1_63FAA, Clostridium sp. 14616, Clostridium bolteae ATCC BAA-613, cf. Clostridium sp.
  • MLG055 Erysipelotrichaceae bacterium 2_2_44A, Clostridium indolis, Anaerostipes caccae, Clostridium bolteae, Lachnospiraceae bacterium DJF_VP30, Lachnospiraceae bacterium 3_1_57FAA_CT1, Anaerotruncus colihominis, Anaerotruncus colihominis DSM 17241, Ruminococcus sp.
  • Clostridiales bacterium 1_7_47FAA, Blautia cocoides, Anaerostipes caccae DSM 14662 in a patient's sample is determined.
  • a patient's sample e.g. a colonic biopsy or a fecal sample
  • a base line value obtained by performing a similar determination on a healthy individual (e.g., an individual who does not have/has not been identified as having a disease or condition for which the bacterial composition is a potential treatment such as an auto-immune disease, an allergic condition, cancer, organ rejection)
  • a healthy individual e.g., an individual who does not have/has not been identified as having a disease or condition for which the bacterial composition is a potential treatment such as an auto-immune disease, an allergic condition, cancer, organ rejection
  • This determination can be used, for example, by a clinician to determine whether an individual or a patient is likely to benefit from treatment with the bacterial composition, or to select an individual or a patient for inclusion in a clinical trial. The clinician can then administer the bacterial composition to the individual or patient based on the determination that the individual or patient is likely to benefit from treatment.
  • This determination can also be used as a method to monitor an individual's response to treatment with the bacterial compositions described, wherein a higher value of the determination after treatment with the bacterial composition (compared to a determination before treatment) indicates that the individual has responded favorably to treatment (e.g. is a positive indicator of successful colonization and enhanced immunosuppression in the individual).
  • the prognosis and monitoring methods described here may further comprise the step of measuring in the individual's samples the percentages or absolute counts of other commensal species belonging to Clostridium Clusters IV and XIVa that are not present in the bacterial composition, wherein lower than baseline values before treatment indicate a higher likelihood of a positive response to treatment, and wherein an increased value after treatment indicates that the individual has responded favorably to treatment.
  • a variety of known methods can be used for determining the composition of the microbiota. For example, 16S rRNA sequencing can be used
  • the bacterial composition can also be used as an adjuvant to improve the efficacy of a vaccine formulation.
  • the bacterial composition can be used as an adjuvant to a vaccine for the prophylaxis or treatment of an autoimmune disease or an allergic disease (for example, as an adjuvant for a vaccination protocol where the amount of an allergen is gradually increased).
  • the bacterial composition can also be administered to an individual who is also receiving antibiotic treatment.
  • antibiotics that act against Gram+ bacteria such as vancomycin or metronidazole
  • vancomycin or metronidazole can effectively eliminate or greatly reduce bacterial species belonging to the Clostridia class from the gastrointestinal tract of mammals and subsequently decrease the levels of regulatory T cells (Example 5, Fig. 30).
  • the key role of bacteria belonging to the Clostridia class in preserving immune tolerance strongly indicates that their absence or reduced levels can play a key role in autoimmune diseases characterized by failures of immune tolerance. Accordingly, individuals undergoing courses of antibiotics against Gram+ bacteria (for example, individuals being treated for infections with pathogens such as C.
  • the bacterial composition described herein can be administered before, simultaneously with, or after the antibiotic treatment, but preferably it is administered simultaneously or after the antibiotic treatment.
  • the bacterial composition described herein is preferably administered in spore form, to improve its resistance to residual antibiotics.
  • Antibiotics against Gram-positive bacteria include, but are not limited to, vancomycin, metronidazole, linezolid, ramoplanin, fidaxomicin, cephalosporin antibiotics (cephalexin, cefuroxime, cefadroxil, cefazolin, cephalothin, cefaclor, cefamandole, cefoxitin, cefprozil, and ceftobiprole); fluoroquinolone antibiotics (cipro, Levaquin, floxin, tequin, avelox, and norflox); tetracycline antibiotics (tetracycline, minocycline, oxytetracycline, and doxycycline); penicillin antibiotics (amoxicillin, ampicillin, penicillin V, dicloxacillin, carbenicillin, vancomycin, and methicillin); and carbapenem antibiotics (ertapenem, doripenem, imipenem/cilastatin, and meropen
  • a method of obtaining bacteria capable of inducing Tregs comprising (1) isolating the bacterial spore-forming fraction from a fecal or biopsy sample obtained from a mammal, preferably a human (e.g. by chloroform treatment or by heat treatment), (2) optionally, orally administering the spore-forming fraction to a non-human mammal, preferably a germ-free non-human mammal; (3) optionally, obtaining a fecal sample from the non-human mammal, diluting the fecal sample (for example diluting it by volume by a factor of 10, 100, 1,000, or 10,000), thereby producing a diluted fecal sample, and orally administering the diluted sample to a second germ-free non-human mammal, wherein optional step (3) can be repeated more than one time, (4) plating serial dilutions, under aerobic condition or strictly anaerobic conditions, of either the spore-forming fraction obtained in (1) or a sample of intestinal
  • mice used in Examples were prepared or produced as follows. In the following description, mice may be referred to as "SPF” or "GF". These "SPF” and “GF” indicate that the mice were maintained in the absence of specific pathogenic bacteria (specific pathogen-free, SPF), and that the mice were maintained under Germ-Free (GF) conditions, respectively.
  • SPF specific pathogenic bacteria
  • GF Germ-Free
  • C57BL/6, Balb/c, and IQI mice maintained under SPF or GF conditions were purchased from Sankyo Labo Service Corporation, Inc. (Japan), JAPAN SLC, INC. (Japan), CLEA Japan, Inc. (Japan), or The Jackson Laboratory (USA).
  • GF mice and gnotobiotic mice were bred and maintained within the gnotobiotic facility of The University of Tokyo, Yakult Central Institute for Microbiological Research, or Sankyo Labo Service Corporation, Inc.
  • Myd88 -/- , Rip2 -/- , and Card9 -/- mice were produced as described in NPL 1 to 3, and backcrossed for 8 generations or more, so that a C57BL/6 genetic background was achieved.
  • Foxp3 eGFP mice were purchased from the Jackson Laboratory.
  • a targeting construct was first created. Specifically, a cassette (IRES-Venus-SV40 polyA signal cassette, refer to Non-Patent Document 4) which was made of an internal ribosome entry site (IRES), a yellow fluorescent protein (Venus), and a SV40 polyA signal (SV40 polyA) and which was arranged next to a neomycin-resistant gene (neo), was inserted between a stop codon and a polyA signal (Exon 5) of a 1110 gene. Next, the obtained targeting construct was used to cause homologous recombination with the 1110 gene region in the genome of mice.
  • a cassette (IRES-Venus-SV40 polyA signal cassette, refer to Non-Patent Document 4) which was made of an internal ribosome entry site (IRES), a yellow fluorescent protein (Venus), and a SV40 polyA signal (SV40 polyA) and which was arranged next to a neomycin-resistant gene (neo), was
  • Il10 venus mice having an Il10 venus alleles were produced (refer to Fig. 1 ).
  • tk represents a gene coding thymidine kinase
  • neo represents the neomycin-resistant gene
  • BamHl represents a cleavage site by the restriction enzyme BamH1.
  • Genomic DNAs were extracted from the Il10 venus mice, treated with BamHl, and Southern blotted by use of a probe shown in Fig. 1 .
  • Fig. 2 shows the obtained results. Wild-type and Il10 venus alleles were detected as bands having sizes of 19 kb and 5.5 kb, respectively. Hence, as is apparent from the results obtained, the homologous recombination occurred in the genome of the Il10 venus mice.
  • CD4+ Venus- cells or CD4+ Venus+ cells in the colonic lamina intestinal of the Il10 venus mice were sorted by use of a FACSAria. Then, real-time RT-PCR was carried out on an ABI 7300 system by a method to be described later, to determine the amount of IL-10 mRNA expressed. It was found that, since the development of the IL-10 mRNA was detected only in the CD4 + Venus + cells, the expression of IL-10 mRNA in the Il10 venus mice was correctly reflected in the expression of Venus. Note that the germ-free states of such Il10 venus mice were established in Central Institute for Experimental Animals (Kawasaki, Japan). The Il10 venus mice in the germ-free states were maintained in vinyl isolators in Sankyo Labo Service Corporation, Inc. (Tokyo, Japan), and used in the following Examples.
  • mice in which SFB or Clostridium were colonized were produced.
  • Cecal contents or feces of the obtained gnotobiotic mice were dissolved in sterile water or an anaerobic dilution solution.
  • the dissolved cecal contents or feces as they were or after a chloroform treatment were orally administered to GF mice.
  • Three strains of the Lactobacillus and 16 strains of the Bacteroides were cultured separately from each other in a BL or EG agar medium in an anaerobic manner.
  • the cultured bacteria were harvested, suspended in an anaerobic TS broth, and orally administrated forcibly to GF mice.
  • the state of the colonization of the bacteria in the mice was assessed by microscopic observation conducted on a smear preparation of fecal pellets.
  • the small intestine and colon were collected and opened longitudinally.
  • the cecum was also isolated and cecal content was directly frozen at -80°C or suspended in 2 ml PBS, then added 40% glycerol (final concentration 20%), snap-frozen in liquid nitrogen and stored at -80 °C until use.
  • the colon and small intestine were washed in PBS to remove all luminal contents and shaken in Hanks' balanced salt solution (HBSS) containing 5 mM EDTA for 20 min at 37 °C.
  • HBSS Hanks' balanced salt solution
  • the lamina propria layers were cut into small pieces and incubated with RPMI1640 containing 4% fetal bovine serum, 1 mg/ ml collagenase D, 0.5 mg/ml dispase and 40 micro gram/ml DNase I (all Roche Diagnostics) for 1 h at 37 °C in a shaking water bath.
  • the digested tissues were washed with HBSS containing 5 mM EDTA, resuspended in 5 ml of 40% Percoll (GE Healthcare) and overlaid on 2.5 ml of 80% Percoll in a 15-ml Falcon tube.
  • Percoll gradient separation was performed by centrifugation at 800 g for 20 min at 25 °C.
  • the lamina basement lymphocytes were collected from the interface of Percoll gradient and suspended in ice-cold PBS.
  • isolated lymphocytes were labeled with the LIVE/DEAD fixable violet dead cell stain kit (Invitrogen) to exclude dead cells in the analysis.
  • the cells were washed with staining buffer containing PBS, 2% FBS, 2 mM EDTA and 0.09% NaN3 and stained surface CD4 with PECy7-labeled anti-CD4 Ab (RM4-5, BD Biosciences).
  • Intracellular staining of Foxp3 and Helios was performed using the Alexa700-labeled anti-Foxp3 Ab (FJK-16s, eBioscience), Alexa647-labeled anti-Helios (22F6, eBioscience) and Foxp3 Staining Buffer Set (eBioscience).
  • FJK-16s Alexa700-labeled anti-Foxp3 Ab
  • Alexa647-labeled anti-Helios 22F6, eBioscience
  • Foxp3 Staining Buffer Set eBioscience.
  • Th1 and Th17 cells isolated lymphocytes were stimulated for 4 hours with 50 ng/ml phorbol 12-myristate 13-acetate (PMA, Sigma) and 1 micro gram/ml ionomycin (Sigma) in the presence of GolgiStop (BD Biosciences).
  • RNA prepared by using RNeasy Mini Kit Qiagen
  • a cDNA was synthesized by use of a MMV reverse transcriptase (Promega KK).
  • the cDNA obtained was analyzed by real-time RT-PCR using Power SYBR Green PCR Master Mix (Applied Biosystems) and ABI 7300 real time PCR system (Applied Biosystems),or real-time RT-PCR using SYBR Premix Ex Taq (TAKARA) and Light Cycler 480.
  • TAKARA SYBR Premix Ex Taq
  • Light Cycler 480 For each sample, a value obtained was normalized for the amount of GAPDH.
  • a primer set was designed by using Primer Express Version 3.0 (Applied Biosystems), and those exhibiting a 90% or higher sequence identity at an initial evaluation were selected. The primer set used was as follows:
  • the colon was collected, cut open longitudinally, and rinsed with PBS. Subsequently, the colon was treated with 1mM dithiothreitol (DTT) at 37 °C for 30 minutes on a shaker, and then vortexed for one minute to disrupt the epithelial integrity.
  • DTT dithiothreitol
  • the released intestinal epithelial cells (IECs) were collected, and suspended in 5 ml of 20% percoll. The suspension was overlayered on 2.5 ml of 80% percoll in a 15-ml Falcon tube. Then, the tube was centrifuged at 25 °C and 780 g for 20 minutes to conduct cell separation by percoll density gradient centrifugation.
  • IECs obtained collected were suspended in RPMI containing 10% FBS, and 1 x 10 5 cells of the IECs were cultured in a 24-well plate for 24 hours. Thereafter, the culture supernatant was collected, and measured for active TGF- beta 1 level by ELISA (Promega).
  • a fecal suspension from Clostridium-colonized mice was orally administered to C57BL/6 mice (2-week old), which were grown in a conventional environment for six weeks.
  • mice were presensitized by transdermally applying, onto the mice, 150 micro liter of a 3% oxazolone (4-ethoxymethylene-2-phenyl-2-oxazolin-5-one, Sigma-Aldrich)/100% ethanol solution.
  • 150 micro liter of a 1% oxazolone/50% ethanol solution was intrarectally administered again to the presensitized mice under a light anesthesia. Note that the intrarectal administration was conducted by using a 3.5F catheter.
  • Each mouse was analyzed daily for body weight, occult blood, bleeding visible with the naked eyes (gross blood), and the hardness of stool. Moreover, the body weight loss percentage, intestinal bleeding (no bleeding, occult blood (hemoccult+), or bleeding visible with the naked eyes), and the hardness of stool (normal stool, loose stool, or diarrhea) were evaluated numerically, and the disease activity index (DAI) was calculated in accordance with the description in " S. Wirtz, C. Neufert, B. Weigmann, M. F. Neurath, Nat Protoc 2, 541 (2007 )."
  • mice BALB/c SPF mice were inoculated with a fecal suspension from Clostridium-colonized mice (2-week old), and grown in a conventional environment. Then, 1 micro gram of OVA (grade V, Sigma) and 2 mg of alum (Thermo Scientific), 0.2 ml in total, were intraperitoneally injected to the mice (at their ages of 4 weeks and 6 weeks). Sera were collected every week from the mice at the root of their tail, and OVA-specific IgE was measured by ELISA (Chondrex).
  • splenic cells were collected, inoculated in a 96-well plate at 1 x 10 6 cells per well, and stimulated with OVA (100 micro gram/ml) for three days. Thereafter, the culture supernatant was collected, and measured for IL-4 and IL-10 levels by ELISA (R&D).
  • control and experimental groups were evaluated by the Student's t-test.
  • Human stool (2g) from a healthy volunteer (Japanese, male, 29y old) was suspended with 20ml phosphate-buffered saline (PBS) and passed through a 70 micro meter cell strainer to eliminate clumps and debris. Then fecal suspension was mixed with or without chloroform (final concentration 3%), and incubated in a shaking water bath for 60 min. The fecal suspensions without chloroform treatment were orally inoculated into germ-free (GF) mice (250 micro liter/mouse). After evaporation of chloroform by bubbling with N2 gas for 30 min, the aliquots containing chloroform-resistant (spore-forming) fraction of human intestinal bacteria were inoculated into IQI GF mice. Each group of ex-GF mice was separately kept in a vinyl isolator for 3 or 4 weeks.
  • PBS phosphate-buffered saline
  • IQI GF mice were co-housed for 4 weeks with ex-GF mice colonized with chloroform-treated human feces (Example 21 mice) in a vinyl isolator (6 mice, designated as mouse #D1 to #D6
  • the frozen cecal content from ex-GF mice inoculated with chloroform-treated human feces was suspended in 10 times volume (w/v) of PBS, passed through a 70 micro meter cell strainer and treated 3% chloroform. Then the suspension was diluted 2000 (for 4 mice, designated as mouse #E1 to #E4) or 20000 (for 8 mice, designated as mouse #F1 to #F8) -fold with PBS and orally inoculated into GF IQI mice (2.5x10 5 or 2.5x10 4 cells/250 micro liter/mouse). After 4 weeks, lymphocytes were collected from colon and small intestine and analyzed for Foxp3+ Treg cell proportion and their Helios expression. Cecal contents were frozen and stored at -80 °C until use.
  • the frozen cecal content from ex-GF mice inoculated with 20000-fold dilution was suspended in 10 times volume (w/v) of PBS, passed through a 70 micro meter cell strainer and treated 3% chloroform.
  • the suspensions were orally inoculated into GF IQI mice (5, 4 or 4 mice; designated as mouse #G1 to #G5, #H1 to #H4 or #11 to #14, respectively).
  • colon and small intestine were collected and analyzed for Foxp3+ Treg cell proportion and their Helios expression.
  • Cecal contents were suspended in 20% glycerol solution, snap-frozen in liquid nitrogen and stored at - 80 °C.
  • mice The glycerol stock of cecal content from #G2 mouse was diluted with PBS and seeded onto BL agar plate. After 48 hours, all bacterial colonies were collected by scraping the plates with a plate scraper and inoculated into GF IQI mice (4 mice, designated as mouse #K1 to #K 4). Six bacterial strains were isolated from the freeze stock of cecal content from #F8 mouse using BL agar plate. These isolated strains were inoculated into GF IQI mice (4 mice, designated as mouse #J1 to #J4). (Details of the culture method are described below.)
  • bacterial genomic DNA was isolated from the human stool from a healthy volunteer as described above (human stool), cecal contents from GF mice gavaged with chloroform-treated human stool (cecal content of B-4 mouse) or feces from SPF ICR mouse (feces of SPF mouse).
  • the isolated DNA was used as template for quantitative PCR.
  • the amplification program consisted of one cycle at 95°C for 1 min, followed by 50 cycles at 95°C for 10 s and 60 °C for 30 s.
  • Quantitative PCR analysis was carried out using a LightCycler 480 (Roche). Relative quantity was calculated by the delta Ct method and normalized to the amount of total bacteria.
  • the following primer sets were used: total bacteria, 5'-GGTGAATACGTTCCCGG-3'(SEQ ID NO.: 45) and 5'-TACGGCTACCTTGTTACGACTT-3'(SEQ ID NO.: 46); Clostridium cluster XIVa (Clostridium coccoides subgroup), 5'-AAATGACGGTACCTGACTAA-3' (SEQ ID NO.: 47) and 5'-CTTTGAGTTTCATTCTTGCGAA-3'(SEQ ID NO.: 48); Clostridium cluster IV (Clostridium leptum) 5'-CCTTCCGTGCCGSAGTTA-3'(SEQ ID NO.: 49) and 5'-GAATTA AACCACATACTCCACTGCTT-3'(SEQ ID NO.: 50); Bacteroides, 5'-GAGAGGAAGGTCCCCCAC-3'(SEQ ID NO.: 51) and 5'-CGCTACTTGGCTGGTTCAG-3'(SEQ ID NO.: 52); Bifidobacterium
  • mice gavaged with chloroform-treated human stool exhibited high levels of spore-forming bacteria, such as Clostridium clusters XIVa and IV, and a severe decrease of non-spore-forming bacteria, such as Bacteroides and Bifidobacterium, compared with the human stool before chloroform treatment.
  • spore-forming bacteria such as Clostridium clusters XIVa and IV
  • non-spore-forming bacteria such as Bacteroides and Bifidobacterium
  • each 50- micro L reaction contained 40 ng of DNA, 5 micro liter of 10 X Ex Taq buffer (TAKARA), 5 micro liter of 2.5 mM dNTP mixture, 0.2 micro liter Ex Taq and 0.2 micro M of each primer.
  • PCR conditions consisted of an initial denaturation step performed at 96 °C for 2 min, followed by 20 cycles of denaturation (96 °C, 30 s), annealing (55 °C, 45 s) and amplification (72 °C, 1 min) and final amplification step performed at 72 °C for 10 min.
  • Amplicons generated from each sample were subsequently purified using AMPur XP (Beckman Coulter).
  • the amount of DNA was quantified using Quant-iT Picogreen dsDNA Assay Kit (Invitrogen) and TBS-380mini Fluorometer (Turner Biosystems).
  • the amplified DNA were used as template for 454 GS Junior (Roche) pyrosequencing.
  • sequences were performed using GS Junior Titanium emPCR Kit-Lib-L, GS Junior Titanium Sequencing Kit and GS Junior Titanium PicoTiterPlate Kit (all Roche) according to the manufacturer's manuals (GS Junior Titanium Series, emPCR Amplification Method Manual - Lib-L and Sequencing Method Manual).
  • Resulting sequences (3400 reads were produced for each sample) were classified into OTU on the basis of sequence similarity (>97% identity). Representative sequences from each OTU were compared with sequences in nucleic acid databases (Ribosomal Database Project) using BLAST to determine the closest relatives. Then, OTUs were classified into species on the basis of the closest relatives. All data of close relatives and the number of reads are shown in Table. 1.
  • Bacterial strains were isolated from the cecal contents of #F8, #G2, #11 and #K3 by plating serial dilutions of the cecal samples under aerobic condition or strictly anaerobic conditions (80% N2 10% H2 10% CO2) onto BL agar (Eiken Chemical) or EG agar plates containing medium with the following components (quantities expressed per liter): Meat extract 500 ml; Proteose peptone No.3 (10.0 g, Difco); Yeast Extract (5.0 g, Difco); Na2HPO4 (4.0 g); D(+)-Glucose (1.5 g); Soluble Starch (0.5 g); L-cystine (0.2 g), L-cysteine-HCl-H2O (0.5g); Tween80 (0.5 g); Bacto Agar (16.0 g, Difco); defibrinated horse blood (50 ml).
  • TS medium (27.5g of trypticase soy broth w/o dextrose, 0.84 g of Na2CO3, 0.5 g of L-cysteine-HCl-H2O, 1000 ml of distilled water, pH adjusted to 7.2 +/- 0.2 with NaOH, then autoclaved for 15 minutes at 115 degrees Celsius).
  • 16SrRNA coding gene sequences were performed.
  • the 16S rRNA genes were amplified by colony-PCR using KOD FX (TOYOBO), 16S rRNA gene-specific primer pairs: 8F (5'-AGAGTTTGATCMTGGCTCAG-3'(SEQ ID NO.: 57)) and 519R (5'-ATTACCGCGGCKGCTG-3'(SEQ ID NO.: 58)) for C. indolis, C. bolteae, Bacteroides sp. MANG, L. bacterium DJF_VP30, A.colihominis, Ruminococcus sp. ID8, C. lavalense, C. symbiosum and E.
  • Each amplified DNA was purified from the reaction mixture using Illustra GFX PCR DNA and Gel Band Purification Kit (GE Healthcare). Sequence analysis was performed using BigDye Terminator V3.1 Cycle Sequencing Kit (Applied Biosystems) and Applied Biosystems 3730xl DNA analyzer (Applied Biosystems). The resulting sequences were compared with sequences in nucleic acid databases using BLAST to determine the closest relatives. The closest relatives and % identity of all isolated strains, information for genus-species of the closest relatives, Clostridium cluster, ID of mouse from which was derived, maximum similarity and culture medium of isolated strains were summarized in Table 2.
  • Example 1 First, it was investigated whether or not accumulation of regulatory T cells (Treg cells) in the colonic lamina intestinal was dependent on commensal bacteria. Specifically, lymphocytes were isolated from peripheral lymph nodes (pLN) of Balb/c mice bred in the absence of specific pathogenic bacteria (SPF) or from lamina intestinal of the colon or the small intestine (SI) of the mice. The CD4 and Foxp3 were stained by antibodies. Then, the ratio of Foxp3 + cells in CD4 + lymphocytes was analyzed by flow cytometry.
  • SPPF peripheral lymph nodes
  • SI small intestine
  • Example 2 Next, it was investigated whether or not the temporal accumulation of the Treg cells in the colon as found in Example 1 had a relationship with the colonization of intestinal commensal microbiota. Specifically, the expression of CD4 and the expression of Foxp3 in lymphocytes isolated from the small intestine, the colon, and the peripheral lymph nodes of mice bred under a germ-free (GF) or SPF environment (8 weeks old: Balb/c mice, IQI mice, and C57BL/6 mice) were analyzed. Similar results were obtained in three or more independent experiments. In addition, lamina intestinal lymphocytes were collected from SPF mice and GF mice (Balb/c mice or C57BL/6 mice). CD4 and Foxp3 were stained with antibodies.
  • GF germ-free
  • SPF environment 8 weeks old: Balb/c mice, IQI mice, and C57BL/6 mice
  • lymphocytes were analyzed by FACS. Further, lymphocytes were isolated from the lamina intestinal of the colon, the lamina intestinal of the small intestine (SI), Peyer's patches (PPs), and mesenteric lymph nodes (MLNs) of mice (SPF C57BL/6 mice) to which antibiotics were orally administered with water for eight weeks. CD4 and Foxp3 were stained with antibodies. Then, the lymphocytes were analyzed by FACS. Similar results (the ratio of the Foxp3 + cells in the CD4 + cells of an individual mouse) were obtained in two or more independent experiments. Note that the following antibiotics were used in combination in accordance with the description in the following document:
  • Example 3 Next, it was directly checked whether or not the decrease in the number of the Treg cells in the colonic lamina intestinal lamina intestinal of the GF mice shown in Example 2 was attributed to the absence of microbiota. Specifically, a fecal suspension of B6 SPF mice purchased from The Jackson Laboratory was orally administered to GF-IQI mice (conventionalization). Three weeks after the administration, lymphocytes were isolated from the colonic lamina intestinal lamina intestinal lamina intestinal lamina intestinal lamina intestinal lamina intestinal lamina intestinal lamina intestinal lamina basement was not change. However, the number of the Treg cells in the colonic lamina basement increased significantly. Hence, it was shown that host-microbial interaction played an important role in the accumulation of Foxp3 + Treg cells in the colonic lamina intestinal lamina intestinal lamina intestinal lamina intestinal lamina intestinal lamina intestinal lamina intestinal lamina intestinal lamina intestinal lamina intestinal lamina intestinal lamina intestinal lamina intestinal lamina
  • Example 4 Next, the relationship between the gut-associated lymphoid tissues of mice and the number of Foxp3 + cells in the colonic lamina intestinal of the mice was investigated in accordance with the method described in M. N. Kweon et al., J Immunol 174, 4365 (Apr 1, 2005 ). Specifically, 100 micro gram of an extracellular domain recombinant protein (a fusion protein (LT beta R-Ig) between a lymphotoxin beta receptor (LT beta R) and a Fc region of human IgG1, refer to Honda et al., J Exp Med 193, 621 (Mar 5, 2001 )) was injected intraperitoneally into pregnant C57BL/6 mice 14 days after conception.
  • a fusion protein LT beta R-Ig
  • LT beta R lymphotoxin beta receptor
  • the LT beta R-Ig was again injected intraperitoneally into fetuses obtained from such mice, so that mice from which isolated lymphoid follicles (ILFs), Peyer's patches (PPs), and colonic-patches (CPs) were completely removed were produced. Then, the ratios of Foxp3 + cells in CD4+ cells in the colonic lamina intestinal of the mice treated with the LT beta R-Ig, and mice treated with rat IgG (control) were analyzed by FACS.
  • IPFs isolated lymphoid follicles
  • PPs Peyer's patches
  • CPs colonic-patches
  • Example 5 To investigate whether or not a specific intestinal flora induced the accumulation of colonic Treg cells, vancomycin as an antibiotic against Gram-positive bacteria or polymyxin B as an antibiotic against Gram-negative bacteria was administered to SPF mice (from 4 weeks of age) for four weeks, and analyzed for the ratio of Foxp3 + cells in the CD4 + cell group ([%] Foxp3 + in CD4).
  • Example 6 A recent report has suggested that spore-forming bacteria play an important role in intestinal T cells response (see V. Gaboriau-Routhiau et al., Immunity 31, 677 (Oct 16, 2009 )).
  • fecal microorganisms spore-forming fraction
  • 3% chloroform were orally administered to GF mice, which were then analyzed for the ratio of Foxp3 + cells in the CD4+ cell group ([%] Foxp3 + in CD4).
  • the number of Treg cells in the administered mice was markedly increased to the same level as those of the SPF mice and the GF mice to which the untreated feces was forcibly administered.
  • Example 5 it was revealed that the specific components of the indigenous microbiota were highly likely to belong to the Gram-positive group, and that the spore-forming fraction played an important role in the induction of Treg cells.
  • Example 7 Next, the species of the intestinal microbiota which induced the accumulation of Treg cells in the colon as suggested in Examples 4 to 6 were identified. Specifically, segmented filamentous bacteria (SFB), 16 strains of the Bacteroides spp. (Bactero. (6 strains of B. vulgatus, 7 of the B. acidifaciens group 1, and 3 of the B. acidifaciens group 2)), 3 strains of the Lactobacillus (Lacto. (L. acidophilus, L . fermentum , and L. murinum) ), and 46 strains of Clostridium spp. (Clost., refer to " Itoh, K., and Mitsuoka, T.
  • mice Characterization of clostridia isolated from faeces of limited flora mice and their effect on caecal size when associated with germ-free mice. Lab. Animals 19: 111-118 (1985 ))"), or microbiota collected from mice (SPF) bred under a conventional environment was orally administered to GF-Balb/c mice or GF-IQI mice. The mice were maintained in vinyl isolators for three weeks. Then, CD4 cells were isolated from the colon and the small intestine of these mice. The numbers of Treg cells in the colon and the small intestine were analyzed by flow cytometry.
  • the bacteria belonging to the genus Clostridium are classified by sequencing of 16S rRNA gene, as follows. Specifically, the 16S rRNA genes of the bacteria were amplified by PCR using 16S rRNA gene-specific primer pairs:
  • mice in which the segmented filamentous bacteria (SFB) were colonized gave similar results.
  • the accumulation of Foxp3 + cells in the colonic lamina intestinal was strongly induced in the mice in which 46 strains of Clostridium spp. were colonized.
  • such accumulation was promoted irrespective of the genetic backgrounds of the mice, and led to the increase in number similar to that in the SPF mice although intestinal microbiota of only a single genus were colonized.
  • Example 8 Next, CD4 expression, Foxp3 expression, and Helios expression in LP lymphocytes of the thymuses and the colons of SPF mice, GF mice, Lactobacillus-colonized mice, and Clostridium-colonized mice were analyzed by flow cytometry.
  • Example 9 Next, it was investigated whether or not the colonization of the Clostridium or the like had an influence on other T cells. Specifically, SFB, 16 strains of Bacteroides spp. (Bactero.), 46 strains of Clostridium spp. (Clost.), or microbiota collected from mice bred under a conventional environment (SPF) was colonized in GF IQI mice. Three weeks later, lymphocytes in the colonic lamina intestinal were isolated from these mice, and stimulated with PMA (50 ng/ml) and ionomycin (1 micro gram/ml) for four hours in the presence of Golgistop (BD Bioscience).
  • PMA 50 ng/ml
  • ionomycin (1 micro gram/ml
  • Example 10 It has been reported that 46 strains of Clostridium spp. exert an influence on the accumulation of CD8 + intestinal tract intraepithelial lymphocytes (IELs) in the colon. Accordingly, it is conceivable that Clostridium regulates the immune system in various aspects, and that Clostridium exhibits a marked ability to induce and maintain Treg cells especially in the colon, as described above. In addition, a kind of cytokines, transforming growth factor- beta (TGF- beta), is known to play an important role in regulation of Treg cell generation.
  • TGF- beta transforming growth factor- beta
  • intestinal epithelial cells IECs
  • Clostridium-colonized mice were cultured for 24 hours, and the culture supernatants thereof were measured for the concentration of active TGF- beta (TGF- beta 1) by ELISA (the number of mice analyzed was four per group).
  • TGF- beta was detected in the culture supernatant of the IECs isolated from the Clostridium-colonized mice, whereas no TGF- beta was detected in the culture supernatant of the IECs isolated from the GF mice.
  • splenic CD4 + T cells were cultured for five days together with a 50% conditioned medium in which IECs isolated from the GF mice or the Clostridium-colonized mice were cultured, and with the anti-CD3 antibody, in the presence or absence of an anti-TGF- beta antibody. Then, the T cells were collected, and analyzed for expression of Foxp3 by real-time RT-PCR.
  • MMP2, MMP9, and MMP13 which are thought to contribute to the activation of latent TGF- beta was investigated.
  • IDO indoleamine 2,3-dioxygenase
  • 46 bacterial strains of the genus Clostridium (Clost.), or three bacterial strains of the genus Lactobacillus (Lacto.) were orally administered to C57BL/6 germ-free mice. Three weeks after administration, IECs were collected, and analyzed for relative mRNA expression levels of MMP2, MMP9, MMP13, and IDO genes by real-time RT-PCR (the number of mice analyzed was three per group).
  • IDO was expressed only in the Clostridium-colonized mice. Accordingly, it was revealed that the Clostridium activated the IECs, and led to the production of TGF- beta and other Treg cell-inducing molecules in the colon.
  • Example 11 Next, it was investigated whether or not the Treg cell accumulation induced by the colonization of the Clostridium was dependent on signal transmission by pathogen-associated molecular pattern recognition receptors. Specifically, the numbers of Treg cells in the colonic lamina intestinal of each SPF mice of Myd88 -/- (deficient in Myd88 (signaling adaptor for Toll-like receptor)), Rip2 -/- (deficient in Rip2 (NOD receptor adaptor)), and Card9 -/- (deficient in Card9 (essential signal transmission factor for Dectin-1 signal transmission)) were examined. In addition, Clostridium spp.
  • Example 12 Intestinal tract Foxp3 + Treg cells are known to exert some immunosuppressive functions through IL-10 production (refer to NPL 9). Meanwhile, animals having CD4+Foxp3 + cells from which IL-10 is specifically removed are known to develop inflammatory bowel disease (refer to NPL 18). In this respect, first, the expression of IL-10 in lymphocytes of various tissues was examined. Specifically, lymphocytes were isolated from various tissues of SPF Il10 venus mice, and the expression of CD4 and the expression of Venus were analyzed by flow cytometry.
  • T cell receptor beta chain TCR beta
  • Lymphocytes in the colonic lamina intestinal lamina intestinal lymphocytes were isolated from Il10 venus mice.
  • the lymphocytes were stimulated with PMA (50 ng/ml) and ionomycin (1 micro gram/ml) for four hours in the presence of Golgistop (BD Bioscience).
  • PMA 50 ng/ml
  • ionomycin 1 micro gram/ml
  • Golgistop Golgistop
  • intracellular cytokines were stained by using an anti-IL-17 PE antibody, an anti-IL-4 APC antibody (11B11), and an anti-IFN-g FITC antibody (BD Bioscience) in accordance with the manual of a cytofix/cytoperm kit (BD Bioscience).
  • Foxp3 + CD4 + cells and Foxp3 - CD4 + cells were isolated from the spleen (Spl) of Foxp3 eGFP reporter mice, and Venus + cells were isolated from the colonic lamina intestinal and the small intestine (SI) lamina intestinal of Il10 venus mice.
  • the obtained cells were analyzed in terms of expression of predetermined genes.
  • the gene expression was analyzed by real-time RT-PCR using a Power SYBR Green PCR Master Mix (Applied Biosystems) and an ABI 7300 real time PCR system (Applied Biosystems). Here, the value for each cell was normalized for the amount of GAPDH.
  • the Venus + CD4 + T cells expressed Foxp3 and other Treg cell-associated factors such as a cytotoxic T-Lymphocyte antigen (CTLA-4) and a glucocorticoid-induced TNFR-associated protein (GITR), although the Venus + CD4 + T cells showed none of the phenotypes of Th2 (IL-4-producing) and Th17 (IL-17-producing). It was shown that the expression level of CTLA-4 in the intestinal Venus + cells was higher than that in the splenic GFP + Treg cells isolated from the Foxp3 eGFP reporter mice.
  • CTLA-4 cytotoxic T-Lymphocyte antigen
  • GITR glucocorticoid-induced TNFR-associated protein
  • Example 13 Venus + cells can be classified into at least two subsets, namely, Venus + Foxp3 + double positive (DP) Treg cells and Venus+ Foxp3 - Treg cells on the basis of intracellular Foxp3 expression.
  • Cells of the latter subset correspond to type 1 regulatory T cells (Trl) (refer to NPL 8 and 9).
  • Trl type 1 regulatory T cells
  • the Venus + cells (IL-10-producing cells) observed in Example 8 were investigated in terms of the expression of Foxp3.
  • antibiotics were orally given with water to five or six Il10 venus mice per group for 10 weeks.
  • the following antibiotics were used in combination.
  • ampicillin A; 500 mg/L Sigma
  • vancomycin V; 500 mg/L NACALAI TESQUE, INC.
  • metronidazole M; 1 g/L NACALAI TESQUE, INC.
  • neomycin N; 1 g/L NACALAI TESQUE, INC.
  • CD4 and Foxp3 of lymphocytes in the lamina intestinal of the colon, the lamina intestinal of the small intestine (SI), mesenteric lymph nodes (MLN), and Peyer's patches (PPs) were stained with antibodies, and analyzed by FACS. The results were obtained from two or more independent experiments which gave similar results.
  • Example 14 It was investigated whether or not Venus + cells induced by the genus Clostridium had an immunosuppressive function similar to that of Venus + cells in the colon of SPF mice. Specifically, CD4 + CD25 - cells (effector T cells, Teff cells) isolated from the spleen were seeded in a flat-bottomed 96-well plate at 2 x 10 4 /well, and cultured for three days together with 2 x 10 4 splenic CD11c + cells (antigen-representing cells) subjected to 30 Gy radiation irradiation treatment, 0.5 micro gram/ml of an anti-CD3 antibody, and a lot of Treg cells.
  • CD4 + CD25 - cells effector T cells, Teff cells isolated from the spleen were seeded in a flat-bottomed 96-well plate at 2 x 10 4 /well, and cultured for three days together with 2 x 10 4 splenic CD11c + cells (antigen-representing cells) subjecte
  • CD4 + CD25 - cells were cultured, with [3H]-thymidine (1 micro Ci/well) was added thereto.
  • Treg cells used in Example 14 were CD4 + GFP + T cells isolated from the spleen of Foxp3 eGFP reporter mice, or CD4 + Venus + T cells in the colonic lamina intestinal of GF Il10 v enus mice in which Clostridium spp. were colonized or SPF Il10 venus mice. Then, proliferation of the cells was determined based on the uptake amount of [ 3 H]-thymidine, and represented by a count per minute (cpm) value.
  • cpm count per minute
  • Example 15 Next, the influence of the colonization of a large number of Clostridium on the local immune response and the resultant proliferation of Treg cells were investigated.
  • the DSS-induced colitis model was prepared as described above, and the influence on the model mice of the inoculation of the Clostridium and the proliferation of Treg cells was investigated. Specifically, control mice and Clostridium-inoculated mice were treated with 2% DSS, then observed and measured for six days for body weight loss, the hardness of stool, and bleeding, and then were evaluated numerically. In addition, on day 6, the colons were collected, dissected, and analyzed histologically by HE staining.
  • mice having a large number of Clostridium hereinafter also referred to as "Clostridium-abundant mice”
  • control mice C57BL/6 mice grown in a conventional environment for six weeks and not inoculated with the fecal suspension.
  • histological features such as mucosal erosion, edema, cellular infiltration, and crypt loss were less severe in the DSS-treated Clostridium-abundant mice than in the control mice.
  • mice and Clostridium-inoculated mice were sensitized with oxazolone, and subsequently the inside of the rectums thereof were treated with a 1% oxazolone/50% ethanol solution. Then, body weight loss was observed and measured. In addition, the colons were dissected, and analyzed histologically by HE staining.
  • the results show that the colitis proceeded along with persistent body weight loss in the control mice. Meanwhile, the body weight loss of the Clostridium-abundant mice was reduced. In addition, it was also revealed that portions having histological diseases such as mucosal erosion, edema, cellular infiltration , and hemorrhage were reduced in the colon of the Clostridium-abundant mice.
  • Example 16 Next, the influence, on the systemic immune response (systemic IgE production), of the colonization of a large number of Clostridium and the resultant proliferation of Treg cells was investigated. Specifically, as described above, control mice and Clostridium-inoculated mice were immunized by administering alum-absorbed ovalbumin (OVA) twice at a 2-week interval. Then, sera were collected from these mice, and the OVA-specific IgE level thereof was investigated by ELISA. In addition, splenic cells were collected from the mice in each group, and IL-4 and IL-10 production by in-vitro OVA restimulation was investigated.
  • OVA ovalbumin
  • Results show that the IgE level was significantly lower in the Clostridium-abundant mice than in the control mice. Moreover, the IL-4 production by the OVA restimulation was reduced and the IL-10 production thereby was increased in the splenic cells of the Clostridium-abundant mice sensitized with OVA and alum, in comparison with those of the control mice.
  • Example 17 Next, GF Balb/c were colonized with three strains of Clostridium belonging to cluster IV(strains 22, 23 and 32 listed in Fig.49). Three weeks later, colonic Foxp3 + Treg cells were analyzed by FACS. Results show that gnotobiotic mice colonized with three strains of Clostridium showed an intermediate pattern of Treg induction between GF mice and mice inoculated with all 46 strains.
  • Example 18 Next, it was investigated whether or not a spore-forming (for example, a chloroform resistant) fraction of a fecal sample obtained from humans had the effect of inducing proliferation or accumulation of regulatory T cells similar to the spore-forming fraction of the fecal sample obtained from mice.
  • a spore-forming (for example, a chloroform resistant) fraction of a fecal sample obtained from humans had the effect of inducing proliferation or accumulation of regulatory T cells similar to the spore-forming fraction of the fecal sample obtained from mice.
  • the colon was collected and opened longitudinally, washed to remove fecal content, and shaken in Hanks' balanced salt solution (HBSS) containing 5 mM EDTA for 20 min at 37 °C. After removing epithelial cells and fat tissue, the colon was cut into small pieces and incubated with RPMI1640 containing 4% fetal bovine serum, 1 mg/ml collagenase D, 0.5 mg/ml dispase and 40 micro gram/ml DNase I (all manufactured by Roche Diagnostics) for 1 hour at 37 °C in a shaking water bath.
  • HBSS Hanks' balanced salt solution
  • the digested tissue was washed with HBSS containing 5 mM EDTA, resuspended in 5 ml of 40% Percoll (manufactured by GE Healthcare) and overlaid on 2.5 ml of 80% Percoll in a 15-ml Falcon tube. Percoll gradient separation was performed by centrifugation at 780 g for 20 min at 25 °C. The interface cells were collected and suspended in staining buffer containing PBS, 2% FBS, 2 mM EDTA and 0.09% NaN3 and stained for surface CD4 with Phycoerythrin-labeled anti-CD4 Ab (RM4-5, manufactured by BD Biosciences).
  • RM4-5 Phycoerythrin-labeled anti-CD4 Ab
  • Intracellular staining of Foxp3 was performed using the Alexa647-labeled anti-Foxp3 Ab (FJK-16s, manufactured by eBioscience) and Foxp3 Staining Buffer Set (manufactured by eBioscience).
  • the percentage of Foxp3 positive cells within the CD4 positive lymphocyte population was analyzed by flow cytometry. Results show that when the spore-forming (for example, the chloroform resistant) fraction of human intestinal bacteria was colonized in GF mice, the accumulation of Foxp3+ regulatory (Treg) cells in the colonic lamina intestinal of the mice was induced. Next, it was investigated what species of bacteria grew by gavaging with chloroform-treated human stool.
  • bacterial genomic DNA was isolated from the human stool from a healthy volunteer as described above (human stool) or fecal pellets from GF mice gavaged with chloroform-treated human stool (GF+Chloro.).
  • Quantitative PCR analysis was carried out using a LightCycler 480 (manufactured by Roche). Relative quantity was calculated by the delta Ct method and normalized to the amount of total bacteria, dilution, and weight of the sample. The following primer sets were used:
  • Results show that gavaged with chloroform-treated human stool had large amounts of spore-forming bacteria, such as Clostridium clusters XIVa and IV, and a severe decrease of non-spore-forming bacteria, such as Bacteroides, compared with the human stool before chloroform treatment.
  • spore-forming bacteria such as Clostridium clusters XIVa and IV
  • non-spore-forming bacteria such as Bacteroides
  • Example 19 Human stool (2g) from a healthy volunteer (Japanese, male, 29y old) was suspended with 20ml phosphate-buffered saline (PBS), mixed with or without chloroform (final concentration 3%), and incubated in a shaking water bath for 60 min. The chloroform was then evaporated by bubbling with N2 gas for 30 min. The suspensions of untreated human feces (designated as 'huUT') and chloroform-treated human feces (designated as 'huChloro') were orally inoculated into Germ-free (GF) mice (IQI, 8 week old) (250 micro liter/mouse).
  • PBS phosphate-buffered saline
  • chloroform final concentration 3%
  • the suspension of huUT was inoculated into 4 GF mice, which were numbered from #A1 to #A4, and that of huChloro was inoculated into 4 GF mice numbered from #B1 to #B4.
  • Such GF mice which were inoculated with suspensions of feces or the like are also referred to as "ex-GF mice” hereinafter.
  • Each group of ex-GF mice was separately kept in a vinyl isolator to avoid further microbial contamination.
  • the small intestinal and colonic lamina limba lymphocytes from each mouse were separately collected, and examined for the expressions of surface CD4 and intracellular Foxp3, Helios, IL-17 and IFN- gamma by flow cytometry.
  • IL-17 and IFN- gamma staining isolated lymphocytes were stimulated in vitro with PMA and ionomycin for 4 hours.
  • Foxp3 is the transcription factor essential for the differentiation and function of Treg cells.
  • Helios is a member of the Ikaros transcription factor family and Helios- Foxp3+ Treg cells have been suggested to be Treg cells induced in the periphery [so called induced Treg (iTreg) cells].
  • iTreg induced Treg
  • Example 20 To investigate whether dead bacteria also have an effect on the induction of Treg cells, the suspension of chloroform-treated human feces was autoclaved (121 °C for 20 min) and orally inoculated into GF mice (once a week for 4 weeks). After 4 weeks, mice were sacrificed, and the colonic lamina intestinal lymphocytes from each mouse were examined for the expression of CD4, Foxp3 and Helios by flow cytometry. As shown in Fig. 2 , the inoculation of dead bacteria exhibited no effect on the numbers of Foxp3+ cells or Helios-Foxp3+ cells. These results do not rule out the possibility that the amount of dead bacteria inoculated was not sufficient, but suggest that live bacteria are required for the induction of Treg cells.
  • Example 21 To confirm the induction of Treg cells by chloroform-resistant bacteria, another stool was obtained from the same person on a different day, treated with chloroform, and inoculated into IQI GF mice (7 mice, numbered from #C1 to C7). After 3-4 weeks, mice from #C1 to #C5 were sacrificed, and the small intestinal and colonic lamina intestinal lymphocytes from each mouse were separately collected, and examined for the expression of CD4 and Foxp3 by flow cytometry. Consistent with the findings in Example 19, colonization with chloroform-treated human feces significantly induced the accumulation of Foxp3+CD4+ Treg cells in colonic and small intestinal laminalitis ( Fig. 3 ). These results further support the notion that chloroform-resistant spore-forming bacteria can induce differentiation, proliferation and/or recruitment of Treg cells in intestinal lamina limbal.
  • Example 22 To test whether Treg cell induction by chloroform-resistant spore-forming fraction of human intestinal bacteria is horizontally transmissible, IQI GF mice (6 mice, numbered from #D1 to #D6) were cohoused for 4 weeks with mice #C6 and #C7 in the same cage in a vinyl isolator. Lamina basement lymphocytes from colon and small intestine were isolated and examined for CD4 and Foxp3. Cohoused mice exhibited a significant increase in the percentage of Foxp3+ cells among CD4+ cells ( Fig. 4 ). Therefore, Treg cell induction by human intestinal bacteria is horizontally transmissible. These results let us assume a role of prominent components of the intestinal microbiota, rather than minor components, for the induction of Treg cells.
  • Example 23 The frozen stock of cecal content from mouse #C4 was thawed, suspended in 10 times its volume (w/v) of PBS, and passed through a 70 micro meter cell strainer. The suspension was then treated with 3% chloroform, diluted 2000- or 20000-fold with PBS, and orally inoculated into GF IQI mice (2.5x10 5 or 2.5x10 4 bacterial cells / 250 micro liter / head, respectively). The 2000-fold diluted sample was orally inoculated into 4 mice (designated as exGF+2000, numbered from #E1 to #E4), whereas 20000-fold diluted sample was inoculated into 8 mice (designated as exGF+20000, numbered from #F1 to #F8).
  • the intestinal lamina propria lymphocytes were isolated and examined for CD4, Foxp3 and Helios. Both 2000- and 20000-fold diluted samples similarly induced a marked accumulation of Foxp3+CD4+ cells in the intestinal lamina propria ( Fig. 5 ). Therefore, the dose of bacteria for oral inoculation can be minimized to less than 2.5x10 4 bacterial cells.
  • Example 24 The frozen stock of cecal content from mouse #F3, #F7 or #F8 was suspended in 10 times its volume (w/v) of PBS, passed through a 70 micro meter cell strainer, and treated with 3% chloroform. Then, the fecal suspension from mouse #F3 was orally inoculated into 5 GF mice (numbered from #G1 to #G5), that from #F7 mouse into 4 GF mice (numbered from #H1 to #H4), and that from #F8 mouse into 4 GF mice (numbered from #11 to #14). After 4 weeks, lymphocytes from colonic and small intestinal lamina basement were isolated and examined for CD4, Foxp3 and Helios expression by flow cytometry.
  • mice exhibited a significant increase in the percentage of Foxp3 + cells among CD4 + cells in the intestinal lamina propria compared with untreated GF mice ( Fig. 6 ). Therefore, the Treg cell induction by human intestinal bacteria colonizing in exGF+20000 mice is also transmissible. Moreover, as shown in the later meta 16S rDNA sequencing data ( Fig. 8 ), these mice commonly had bacteria having 16S rDNA sequence similarities with 16S rDNA sequence similarities with 20 species of known bacteria (C. aminophilum, H. saccgarovorans, E. fissicatena, H.filiformis, C. clostridioforme, C. indolis, C.
  • Example 25 A frozen stock of the cecal content from #F8 mouse was serially diluted with 0.85% NaCl under an aerobic condition and plated onto BL agar. After culture at 37 °C for 2 or 4 days, 50 single colonies were observed. Of the 50 colonies, 29 were picked up, cultured for additional 2 or 4 days at 37 °C by ABCM broth, and stored in EG stock medium (10% DMSO) at -80°C. The genomic DNA from each colony was isolated, and 16S rRNA coding gene sequence was analyzed.
  • the sequence of 16S rRNA of each colony revealed that the 29 colonies observed were represented by three strains, each having 100 % similarity with Clostridium ramosum, 99.75 % with Clostridium saccharogumia, 100 % with Flavonifractor plautii, 99.17 % with Clostridium hathewayi, 99.23 % with Clostridium scindens, or 99.66 % with Clostridium sp. 2335. Within the 29 colonies that were selected from the original 50 colonies, only Clostridium saccharogumia, Clostridium ramosum, and Flavonifractor plautii were present (25, 3, and 1 colonies, respectively).
  • Example 26 The frozen glycerol stock of cecal content from #G2 mouse was suspended with PBS, seeded onto BL agar plate, and incubated for 48 hours, similarly to the procedure done in Example 19. Different from Example 19, all bacteria on the plate were collected by scraping with a plate scraper, suspended in TS broth and inoculated into GF IQI mice (4 mice, numbering from #K1 to #K4). It should be noted that the bacterial suspension used in this experiment included bacteria that did not propagate but survived on the plate. After 4 weeks, lamina intestinal lymphocytes from colon and small intestine of K1 ⁇ K4 mice were isolated and examined for CD4, Foxp3 and Helios expression.
  • mice exhibited a significant increase in the percentages of Foxp3 + cells among CD4 + cells ( Figs. 9A, 9B ) and Helios - cells among Foxp3 + Treg cells ( Figs. 9A, 9C ) in the intestinal lamina intestinal compared with untreated GF mice.
  • Figs. 9A, 9B CD4 + cells
  • Figs. 9A, 9C Helios - cells among Foxp3 + Treg cells
  • Example 27 Bacterial DNA was extracted from the cecal contents of mouse #A1, #C4, #F8, #G2, #H3, #13, #J3 and #K3.
  • Variable region 1-2 (V1-2) in bacterial 16S rRNA coding gene were amplified by PCR and used as template for metasequencing.
  • Resulting sequences (3400 reads for each sample) were classified into operational taxonomic units (OTUs) on the basis of sequence similarity (>97 % identity). Representative sequences from each OTU were compared with sequences in nucleic acid databases using BLAST to determine their closest relatives in known species. The numbers of detected reads and the closest relatives for each OTU are shown in Table 1.
  • Fig. 8 The relative abundances of OTUs having the same closest relative in each cecal sample are shown in Fig. 8 .
  • mouse #A1 153 OTUs (their closest relatives were 93 species) were identified and half of them were related to Bacteroides species.
  • mouse #C4 113 OTUs were identified and most of them were related to species belonging to the family Clostridiaceae.
  • mouse #F8, #G2, #H3, #13, #J3 and #K3, 97-68 OTUs were identified.
  • Treg cell accumulation was observed in the intestine
  • the majority of bacteria consisted of bacteria having 16S rDNA sequence similarities with C. aminophilum, H. saccgarovorans, E.
  • fissicatena H.filiformis, C. clostridioforme, C. indolis, C. bolteae, Bacteroides sp. MANG, L. bacterium DJF_VP30, Ruminococcus sp. ID8, C. lavalense, C. symbiosum, E. contortum, C. saccharogumia, C. ramosum, F. plautii, C. scindens, Clostridium sp. 2335, Clostridium sp. 14616 and cf Clostridium sp. MLG055.
  • Example 28 Bacterial strains were isolated from the cecal contents of mouse #F8, #G2, #11 and #K3 using BL agar or EG agar plates. Applicant picked-up 144 colonies from EG agar plates and 116 colonies from BL agar plates. BLAST search of 16S rRNA coding sequence of these clones revealed that they belonged to 17 species, and each had 93 - 100% similarities with C. indolis, C. bolteae, Bacteroides sp. MANG, L. bacterium DJF_VP30, A.colihominis, Ruminococcus sp. ID8, C. lavalense, C. symbiosum, E. contortum, C.
  • Clostridium clusters IV, XIVa or XVIII (2 species of cluster IV, 12 of cluster XIVa, 1 of cluster XVI and 2 of cluster XVIII).
  • Example 29 Of the colonies selected in Example 28, additional colonies were picked and isolated and these strains were cultured using EG and BL media. BLAST search of 16S rRNA coding sequence of these clones revealed that they belonged to a total of 31 species (including the species mentioned in Example 28), and each had 93 - 100% similarities with Clostridium saccharogumia, Clostridium ramosum JCM1298, Clostridium ramosum, Flavonifractor plautii, Pseudoflavonifractor capillosus ATCC 29799, Clostridium hathewayi, Clostridium saccharolyticum WM1, Bacteroides sp.
  • MANG Clostridium saccharolyticum, Clostridium scindens, Lachnospiraceae bacterium 5_1_57FAA, Lachnospiraceae bacterium 6_1_63FAA, Clostridium sp. 14616, Clostridium bolteae ATCC BAA-613, cf. Clostridium sp.
  • MLG055 Erysipelotrichaceae bacterium 2_2_44A, Clostridium indolis, Anaerostipes caccae, Clostridium bolteae, Lachnospiraceae bacterium DJF_VP30, Lachnospiraceae bacterium 3_1_57FAA_CT1, Anaerotruncus colihominis, Anaerotruncus colihominis DSM 17241, Ruminococcus sp.
  • Example 30 To investigate whether the strains in Example 29 have the ability to induce Tregs in GF mice, 31 strains on Table 3 were mixed at equal amounts of media volume using TS media and inoculated into GF mice. A detailed analysis of the 16S rRNA sequences revealed that 8 of the 31 strains overlapped with other strains (see Table 3, indicated by an asterisk), resulting in 23 distinct bacterial strains. As shown in Figure 10 , when orally administered to GF mice, the mixture of the 23 strains (23mix) induced very strong levels of Tregs (35-40% in the colon lamina intestinal, >10% in the small intestine; Figure 10 ). These Tregs observed with colonization by 23mix were mostly Helios - .
  • Example 31 To investigate whether the abundant members of the intestinal microbiota in the chloroform-resistant fraction of human intestinal bacteria, rather than the minor members, drive the induction of Treg cells, adult GF mice were inoculated with diluted caecal samples from mice that had been inoculated with the chloroform-resistant fraction of human intestinal bacteria (+huChlo mice) as described in example 19. As shown in Figure 11 , even when the huChlo mice cecal samples were diluted (diluted 2x10 4 and 2x10 5 ) to create +2x10 4 mice and 2x10 5 mice respectively, Tregs were induced in these adult GF mice.
  • Example 32 To investigate whether the mix of 23 strains in Example 30 has the ability to induce Tregs in adult GF IQI mice more effectively than Faecalibacterium prausnitzii, a well-known human Clostridia strain characterized for enhancing regulatory cell functions, 23 strains in table 4 were mixed in equal amounts with media to make a cocktail, which was then administered to adult IQI GF mice. For comparison, Faecalibacterium prausnitzii was administered to another group of IQI GF mice. As shown in Figure 12 , when orally administered to adult IQI GF mice, the mixture of the 23 strains (23-mix) induced higher levels of Tregs than Faecalibacterium prausnitzii. Faecalibacterium prausnitzii (+Faecali.) showed negligible levels of Treg induction.
  • Example 33 To investigate whether the microbiota communities in the +2x10 4 mice, described in example 31, were stable, serial oral inoculation of adult GF mice was performed to create +2x10 4 -re mice(secondary inoculation) and +2x10 4 -re-re(tertiary inoculation). As shown in Figure 13 there was significant induction of Tregs in both the +2x10 4 -re mice and the +2x10 4 -re-re mice.
  • the caecal content of +2x10 4 mice, described in example 31, was again diluted 2x10 4 -fold and orally inoculated into another set of adult GF mice (+(2x10 4 ) 2 mice). As shown in Figure 13 , the +(2x10 4 ) 2 mice exhibited a marked accumulation of Treg cells in the colon.
  • Example 34 To assess the composition of the gut microbiota in +huUT (+hu), +huChlo, +2x10 4 , +2x10 4 -re and +(2x10 4 ) 2 , described in example 19, example 31, and example 33, bacterial DNA was extracted from the caecal contents of these adult mice.
  • the variable region (V1-V2) of the bacterial 16S ribosomal DNA (rDNA) was amplified and metasequencing using a 454 sequencer was performed.
  • the resulting sequences (3400 reads for each sample) were classified into operational taxonomic units (OTUs) based on sequence similarity (>96 % identity).
  • Example 36 To investigate whether each of the 17 strains defined in example 35 could individually induce Tregs, adult GF mice were monocolonized with one of each of the 17 strains. As shown in Figure 16 , adult GF mice monocolonized with a single strain exhibited low to intermediate levels of Treg. Importantly, no single strain induced Tregs to the same extent as the mix of 17 strains.
  • Example 37 To investigate whether subsets of the 17 strains described in example 35 could induce Tregs, randomly selected combinations of 3-5 strains were made: 3-mix, 5mixA, 5-mix B, and 5-mix C, as shown in table 4, and used to inoculate adult GF mice. As shown in Figure 17 , only the 5-species mixes induced significant increases in the frequency of Treg cells, the magnitude of which was intermediate compared with that observed in +17-mix mice.
  • Example 38 To investigate the benefits of administration of the mix of the 17 strains described in example 35 (17-mix), adult SPF mice were orally inoculated with either 17-mix or control media and assessed for the induction of Foxp3+ Treg cells three weeks later. As shown in Figure 18 , there was a significant increase in the frequency of colonic Foxp3 + Treg (CD4) cells after three weeks of treatment.
  • Example 39 To evaluate the benefit of administration of 17-mix in an animal model of allergic diarrhea, adult SPF mice were orally inoculated with 17-mix or control media while being treated with ovalbumin (OVA), an inducer of allergic diarrhea. As shown in Figure 19 , the occurrence and severity of diarrhea (diarrhea score) was significantly reduced in mice fed 17-mix relative to control mice.
  • OVA ovalbumin
  • Example 40 To evaluate the benefit of administration of 17-mix in an animal model of colitis, .
  • Adult SPF mice were orally inoculated with either 17-mix or control media while being treated with trinitrobenzene sulfonic acid (TNBS),a frequently used experimental inducer of colitis.
  • TNBS trinitrobenzene sulfonic acid
  • SPF 17-mix mice demonstrated lower mortality than control mice on exposure to TNBS.
  • the compositions and methods described herein make it possible to provide an excellent and well-characterized composition for inducing proliferation or accumulation of regulatory T cells (Treg cells) by utilizing certain human-derived bacteria belonging to the Clostridia class or a physiologically active substance or the like derived from the bacteria.
  • the bacterial composition has immunosuppressive effects, the bacterial composition can be used, for example, to prevent or treat autoimmune diseases or allergic diseases, as well as to suppress immunological rejection in organ transplantation or the like.
  • healthy individuals can easily and routinely ingest the bacterial composition, such as in food or beverage, (e.g., a health food), to improve their immune functions.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)

Description

    Technical Field
  • The subject matter described herein relates to a composition which induces proliferation and/or accumulation of regulatory T cells.
    • Background Art
  • Hundreds of species of commensal microorganisms are harbored in the gastrointestinal tracts of mammals, where they interact with the host immune system. Research using germ-free (GF) animals has shown that the commensal microorganisms influence the development of the mucosal immune system, such as histogenesis of Peyer's patches (PPs) and isolated lymphoid follicles (ILFs), secretion of antimicrobial peptides from the epithelium, and accumulation of unique lymphocytes in mucosal tissues, including immunoglobulin A-producing plasma cells, intraepithelial lymphocytes, IL-17-producing CD4-positive T cells (Th 17), and IL-22-producing NK-like cells (Non-Patent Literature (NPL) 1 to 7). Consequently, the presence of intestinal bacteria enhances protective functions of the mucous membranes, enabling the host to mount robust immune responses against pathogenic microbes invading the body. On the other hand, the mucosal immune system maintains unresponsiveness to dietary antigens and harmless microbes (NPL Document 3). Abnormality in the regulation of crosstalk between commensal bacteria and the immune system (intestinal dysbiosis) may lead to overly robust immune response to environmental antigens and inflammatory bowel disease (IBD) may result (NPL 8 to 10) .
  • Recent studies have shown that individual commensal bacteria control differentiation of their specific immune cells in the mucosal immune system. For example, Bacteroides fragilis, which is a commensal bacterium in humans, specifically induces a systemic Th1 cell response and a mucosal IL-10-producing T cell response in mice, and plays a role in protecting the host from colitis, which is caused by a pathogen (NPL 3). Segmented filamentous bacteria, which are intestinal commensal bacteria in mice, induce mucosal Th17 cell response and enhance resistance against infection of gastrointestinal tracts of the host with a pathogen (NPL 11 to 13). In addition, short-chain fatty acids derived from several commensal bacteria are known to suppress intestinal inflammation (NPL 14). Moreover, it has been observed that the presence of some species of intestinal microbiota greatly influences the differentiation of regulatory T cells (hereafter referred to as "Treg cells") which help maintain homeostasis of the immune system. Although specific species of murine bacterial commensals that can strongly stimulate Tregs have been identified (NPL 15), it is still unknown whether species of human commensal bacteria exert an equivalent influence on the human immune system. Furthermore, the human intestinal tract harbors more than a thousand bacterial species, many of which have not yet been cultured (NPL 16). It is not feasible to guess a priori which ones, if any, might have an effect on Tregs.
  • In order to develop drugs, dietary supplements, or foods with beneficial immune functions for human use, it is desirable to identify commensal microorganisms that naturally colonize humans and have immune-modulating properties. Furthermore, since many of the commensals in the human microbiome have yet to be cultured, it is necessary to develop methods to cultivate them so that they can be produced by traditional industrial fermentation processes and subsequently incorporated in pharmaceutical or food formulations.
  • CD4+ T cells are regulatory T cells that have been identified as a cell subset that suppresses immunity. A transcription factor, Foxp3, is expressed in CD4+ T cells, which are known to play an important role in maintaining immunological homeostasis ( NPL 8, 9, 17, and 18). Foxp3-expressing cells are present in large numbers in the colon and only Treg cells present locally in the colon constantly express IL-10, an immunosuppressive cytokine, at a high level (NPL 19). Animals having CD4+ Foxp3+ cells from which IL-10 is specifically removed develop inflammatory bowel disease (NPL 20).
  • Accordingly, there is a need to identify human-derived commensal bacterial species with the ability to strongly induce Treg cells to produce IL-10 in the colon at a high level and to develop methods to culture such species. Such species could be used to enhance immunosuppression, which, in turn, can be applied to treatment of autoimmune diseases, such as inflammatory bowel disease, inflammatory diseases, allergies, or organ transplantation, among other diseases and conditions.
    • [Citation List] [Non Patent Literature]
    • [NPL 1]J. J. Cebra, "Am J Clin Nutr", May, 1999, 69, 1046S
    • [NPL 2]A. J. Macpherson, N. L. Harris, "Nat Rev Immunol", June 2004, 4, 478
    • [NPL 3]J. L. Round, S. K. Mazmanian, "Nat Rev Immunol", May 2009, 9, 313
    • [NPL 4]D. Bouskra et al., "Nature", November 27, 2008, 456, 507
    • [NPL 5]K. Atarashi et al., "Nature", October 9, 2008, 455, 808
    • [NPL 6]Ivanov, II et al., "Cell Host Microbe", October 16, 2008, 4, 337
    • [NPL 7]S. L. Sanos et al., "Nat Immunol", January 2009, 10, 83
    • [NPL 8]M. A. Curotto de Lafaille, J. J. Lafaille, "Immunity", May 2009, 30, 626
    • [NPL 9]M. J. Barnes, F. Powrie, "Immunity", September 18, 2009, 31, 401
    • [NPL 10]W. S. Garrett et al., "Cell", October 5, 2007, 131, 33
    • [NPL 11]Ivanov, II et al., "Cell", October 30, 2009, 139, 485.
    • [NPL 12]V. Gaboriau-Routhiau et al., "Immunity", October 16, 2009, 31, 677
    • [NPL 13]N. H. Salzman et al., "Nat Immunol", 11, 76.
    • [NPL 14]K. M. Maslowski et al., "Nature", October 29, 2009, 461, 1282
    • [NPL 15]K. Atarashi et al., "Science", January 21, 2011, 331, 337
    • [NPL 16]J. Quin et al., "Nature", March 4, 2010, 464, 59
    • [NPL 17]L. F. Lu, A. Rudensky, "Genes Dev", June 1, 2009, 23, 1270
    • [NPL 18]S. Sakaguchi, T. Yamaguchi, T. Nomura, M. Ono, "Cell", May 30, 2008, 133, 775
    • [NPL 19]C. L. Maynard et al., "Nat Immunol", September 2007, 8, 931
    • [NPL 20]Y. P. Rubtsov et al., "Immunity", April 2008, 28, 546
  • ATARASHI ET AL, "Induction of Colonic Regulatory T Cells by Indigenous Clostridium Species", SCIENCE, (20110121), vol. 331, no. 6015, doi:10.1126/science.1198469, ISSN 0036-8075, pages 337 - 341 and ATARASHI ET AL, "Induction of Colonic Regulatory T Cells by Indigenous Clostridium Species - Supporting Online Material", SCIENCE, (20101223), vol. 331, no. 6015, oi:10.1126/science.1198469, ISSN 0036-8075, pages 337 - 341, describe the induction of regulatory Foxp3+ T-cells by clostridia, in particular of clusters IV and XIVa. ATARASHI and HONDA, "Microbiota in autoimmunity and tolerance", CURRENT OPINION IN IMMUNOLOGY, vol. 23, no. 6, doi:10.1016/J.COI.2011.11.002, ISSN 0952-7915, (20111122), pages 761 - 768, (20111116), review the role of microbiota in autoimmunity and tolerance and reference the effects shown in ATARASHI ET AL (above).
  • V. Gaboriau-Routhiau et al., "Immunity", October 16, 2009, 31, 677-689 describe Segmented-Filamentous Bacteria (SFBs) which do not belong to the genus Clostridium, and indeed are phylogenetically remote therefrom.
  • SOKOL HARRY ET AL: "Faecalibacterium prausnitzii is an antiinflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, WASHINGTON, DC; US, vol. 105, no. 43,28 October 2008 (2008-10-28), pages 16731-16736, proposes Faecalibacterium prausnitzii (belonging to Clostridium cluster IV) as candidate probiotic agent in the treatment of Crohn's disease (CD).
  • EP1955706 discloses a synergistic composition containing an interferon and a natural bile pigment, useful for treating autoimmune diseases, allergy and cancer, by inducing regulatory T cells.
  • ITOH and MITSUOKA: "Characterization of clostridia isolated from faeces of limited flora mice and their effect on caecal size when associated with germ-free mice." LABORATORY ANIMALS APR 1985 vol. 19, no. 2, April 1985 (1985-04), pages 111-118 discloses the characterization of 115 strains of clostridia accumulated from 3 separate isolations from the faeces of 1 limited flora (LF) mouse produced by inoculation of germ-free mice with chloroform-treated faeces of conventional mice, and the effect on caecal size when associated with germ-free mice was studied.
    • Summary of Invention
  • In one aspect, the present invention provides compositions which induce proliferation and/or accumulation of regulatory T cells as defined in the claims appended hereto. Other aspects of the invention are defined in the claims appended hereto. The present compositions and methods have been made in view of the above-described problems in the art. Described herein are methods of identifying and culturing intestinal commensal bacteria, isolated from humans, which induce, preferably strongly induce, the proliferation, accumulation, or proliferation and accumulation of regulatory T cells. Described are compositions, also referred to as bacterial compositions, that (1) comprise (a) one or more of the identified intestinal commensal (human-derived) bacteria; (b) a culture supernatant of one or more of the bacteria; (c) one or more physiologically active substance derived from one or more of the bacteria or from one or more of the culture supernatant; (d) or a combination of any two or three of (a)-(c) and (2) induce the proliferation and/or accumulation of regulatory T cells (Treg cells). Also described is a composition which comprises (a) one or more of the identified intestinal commensal (human-derived) bacteria; (b) a culture supernatant of one or more of the bacteria; or (c) one or more physiologically active substance derived from the bacteria or from the culture supernatant, wherein the composition induces proliferation and/or accumulation of regulatory T cells. In some cases, the composition comprises one or more of the identified intestinal commensal (human-derived) bacteria. In some cases, the composition comprises a culture supernatant of one or more of the bacteria. In some cases, the composition comprises one or more physiologically active substance derived from the bacteria or from the culture supernatant. In some cases, the one or more bacteria or one or more physiologically active substance derived from the bacteria is three or more. In some cases, the one or more bacteria or one or more physiologically active substance derived from the bacteria is five or more. In some cases, the one or more bacteria or one or more physiologically active substance derived from the bacteria is seventeen or more. In some cases, the one or more bacteria or one or more physiologically active substance derived from the bacteria is twenty-three or more. In some cases, the one or more bacteria or one or more physiologically active substance derived from the bacteria is 23. In specific cases, the bacterial compositions induce, and preferably strongly induce, proliferation, accumulation, or proliferation and accumulation of regulatory T cells that produce an immunosuppressive cytokine, such as IL-10, in the colon (e.g., the human colon) at high levels.
  • Such bacterial compositions are useful, for example, to enhance immunosuppression and, as a result, to treat autoimmune diseases. Bacterial compositions comprise, as an active component, at least one organism and/or at least one substance selected from the group consisting of: Clostridium saccharogumia, Clostridium ramosum JCM1298, Clostridium ramosum, Flavonifractor plautii, Pseudoflavonifractor capillosus ATCC 29799, Clostridium hathewayi, Clostridium saccharolyticum WM1, Bacteroides sp. MANG, Clostridium saccharolyticum, Clostridium scindens, Lachnospiraceae bacterium 5_1_57FAA, Lachnospiraceae bacterium 6_1_63FAA, Clostridium sp. 14616, Clostridium bolteae ATCC BAA-613, cf. Clostridium sp. MLG055, Erysipelotrichaceae bacterium 2_2_44A, Clostridium indolis, Anaerostipes caccae, Clostridium bolteae, Lachnospiraceae bacterium DJF_VP30, Lachnospiraceae bacterium 3_1_57FAA_CT1, Anaerotruncus colihominis, Anaerotruncus colihominis DSM 17241, Ruminococcus sp. ID8, Lachnospiraceae bacterium 2_1_46FAA, Clostridium lavalense, Clostridium asparagiforme DSM 15981, Clostridium symbiosum, Clostridium symbiosum WAL-14163, Eubacterium contortum, Clostridium sp. D5, Oscillospiraceae bacterium NML 061048, Oscillibacter valericigenes, Lachnospiraceae bacterium A4, Clostridium sp. 316002/08, and Clostridiales bacterium 1_7_47FAA, Blautia cocoides, Anaerostipes caccae DSM 14662.; a culture supernatant of at least one (a, one or more) of the bacteria described/listed herein; a physiologically active substance derived from (a, one or more) bacteria described/listed herein or any combination of two or three of the foregoing. Alternatively, bacterial compositions comprise, as an active component, at least one organism or at least one substance selected from the group consisting of: Clostridium saccharogumia, Clostridium ramosum JCM1298, Clostridium ramosum, Flavonifractor plautii, Pseudoflavonifractor capillosus ATCC 29799, Clostridium hathewayi, Clostridium saccharolyticum WM1, Bacteroides sp. MANG, Clostridium saccharolyticum, Clostridium scindens, Lachnospiraceae bacterium 5_1_57FAA, Lachnospiraceae bacterium 6_1_63FAA, Clostridium sp. 14616, Clostridium bolteae ATCC BAA-613, cf. Clostridium sp. MLG055, Erysipelotrichaceae bacterium 2_2_44A, Clostridium indolis, Anaerostipes caccae, Clostridium bolteae, Lachnospiraceae bacterium DJF_VP30, Lachnospiraceae bacterium 3_1_57FAA_CT1, Anaerotruncus colihominis, Anaerotruncus colihominis DSM 17241, Ruminococcus sp. ID8, Lachnospiraceae bacterium 2_1_46FAA, Clostridium lavalense, Clostridium asparagiforme DSM 15981, Clostridium symbiosum, Clostridium symbiosum WAL-14163, Eubacterium contortum, Clostridium sp. D5, Oscillospiraceae bacterium NML 061048, Oscillibacter valericigenes, Lachnospiraceae bacterium A4, Clostridium sp. 316002/08, and Clostridiales bacterium 1_7_47FAA, Blautia cocoides, Anaerostipes caccae DSM 14662.; a culture supernatant of at least one (a, one or more) of the bacteria described/listed herein; a physiologically active substance derived from (a, one or more) bacteria described/listed herein.
  • In some cases, a bacterial composition comprises at least one organism selected from the group consisting of: Clostridium saccharogumia, Clostridium ramosum JCM1298, Clostridium ramosum, Flavonifractor plautii, Pseudoflavonifractor capillosus ATCC 29799, Clostridium hathewayi, Clostridium saccharolyticum WM1, Bacteroides sp. MANG, Clostridium saccharolyticum, Clostridium scindens, Lachnospiraceae bacterium 5_1_57FAA, Lachnospiraceae bacterium 6_1_63FAA, Clostridium sp. 14616, Clostridium bolteae ATCC BAA-613, cf. Clostridium sp. MLG055, Erysipelotrichaceae bacterium 2_2_44A, Clostridium indolis, Anaerostipes caccae, Clostridium bolteae, Lachnospiraceae bacterium DJF_VP30, Lachnospiraceae bacterium 3_1_57FAA_CT1, Anaerotruncus colihominis, Anaerotruncus colihominis DSM 17241, Ruminococcus sp. ID8, Lachnospiraceae bacterium 2_1_46FAA, Clostridium lavalense, Clostridium asparagiforme DSM 15981, Clostridium symbiosum, Clostridium symbiosum WAL-14163, Eubacterium contortum, Clostridium sp. D5, Oscillospiraceae bacterium NML 061048, Oscillibacter valericigenes, Lachnospiraceae bacterium A4, Clostridium sp. 316002/08, and Clostridiales bacterium 1_7_47FAA, Blautia cocoides, Anaerostipes caccae DSM 14662. In some cases, a bacterial composition comprises a culture supernatant of at least one (a, one or more) of the bacteria described/listed herein. In some cases, a bacterial composition comprises a physiologically active substance derived from (a, one or more) bacteria described/listed herein. In some cases, the one or more bacteria or one or more physiologically active substance derived from the bacteria is three or more. In some cases, the one or more bacteria or one or more physiologically active substance derived from the bacteria is five or more. In some cases, the one or more bacteria or one or more physiologically active substance derived from the bacteria is 17 or more.
  • In some cases, the one or more bacteria or one or more physiologically active substance derived from the bacteria is 23 or more. In some cases, the one or more bacteria or one or more physiologically active substance derived from the bacteria is 23. Bacterial compositions can comprise any bacteria (Clostridia or other bacteria) that contain DNA comprising a nucleotide sequence having sufficient homology with sequences provided herein and that exhibit substantially the same effect on regulatory T cells as that exerted by any one of the following: Clostridium saccharogumia, Clostridium ramosum JCM1298, Clostridium ramosum, Flavonifractor plautii, Pseudoflavonifractor capillosus ATCC 29799, Clostridium hathewayi, Clostridium saccharolyticum WM1, Bacteroides sp. MANG, Clostridium saccharolyticum, Clostridium scindens, Lachnospiraceae bacterium 5_1_57FAA, Lachnospiraceae bacterium 6_1_63FAA, Clostridium sp. 14616, Clostridium bolteae ATCC BAA-613, cf. Clostridium sp. MLG055, Erysipelotrichaceae bacterium 2_2_44A, Clostridium indolis, Anaerostipes caccae, Clostridium bolteae, Lachnospiraceae bacterium DJF_VP30, Lachnospiraceae bacterium 3_1_57FAA_CT1, Anaerotruncus colihominis, Anaerotruncus colihominis DSM 17241, Ruminococcus sp. ID8, Lachnospiraceae bacterium 2_1_46FAA, Clostridium lavalense, Clostridium asparagiforme DSM 15981, Clostridium symbiosum, Clostridium symbiosum WAL-14163, Eubacterium contortum, Clostridium sp. D5, Oscillospiraceae bacterium NML 061048, Oscillibacter valericigenes, Lachnospiraceae bacterium A4, Clostridium sp. 316002/08, and Clostridiales bacterium 1_7_47FAA, Blautia cocoides, and Anaerostipes caccae DSM 14662.
  • In some cases, bacteria present in bacterial compositions have at least 90% (90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) homology with sequences provided herein, such as, but not limited to, the nucleotide sequences designated OTU herein and listed, for example, at the pages following the last Example. In specific cases, such bacteria contain DNA comprising a nucleotide sequence that has at least 90% (90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) homology with one or more DNA sequence designated herein as follows: OTU136; OTU46; OTU221; OTU9; OTU296; OTU21; OTU166; OTU73; OTU174; OTU14; OTU55; OTU337; OTU314; OTU195; OTU306; OTU87; OTU86; OTU152; OTU253; OTU259; OTU281; OTU288; OTU334; OTU359; OTU362; or OTU367. Alternatively, bacteria contain DNA comprising a nucleotide sequence that has at least 90% (90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) homology with DNA of one or more of the following: Clostridium saccharogumia, Clostridium ramosum JCM1298, Clostridium ramosum, Flavonifractor plautii, Pseudoflavonifractor capillosus ATCC 29799, Clostridium hathewayi, Clostridium saccharolyticum WM1, Bacteroides sp. MANG, Clostridium saccharolyticum, Clostridium scindens, Lachnospiraceae bacterium 5_1_57FAA, Lachnospiraceae bacterium 6_1_63FAA, Clostridium sp. 14616, Clostridium bolteae ATCC BAA-613, cf. Clostridium sp. MLG055, Erysipelotrichaceae bacterium 2_2_44A, Clostridium indolis, Anaerostipes caccae, Clostridium bolteae, Lachnospiraceae bacterium DJF_VP30, Lachnospiraceae bacterium 3_1_57FAA_CT1, Anaerotruncus colihominis, Anaerotruncus colihominis DSM 17241, Ruminococcus sp. ID8, Lachnospiraceae bacterium 2_1_46FAA, Clostridium lavalense, Clostridium asparagiforme DSM 15981, Clostridium symbiosum, Clostridium symbiosum WAL-14163, Eubacterium contortum, Clostridium sp. D5, Oscillospiraceae bacterium NML 061048, Oscillibacter valericigenes, Lachnospiraceae bacterium A4, Clostridium sp. 316002/08, and Clostridiales bacterium 1_7_47FAA, Blautia cocoides, and Anaerostipes caccae DSM 14662.
  • In specific cases, bacterial compositions comprise bacteria (such as human-derived bacteria) that contain DNA comprising a nucleotide sequence having at least 97%, 98% or 99% homology with sequences provided herein, such as, but not limited to, the nucleotide sequences designated OTU herein and listed, for example, at the pages following the last Example. In specific cases, the bacteria in bacterial compositions contain DNA comprising a nucleotide sequence that has at least 97%, 98% or 99% homology with one or more DNA sequence designated herein as follows: OTU136; OTU46; OTU221; OTU9; OTU296; OTU21; OTU166; OTU73; OTU174; OTU14; OTU55; OTU337; OTU314; OTU195; OTU306; OTU87; OTU86; OTU152; OTU253; OTU259; OTU281; OTU288; OTU334; OTU359; OTU362; or OTU367. Alternatively, the bacteria contain DNA comprising a nucleotide sequence that has at least 97%, 98% or 99% homology with DNA of one or more of the following: Clostridium saccharogumia, Clostridium ramosum JCM1298, Clostridium ramosum, Flavonifractor plautii, Pseudoflavonifractor capillosus ATCC 29799, Clostridium hathewayi, Clostridium saccharolyticum WM1, Bacteroides sp. MANG, Clostridium saccharolyticum, Clostridium scindens, Lachnospiraceae bacterium 5_1_57FAA, Lachnospiraceae bacterium 6_1_63FAA, Clostridium sp. 14616, Clostridium bolteae ATCC BAA-613, cf. Clostridium sp. MLG055, Erysipelotrichaceae bacterium 2_2_44A, Clostridium indolis, Anaerostipes caccae, Clostridium bolteae, Lachnospiraceae bacterium DJF_VP30, Lachnospiraceae bacterium 3_1_57FAA_CT1, Anaerotruncus colihominis, Anaerotruncus colihominis DSM 17241, Ruminococcus sp. ID8, Lachnospiraceae bacterium 2_1_46FAA, Clostridium lavalense, Clostridium asparagiforme DSM 15981, Clostridium symbiosum, Clostridium symbiosum WAL-14163, Eubacterium contortum, Clostridium sp. D5, Oscillospiraceae bacterium NML 061048, Oscillibacter valericigenes, Lachnospiraceae bacterium A4, Clostridium sp. 316002/08, and Clostridiales bacterium 1_7_47FAA, Blautia cocoides, Anaerostipes caccae DSM 14662. Any of the bacteria of the Clostridia class can be present in spore form or vegetative form.
    • [Solution to Problem]
  • As described herein, among the more than a thousand species of bacteria in the human microbiome, there are several species that strongly induce the accumulation of Tregs in the colon.
  • As also described, although most bacterial species present in fecal samples from healthy individuals do not have the ability to stimulate Tregs, species that belong to the Clostridia class have the ability to cause a robust induction of Tregs in the colon. Moreover, the inventors have obtained in vitro cultures of each of the bacterial species identified and shown that inoculating mice with the in vitro cultured species also leads to a robust accumulation of Tregs in the colon.
    As described herein, compositions that comprise, as an active component, (a) one or more of certain species of bacteria that belong to the Clostridia class or bacteria that contain DNA comprising a nucleotide sequence having at least 90% homology with sequences provided herein, in spore form or in vegetative form; (b) a culture supernatant of one or more such bacteria; (c) one or more physiologically active substance derived from (a) or (b); or (d) a combination of any two or three of (a), (b) and (c) and induce the proliferation and/or accumulation of regulatory T cells (Treg cells) suppress immune functions.
  • More specifically described is a composition that induces proliferation, accumulation or both proliferation and accumulation of regulatory T cells, the composition comprising, as an active component, at least one organism and/or at least one substance selected from the group consisting of: Clostridium saccharogumia, Clostridium ramosum JCM1298, Clostridium ramosum, Flavonifractor plautii, Pseudoflavonifractor capillosus ATCC 29799, Clostridium hathewayi, Clostridium saccharolyticum WM1, Bacteroides sp. MANG, Clostridium saccharolyticum, Clostridium scindens, Lachnospiraceae bacterium 5_1_57FAA, Lachnospiraceae bacterium 6_1_63FAA, Clostridium sp. 14616, Clostridium bolteae ATCC BAA-613, cf. Clostridium sp. MLG055, Erysipelotrichaceae bacterium 2_2_44A, Clostridium indolis, Anaerostipes caccae, Clostridium bolteae, Lachnospiraceae bacterium DJF_VP30, Lachnospiraceae bacterium 3_1_57FAA_CT1, Anaerotruncus colihominis, Anaerotruncus colihominis DSM 17241, Ruminococcus sp. ID8, Lachnospiraceae bacterium 2_1_46FAA, Clostridium lavalense, Clostridium asparagiforme DSM 15981, Clostridium symbiosum, Clostridium symbiosum WAL-14163, Eubacterium contortum, Clostridium sp. D5, Oscillospiraceae bacterium NML 061048, Oscillibacter valericigenes, Lachnospiraceae bacterium A4, Clostridium sp. 316002/08, and Clostridiales bacterium 1_7_47FAA, Blautia cocoides, Anaerostipes caccae DSM 14662.; a culture supernatant of at least one of the bacteria described/listed herein, and a physiologically active substance derived from a bacterium described/listed herein.
  • In some cases, the active component is one or more of Clostridium saccharogumia, Clostridium ramosum JCM1298, Clostridium ramosum, Flavonifractor plautii, Pseudoflavonifractor capillosus ATCC 29799, Clostridium hathewayi, Clostridium saccharolyticum WM1, Bacteroides sp. MANG, Clostridium saccharolyticum, Clostridium scindens, Lachnospiraceae bacterium 5_1_57FAA, Lachnospiraceae bacterium 6_1_63FAA, Clostridium sp. 14616, Clostridium bolteae ATCC BAA-613, cf. Clostridium sp. MLG055, Erysipelotrichaceae bacterium 2_2_44A, Clostridium indolis, Anaerostipes caccae, Clostridium bolteae, Lachnospiraceae bacterium DJF_VP30, Lachnospiraceae bacterium 3_1_57FAA_CT1, Anaerotruncus colihominis, Anaerotruncus colihominis DSM 17241, Ruminococcus sp. ID8, Lachnospiraceae bacterium 2_1_46FAA, Clostridium lavalense, Clostridium asparagiforme DSM 15981, Clostridium symbiosum, Clostridium symbiosum WAL-14163, Eubacterium contortum, Clostridium sp. D5, Oscillospiraceae bacterium NML 061048, Oscillibacter valericigenes, Lachnospiraceae bacterium A4, Clostridium sp. 316002/08, and Clostridiales bacterium 1_7_47FAA, Blautia cocoides, Anaerostipes caccae DSM 14662.
  • In some cases, the active component is a culture supernatant of one or more of the bacteria described/listed herein. In some cases, the active component is one or more physiologically active substances derived from a bacterium described/listed herein. In some cases, the one or more bacteria or one or more physiologically active substance derived from the bacteria is three or more. In some cases, the one or more bacteria or one or more physiologically active substance derived from the bacteria is five or more. In some cases, the one or more bacteria or one or more physiologically active substance derived from the bacteria is 17 or more. In some cases, the one or more bacteria or one or more physiologically active substance derived from the bacteria is 23 or more. In some cases, the one or more bacteria or one or more physiologically active substance derived from the bacteria is 23.
  • A bacterial composition as described herein comprises at least one of the following: one bacteria as described herein; at least one culture supernatant obtained from culture in which one (or more) of the bacteria was present (grown or maintained) or a fraction of such a supernatant; one or more physiologically active substance derived from one or more bacteria (such as from the bacteria named herein) or a combination of any two or three of the foregoing. The term composition/bacterial composition refers to all such combinations.
  • The bacteria in the composition can be, for example, Clostridium saccharogumia, Clostridium ramosum JCM1298, Clostridium ramosum, Flavonifractor plautii, Pseudoflavonifractor capillosus ATCC 29799, Clostridium hathewayi, Clostridium saccharolyticum WM1, Bacteroides sp. MANG, Clostridium saccharolyticum, Clostridium scindens, Lachnospiraceae bacterium 5_1_57FAA, Lachnospiraceae bacterium 6_1_63FAA, Clostridium sp. 14616, Clostridium bolteae ATCC BAA-613, cf. Clostridium sp. MLG055, Erysipelotrichaceae bacterium 2_2_44A, Clostridium indolis, Anaerostipes caccae, Clostridium bolteae, Lachnospiraceae bacterium DJF_VP30, Lachnospiraceae bacterium 3_1_57FAA_CT1, Anaerotruncus colihominis, Anaerotruncus colihominis DSM 17241, Ruminococcus sp. ID8, Lachnospiraceae bacterium 2_1_46FAA, Clostridium lavalense, Clostridium asparagiforme DSM 15981, Clostridium symbiosum, Clostridium symbiosum WAL-14163, Eubacterium contortum, Clostridium sp. D5, Oscillospiraceae bacterium NML 061048, Oscillibacter valericigenes, Lachnospiraceae bacterium A4, Clostridium sp. 316002/08, and Clostridiales bacterium 1_7_47FAA, Blautia cocoides, Anaerostipes caccae DSM 14662 or any bacteria (such as human-derived bacteria) that contain DNA comprising at least 90% homology (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% homology) with sequences provided herein, such as, but not limited to, the nucleotide sequences designated OTU herein and listed, for example, at the pages following the last Example.
  • In specific cases, the bacteria contain DNA comprising a nucleotide sequence that has at least 97% , at least 98% or at least 99% homology with one or more DNA sequence designated herein as follows: OTU136; OTU46; OTU221; OTU9; OTU296; OTU21; OTU166; OTU73; OTU174; OTU14; OTU55; OTU337; OTU314; OTU195; OTU306; OTU87; OTU86; OTU152; OTU253; OTU259; OTU281; OTU288; OTU334; OTU359; OTU362; or OTU367. Alternatively, the bacteria contain DNA comprising a nucleotide sequence that has at least 97% (97%, 98%, 99%, 100%) homology with DNA of one or more of the following: Clostridium saccharogumia, Clostridium ramosum JCM1298, Clostridium ramosum, Flavonifractor plautii, Pseudoflavonifractor capillosus ATCC 29799, Clostridium hathewayi, Clostridium saccharolyticum WM1, Bacteroides sp. MANG, Clostridium saccharolyticum, Clostridium scindens, Lachnospiraceae bacterium 5_1_57FAA, Lachnospiraceae bacterium 6_1_63FAA, Clostridium sp. 14616, Clostridium bolteae ATCC BAA-613, cf. Clostridium sp. MLG055, Erysipelotrichaceae bacterium 2_2_44A, Clostridium indolis, Anaerostipes caccae, Clostridium bolteae, Lachnospiraceae bacterium DJF_VP30, Lachnospiraceae bacterium 3_1_57FAA_CT1, Anaerotruncus colihominis, Anaerotruncus colihominis DSM 17241, Ruminococcus sp. ID8, Lachnospiraceae bacterium 2_1_46FAA, Clostridium lavalense, Clostridium asparagiforme DSM 15981, Clostridium symbiosum, Clostridium symbiosum WAL-14163, Eubacterium contortum, Clostridium sp. D5, Oscillospiraceae bacterium NML 061048, Oscillibacter valericigenes, Lachnospiraceae bacterium A4, Clostridium sp. 316002/08, and Clostridiales bacterium 1_7_47FAA, Blautia cocoides, and Anaerostipes caccae DSM 14662.]
  • In one case, the composition induces regulatory T cells that are transcription factor Foxp3-positive regulatory T cells or IL-10-producing regulatory T cells. In another case, the composition has an immunosuppressive effect.
  • Described herein is a pharmaceutical composition that induces proliferation, accumulation or both proliferation and/or accumulation of regulatory T cells and suppresses immune function. The pharmaceutical composition comprises a bacterial composition described herein and a pharmaceutically acceptable component, such as a carrier, a solvent or a diluent. In specific cases, such a pharmaceutical composition comprises (a) (1) one or more species of bacteria belonging to the Clostridia class, as described herein, in spore form or in vegetative form, (2) a culture supernatant of such bacteria, (3) a physiologically active substance derived therefrom or (4) a combination of any two or three of (1), (2) and (3) and (b) a pharmaceutically acceptable component, such as carrier, a solvent or a diluent. In specific cases, (a) above is at least one organism or substance selected from the group consisting of: Clostridium saccharogumia, Clostridium ramosum JCM1298, Clostridium ramosum, Flavonifractor plautii, Pseudoflavonifractor capillosus ATCC 29799, Clostridium hathewayi, Clostridium saccharolyticum WM1, Bacteroides sp. MANG, Clostridium saccharolyticum, Clostridium scindens, Lachnospiraceae bacterium 5_1_57FAA, Lachnospiraceae bacterium 6_1_63FAA, Clostridium sp. 14616, Clostridium bolteae ATCC BAA-613, cf. Clostridium sp. MLG055, Erysipelotrichaceae bacterium 2_2_44A, Clostridium indolis, Anaerostipes caccae, Clostridium bolteae, Lachnospiraceae bacterium DJF_VP30, Lachnospiraceae bacterium 3_1_57FAA_CT1, Anaerotruncus colihominis, Anaerotruncus colihominis DSM 17241, Ruminococcus sp. ID8, Lachnospiraceae bacterium 2_1_46FAA, Clostridium lavalense, Clostridium asparagiforme DSM 15981, Clostridium symbiosum, Clostridium symbiosum WAL-14163, Eubacterium contortum, Clostridium sp. D5, Oscillospiraceae bacterium NML 061048, Oscillibacter valericigenes, Lachnospiraceae bacterium A4, Clostridium sp. 316002/08, and Clostridiales bacterium 1_7_47FAA, Blautia cocoides, Anaerostipes caccae DSM 14662, a culture supernatant of one or more of the bacteria, and a physiologically active substance derived from one or more of the bacteria. In some cases, (a) above is at least one organism selected from the group consisting of: Clostridium saccharogumia, Clostridium ramosum JCM1298, Clostridium ramosum, Flavonifractor plautii, Pseudoflavonifractor capillosus ATCC 29799, Clostridium hathewayi, Clostridium saccharolyticum WM1, Bacteroides sp. MANG, Clostridium saccharolyticum, Clostridium scindens, Lachnospiraceae bacterium 5_1_57FAA, Lachnospiraceae bacterium 6_1_63FAA, Clostridium sp. 14616, Clostridium bolteae ATCC BAA-613, cf. Clostridium sp. MLG055, Erysipelotrichaceae bacterium 2_2_44A, Clostridium indolis, Anaerostipes caccae, Clostridium bolteae, Lachnospiraceae bacterium DJF_VP30, Lachnospiraceae bacterium 3_1_57FAA_CT1, Anaerotruncus colihominis, Anaerotruncus colihominis DSM 17241, Ruminococcus sp. ID8, Lachnospiraceae bacterium 2_1_46FAA, Clostridium lavalense, Clostridium asparagiforme DSM 15981, Clostridium symbiosum, Clostridium symbiosum WAL-14163, Eubacterium contortum, Clostridium sp. D5, Oscillospiraceae bacterium NML 061048, Oscillibacter valericigenes, Lachnospiraceae bacterium A4, Clostridium sp. 316002/08, and Clostridiales bacterium 1_7_47FAA, Blautia cocoides, Anaerostipes caccae DSM 14662.
  • In some cases, (1) above is a culture supernatant of one or more of the bacteria. In some cases, (1) above is a physiologically active substance derived from one or more of the bacteria. In some cases, the at least one organism or substances is three or more. In some cases, the at least one organism or substances is five or more. In some cases, the at least one organism or substances is 17 or more. In some cases, the at least one organism or substances is 23 or more. In some cases, the at least one organism or substances is 23. In further cases, (a)(1) above is bacteria (such as human-derived bacteria) that contain DNA comprising at least 90% homology (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% homology) with sequences provided herein, such as, but not limited to, the nucleotide sequences designated OTU herein and listed, for example, at the pages following the last Example. In specific cases of the pharmaceutical composition, the bacteria contain DNA comprising a nucleotide sequence that has at least 97% , at least 98% or at least 99% homology with one or more DNA sequence designated herein as follows: OTU136; OTU46; OTU221; OTU9; OTU296; OTU21; OTU166; OTU73; OTU174; OTU14; OTU55; OTU337; OTU314; OTU195; OTU306; OTU87; OTU86; OTU152; OTU253; OTU259; OTU281; OTU288; OTU334; OTU359; OTU362; or OTU367. Alternatively, the bacteria in the pharmaceutical composition contain DNA comprising a nucleotide sequence that has at least 97% (97%, 98%, 99%, 100%) homology with DNA of one or more of the following: Clostridium saccharogumia, Clostridium ramosum JCM1298, Clostridium ramosum, Flavonifractor plautii, Pseudoflavonifractor capillosus ATCC 29799, Clostridium hathewayi, Clostridium saccharolyticum WM1, Bacteroides sp. MANG, Clostridium saccharolyticum, Clostridium scindens, Lachnospiraceae bacterium 5_1_57FAA, Lachnospiraceae bacterium 6_1_63FAA, Clostridium sp. 14616, Clostridium bolteae ATCC BAA-613, cf. Clostridium sp. MLG055, Erysipelotrichaceae bacterium 2_2_44A, Clostridium indolis, Anaerostipes caccae, Clostridium bolteae, Lachnospiraceae bacterium DJF_VP30, Lachnospiraceae bacterium 3_1_57FAA_CT1, Anaerotruncus colihominis, Anaerotruncus colihominis DSM 17241, Ruminococcus sp. ID8, Lachnospiraceae bacterium 2_1_46FAA, Clostridium lavalense, Clostridium asparagiforme DSM 15981, Clostridium symbiosum, Clostridium symbiosum WAL-14163, Eubacterium contortum, Clostridium sp. D5, Oscillospiraceae bacterium NML 061048, Oscillibacter valericigenes, Lachnospiraceae bacterium A4, Clostridium sp. 316002/08, and Clostridiales bacterium 1_7_47FAA, Blautia cocoides, Anaerostipes caccae DSM 14662.
  • The pharmaceutical composition described herein induces the proliferation and/or accumulation of regulatory T cells (Treg cells) and suppresses immune function.
  • Also described is a method of inducing proliferation, accumulation or both proliferation and accumulation of regulatory T cells in an individual (e.g., an individual in need thereof, such as an individual in need of induction of proliferation and/or accumulation of regulatory T cells). The method comprises administering to the individual a bacterial composition described herein or a pharmaceutical composition comprising a bacterial composition described herein. In the method at least one organism or substance selected from the group consisting of: Clostridium saccharogumia, Clostridium ramosum JCM1298, Clostridium ramosum, Flavonifractor plautii, Pseudoflavonifractor capillosus ATCC 29799, Clostridium hathewayi, Clostridium saccharolyticum WM1, Bacteroides sp. MANG, Clostridium saccharolyticum, Clostridium scindens, Lachnospiraceae bacterium 5_1_57FAA, Lachnospiraceae bacterium 6_1_63FAA, Clostridium sp. 14616, Clostridium bolteae ATCC BAA-613, cf. Clostridium sp. MLG055, Erysipelotrichaceae bacterium 2_2_44A, Clostridium indolis, Anaerostipes caccae, Clostridium bolteae, Lachnospiraceae bacterium DJF_VP30, Lachnospiraceae bacterium 3_1_57FAA_CT1, Anaerotruncus colihominis, Anaerotruncus colihominis DSM 17241, Ruminococcus sp. ID8, Lachnospiraceae bacterium 2_1_46FAA, Clostridium lavalense, Clostridium asparagiforme DSM 15981, Clostridium symbiosum, Clostridium symbiosum WAL-14163, Eubacterium contortum, Clostridium sp. D5, Oscillospiraceae bacterium NML 061048, Oscillibacter valericigenes, Lachnospiraceae bacterium A4, Clostridium sp. 316002/08, and Clostridiales bacterium 1_7_47FAA, Blautia cocoides, Anaerostipes caccae DSM 14662; a culture supernatant of one or more of the bacteria or one or more component of the culture supernatant; a physiologically active substance derived from one or more of the bacteria or a combination of two or three of the foregoing is administered to an individual (also referred to as an individual in need thereof) who can be a healthy individual or an individual in need of prevention, reduction or treatment of a condition or disease. For example, the compositions described may be administered to an individual in need of treatment, reduction in the severity of or prevention of a disease or condition such as an autoimmune disease, an inflammatory disease, an allergic disease, and an infectious disease.
  • Optionally, administration of the bacterial composition may be in combination with, or preceded by, a course of one or more antibiotics.
  • Optionally, administration of the bacterial composition may be in combination with administration of at least one prebiotic substance that preferentially favors the growth of the species in the bacterial composition over the growth of other human commensal bacterial species. In one case, the prebiotic substance(s) is, for example, a nondigestible oligosaccharide. In specific cases, the one or more prebiotic substance(s) is selected from the group consisting of almond skin, inulin, oligofructose, raffinose, lactulose, pectin, hemicellulose, amylopectin, acetyl-Co A, biotin, beet molasses, yeast extracts, and resistant starch. Also contemplated herein is a composition that comprises the bacterial composition and at least one prebiotic substance.
  • The bacterial composition may be administered in combination with a substance selected from the group consisting of corticosteroids, mesalazine, mesalamine, sulfasalazine, sulfasalazine derivatives, immunosuppressive drugs, cyclosporin A, mercaptopurine, azathiopurine, prednisone, methotrexate, antihistamines, glucocorticoids, epinephrine, theophylline, cromolyn sodium, anti-leukotrienes, anti-cholinergic drugs for rhinitis, anti-cholinergic decongestants, mast-cell stabilizers, monoclonal anti-IgE antibodies, vaccines, anti-TNF inhibitors such as infliximab, adalimumab, certolizumab pegol, golimumab, or etanercept, and combinations thereof. Also described herein is a composition that comprises the bacterial composition and at least one substance selected from the group consisting of corticosteroids, mesalazine, mesalamine, sulfasalazine, sulfasalazine derivatives, immunosuppressive drugs, cyclosporin A, mercaptopurine, azathiopurine, prednisone, methotrexate, antihistamines, glucocorticoids, epinephrine, theophylline, cromolyn sodium, anti-leukotrienes, anti-cholinergic drugs for rhinitis, anti-cholinergic decongestants, mast-cell stabilizers, monoclonal anti-IgE antibodies, vaccines, anti-TNF inhibitors such as infliximab, adalimumab, certolizumab pegol, golimumab, or etanercept, and combinations thereof.
  • As described herein, the bacterial composition can be used as an adjuvant to improve the efficacy of a vaccine formulation. For example, the bacterial composition can be used as an adjuvant to a vaccine for the prophylaxis or treatment of an autoimmune disease or an allergic disease. In some cases, a method for prophylaxis or treatment is described, the method comprising administering the bacterial composition and adminstering a vaccine.
  • Assessment of the extent of induction of proliferation or accumulation of regulatory T cells that results from administration of a composition described herein can be carried out by a variety of approaches, such as by measurement of the number of Foxp3-expressing Tregs in a patient sample (such as a biopsy or a blood sample), promotion of IL-10 expression, promotion of CTLA4 expression, promotion of IDO expression, suppression of IL-4 expression, or colonization of an individual with the bacterial composition. The results of such assessments are used as an index of the induction of proliferation or accumulation of regulatory T cells in the individual.
  • As described herein, administration of a composition described herein causes induction of the regulatory T cells that are transcription factor Foxp3-positive regulatory T cells or IL-10-producing regulatory T cells.
  • The composition described herein can be administered by a variety of routes and in one case, is administered orally to an individual in need thereof, such as a patient in need thereof. The composition may be administered in a number of oral forms, such as in spore-form (in a dry powder or dissolved in a liquid formulation), in enteric capsules, in sachets, or in a food matrix, such as yogurt, or a drink.
  • Also described is a method to predict a subject's response to treatment (predict whether the subject will or will not respond to treatment) with compositions of the invention. The method comprises (a) obtaining a (at least one, one or more) sample, such as a fecal sample or a colonic biopsy, from a patient before he or she is treated with a bacterial composition described herein; (b) measuring or determining the percentage or absolute counts in the sample of at least one bacterial species selected from the group consisting of: Clostridium saccharogumia, Clostridium ramosum JCM1298, Clostridium ramosum, Flavonifractor plautii, Pseudoflavonifractor capillosus ATCC 29799, Clostridium hathewayi, Clostridium saccharolyticum WM1, Bacteroides sp. MANG, Clostridium saccharolyticum, Clostridium scindens, Lachnospiraceae bacterium 5_1_57FAA, Lachnospiraceae bacterium 6_1_63FAA, Clostridium sp. 14616, Clostridium bolteae ATCC BAA-613, cf. Clostridium sp. MLG055, Erysipelotrichaceae bacterium 2_2_44A, Clostridium indolis, Anaerostipes caccae, Clostridium bolteae, Lachnospiraceae bacterium DJF_VP30, Lachnospiraceae bacterium 3_1_57FAA_CT1, Anaerotruncus colihominis, Anaerotruncus colihominis DSM 17241, Ruminococcus sp. ID8, Lachnospiraceae bacterium 2_1_46FAA, Clostridium lavalense, Clostridium asparagiforme DSM 15981, Clostridium symbiosum, Clostridium symbiosum WAL-14163, Eubacterium contortum, Clostridium sp. D5, Oscillospiraceae bacterium NML 061048, Oscillibacter valericigenes, Lachnospiraceae bacterium A4, Clostridium sp. 316002/08, and Clostridiales bacterium 1_7_47FAA, Blautia cocoides, and Anaerostipes caccae DSM 14662, thereby producing a percentage or count, and (c) comparing the resulting percentage or count (measurement) to a baseline value of the same measurement in a healthy subject, wherein a percentage or count in the sample obtained from the patient that is lower than the baseline value indicates that the subject may respond favorably to administration of the bacterial composition.
  • In some cases, the method further comprises (d) administering the bacterial composition to the patient if the percentage or count in the sample obtained from the patient is lower than the baseline value. Optionally, the method may further comprise measuring in a patient's sample (e.g., a fecal sample or a colonic biopsy) the percentages or absolute counts of other commensal species that belong to Clostridium Clusters IV and XIVa, but are not present in the bacterial composition, wherein a value of the percentage or absolute count (measurement) lower than baseline further indicates that the subject may respond favorably to administration of the bacterial compositions. In some cases, the method further comprises administering the bacterial composition to the patient if the value of the percentage or absolute count (measurement) is lower than baseline. In one case, the patient being assessed suffers from inflammatory bowel disease or a C. difficile infection.
  • Also described is a method of monitoring a subject's response to treatment with the bacterial compositions of the invention, comprising: (a) obtaining a (at least one) sample, such as a fecal sample or a colonic biopsy from a patient before treatment with a bacterial composition described herein; (b) obtaining, a (at least one) corresponding sample from the patient after treatment with a bacterial composition described herein; and (c) comparing the percentage or absolute counts of at least one bacterial species selected from the group consisting of: Clostridium saccharogumia, Clostridium ramosum JCM1298, Clostridium ramosum, Flavonifractor plautii, Pseudoflavonifractor capillosus ATCC 29799, Clostridium hathewayi, Clostridium saccharolyticum WM1, Bacteroides sp. MANG, Clostridium saccharolyticum, Clostridium scindens, Lachnospiraceae bacterium 5_1_57FAA, Lachnospiraceae bacterium 6_1_63FAA, Clostridium sp. 14616, Clostridium bolteae ATCC BAA-613, cf. Clostridium sp. MLG055, Erysipelotrichaceae bacterium 2_2_44A, Clostridium indolis, Anaerostipes caccae, Clostridium bolteae, Lachnospiraceae bacterium DJF_VP30, Lachnospiraceae bacterium 3_1_57FAA_CT1, Anaerotruncus colihominis, Anaerotruncus colihominis DSM 17241, Ruminococcus sp. ID8, Lachnospiraceae bacterium 2_1_46FAA, Clostridium lavalense, Clostridium asparagiforme DSM 15981, Clostridium symbiosum, Clostridium symbiosum WAL-14163, Eubacterium contortum, Clostridium sp. D5, Oscillospiraceae bacterium NML 061048, Oscillibacter valericigenes, Lachnospiraceae bacterium A4, Clostridium sp. 316002/08, and Clostridiales bacterium 1_7_47FAA, Blautia cocoides, Anaerostipes caccae DSM 14662 in the sample obtained in (a) with the percentage or absolute counts of the same at least one bacterial species in the sample obtained in (b), wherein a higher value in the sample obtained in (b) (after treatment with the bacterial composition) than in the sample obtained in (a) (before treatment) indicates that the subject has responded favorably to treatment (e.g. is a positive indicator of enhanced immunosuppression in the subject).
  • In some cases, the method further comprises (d) further administering the bacterial composition to the patient or ceasing adminstration of the bacterial composition to the patient based on the comparison in (c). Optionally, the method may further comprise measuring in the subject's samples the percentages or absolute counts of other commensal species that belong to Clostridium Clusters IV and XIVa, but are not present in the bacterial composition, wherein a higher value after treatment than before treatment indicates that the subject has responded favorably to treatment.
    • EFFECTS OF COMPOSITIONS AND METHODS DESCRIBED HEREIN
  • The compositions described herein, which contain, as an active component, selected bacteria belonging to the Clostridia class or other bacteria, as described herein; a culture supernatant of such bacteria; a physiologically active substance derived from such bacteria; or a combination of two or three of the foregoing are excellent at inducing the proliferation or accumulation of regulatory T cells (Treg cells).
  • Immunity in an individual can be suppressed through administration of the subject composition, such as through ingestion of the bacterial composition in a food or beverage or as a dietary supplement or through administration of a pharmaceutical composition comprising the bacterial composition. The subject composition can be used, for example, to prevent or treat autoimmune diseases, allergic diseases, infectious diseases, as well as to suppress immunological rejection in organ transplantation or the like. In addition, if a food or beverage, such as a health food, comprises the subject composition, healthy individuals can ingest the composition easily and routinely. As a result, it is possible to induce the proliferation and/or accumulation of regulatory T cells and thereby to improve immune functions.
  • The composition described herein provides for a natural, long-lasting, patient-friendly, and benign treatment alternative for immune-mediated conditions. For example, inflammatory bowel disease is currently managed with synthetic drugs that may have severe side effects (such as corticosteroids, TNF inhibitors), cannot be administered orally (such as TNF inhibitors), have inconvenient dosing involving several pills a day (such as mesalazine or sulfasalazine) or have limited efficacy and short-lived effects (such as currently marketed probiotics, e.g. Lactobacillus GG, Lactobacillus acidophilus, Bifidobacterium longum, etc).
    • [Brief Description of Drawings]
    • [Fig. 1A-B]
      Fig. 1A is a histogram showing Foxp3 expression gated CD4 cells from colonic lamina propia (C LPL, left panel) and small intestinal lamina propria (SI LPL, right panel) of GF mice or GF mice colonized with untreated (+huUT, n=4, numbering from #A1 to #A4) or chloroform-treated (+huChloro, n=4, numbering from #B1 to #B4) human feces Fig. 1B is a histogram showing Helios expression in Foxp3+CD4+ cells from colonic lamina propia (left panel) and small intestinal lamina propria (right panel) of GF mice or GF mice colonized with untreated (+huUT) or chloroform-treated (+huChloro) human feces. Numbers above bracketed lines in (A) and (B) indicate the percentage of the population.
    • [Fig. 1C-D]
      Figs. 1C-D are graphs showing, respectively, combined data for Foxp3 expression in CD4+ cells, and for Helios expression in Foxp3+CD4+ cells, from colonic lamina propia (left panel) and small intestinal lamina propria (right panel) of GF mice or GF mice colonized with untreated (+huUT) or chloroform-treated (+huChloro) human feces. Each circle in (C) and (D) represents a separate animal, and error bars indicate the SD. *P < 0.05; **P < 0.001, unpaired t test.
    • [Fig. 1E]
      Fig. 1E shows representative flow cytometry dot plots for the intracellular expressions of IL-17 and IFN- in CD4+ cells from colonic lamina propia (upper panel) and small intestinal lamina propria (lower panel) of GF mice or GF mice colonized with untreated (+huUT) or chloroform-treated (+huChloro) human feces. The number in each quadrant in (E) indicates the percentage of the population.
    • [Fig. 1F-G]
      Figs. 1F-G show, respectively, combined data of all mice for IL-17 and IFN- expression in CD4+ cells from colonic lamina propia (left panel) and small intestinal lamina propria (right panel) of GF mice or GF mice colonized with untreated (+huUT) or chloroform-treated (+huChloro) human feces. Each circle in (F, G) represents a separate animal, and error bars indicate the SD. *P < 0.05; ns, not significant (P > 0.05), unpaired t test.
    • [Fig. 2]
      Fig. 2 shows representative plots (A) and combined data (B-C) for Foxp3 expression in CD4+ cells (upper panel in A, left panel in B), or Helios expression in Foxp3+CD4+ cells (lower panel in A, right panel in C)for GF mice and GF mice orally inoculated (once a week for 4 weeks) with a suspension of chloroform-treated human feces that had been previously autoclaved. Numbers above bracketed lines in (A) indicate the percentage of the population. Each circle in (B, C) represents a separate animal, and error bars indicate the SD. ns, not significant (P > 0.05), unpaired t test.
    • [Fig. 3]
      Fig. 3 shows representative plots (A, data of mouse #C4 is shown here) and combined data (B) for Foxp3 expression in CD4+ cells from colonic and small intestinal lamina propria lymphocytes for GF mice and GF mice orally inoculated with chloroform-treated human feces (+huChloro, n=7, numbering from #C1 to #C7). Numbers above bracketed lines in (A) indicate the percentage of the population. Each circle in (B) represents a separate animal, and error bars indicate the SD. **P < 0.001, unpaired t test.
    • [Fig. 4]
      Fig. 4 shows representative plots (A) and combined data (B) for Foxp3 expression in CD4+ cells from colonic lamina propria (C LPL) and small intestinal lamina propria (SI LPL)for GF mice and GF (numbering from #D1 to #D6) that were co-housed with #C6 and #C7 ex-GF mice colonized with chloroform-treated human feces. Numbers above bracketed lines in (A) indicate the percentage of the population. Each circle in (B) represents a separate animal, and error bars indicate the SD. **P < 0.001, unpaired t test.
    • [Fig. 5]
      Fig. 5 shows representative plots and combined data for Foxp3 expression in CD4+ cells (A, B), or Helios expression in Foxp3+CD4+ cells (C) from colonic lamina propria (C LPL) and small intestinal lamina propria (SI LPL)for GF mice, GF mice that were inoculated with 2000-fold (+x2000, n=4, numbering from #E1 to #E4) or 20000-fold (+x20000, n=8, numbering from #F1 to #F8) diluted fecal suspension from #C4 mouse. Numbers above bracketed lines in (A) indicate the percentage of the population. Each circle in (B) and (C) represents a separate animal, and error bars indicate the SD. *P < 0.05; **P < 0.001, unpaired t test.
    • [Fig. 6]
      Fig. 6 shows representative plots (A, B) and combined data (C, D) for Foxp3 expression in CD4+ cells (A, C), or Helios expression in Foxp3+CD4+ cells (B, D)
      from colonic lamina propria (C LPL) and small intestinal lamina propria (SI LPL)for GF mice, and GF mice that were inoculated with fecal suspension of #F3 (n=5), #F7 (n=4) or #F8 (n=4) mouse. Numbers above bracketed lines in (A) and (B) indicate the percentage of the population. Each circle in (C) and (D) represents a separate animal, and error bars indicate the SD. *P < 0.05; **P < 0.001, unpaired t test.
    • [Fig. 7]
      Fig. 7 shows representative plots (A) and combined data (B, C) for Foxp3 expression in CD4+ cells (A, B) or Helios expression in Foxp3+CD4+ cells for GF mice and GF mice that were inoculated with 3 isolated strains of bacteria from cecal content of #F8 mouse (n=4, numbering from #J1 to #J4). Numbers above bracketed lines in (A) indicate the percentage of the population. Each circle in (B) and (C) represents a separate animal, and error bars indicate the SD. ns, not significant (P > 0.05), unpaired t test.
    • [Fig. 8]
      Fig. 8 shows the relative abundances of OTUs having the same closest relative in each cecal sample (bacterial DNA was extracted from the cecal contents of mouse #A1, #C4, #F8, #G2, #H3, #13, #J3 and #K3, shown in the bars). Total number of OTUs detected in each sample is depicted below the bar. The detected OTU names in sample #H3, #13 or #K3, their closest relative and their similarity with the closest relative are depicted in the right table.
    • [Fig. 9]
      Fig. 9 shows representative plots (A) and combined data (B, C) for Foxp3 expression in CD4+ cells (A, B), or Helios expression in Foxp3+CD4+ cells (A, C) from colonic lamina propria (C LPL) and small intestinal lamina propria (SI LPL)for GF mice and GF mice that were inoculated with bacteria collections from culture plate of cecal content of #G2 mouse (n=4, numbering from #K1 to #K4. Numbers above bracketed lines in (A) indicate the percentage of the population. Each circle in (B) and (C) represents a separate animal, and error bars indicate the SD. *P < 0.05; **P < 0.001, unpaired t test.
    • [Fig. 10]
      Fig. 10 shows representative plots (A) and combined data (B, C) for Foxp3 expression in CD4+ cells (A, B), or Helios expression in Foxp3+CD4+ cells (A, C) from colonic lamina propria (C LPL) and small intestinal lamina propria (SI LPL) for GF mice and GF mice that were inoculated with a mixture of 23 bacterial strains that were isolated and shown in Table 2 (23mix). Numbers above bracketed lines in (A) indicate the percentage of the population. Each circle in (B) and (C) represents a separate animal, and error bars indicate the SD. *P < 0.05; **P < 0.001, unpaired t test.
    • [Fig. 11]
      Fig. 11 shows a representative plot of the accumulation of Foxp3+CD4+ cells in adult GF mice that were inoculated with 2x104 to 2x107-fold diluted caecal samples from +huChlo mice. Experiments were performed more than twice. Error bars indicate SD. **P<0.01, *P<0.05, as calculated by Student's t-test.
    • [Fig. 12]
      Fig. 12 shows a representative plot of the accumulation of Foxp3+CD4+ cells in the colon of adult GF mice that were inoculated with a mixture of 23 bacterial strains that were isolated and shown in Table 2 (23-mix), chloroform-treated human feces (+huChlo) and Faecalibacterium prausnitzii (+Faecali). Error bars indicate SD. **P<0.01, as calculated by Student's t-test.
    • [Fig. 13]
      Fig. 13 shows a representative plot of the accumulation of Foxp3+CD4+ cells in adult GF mice that were the secondary (+2x104-re) and tertiary (+2x104-re-re) recipients of inoculations with the caecal content of +2x104 mice, and adult GF mice inoculated with 2x104-fold diluted caecal samples from +2x104 mice (+(2x104)2).
    • [Fig. 14]
      Fig. 14 shows the results of 16s rDNA pyrosequencing the caecal contents from the defined mice(+hu, +huChlo, +2x104, +2x104-re, (+2x104)2, +23-,mix) using a 454 sequencer. The relative abundance of OTUs(%) in the caecal bacterial community in each mouse and the closest strains in the database and the corresponding isolated strain number for the indicated OTUs are shown.
    • [Fig. 15]
      Fig 15 shows a representative plot of the accumulation of Foxp3+CD4+ cells in the colons of adult IQI, BALB and B6 GF mice on inoculation with a mixture of 17 bacterial strains that were isolated and shown in Table 4 (17-mix), **P<0.01, as calculated by Student's t-test.
    • [Fig. 16]
      Fig. 16 shows a representative plot of the accumulation of Foxp3+CD4+ cells in adult IQI GF mice mono-colonized with each of the 17 strains listed in tTable 4 (17-mix).
    • [Fig. 17]
      Fig. 17 shows a representative plot of the accumulation of Foxp3+CD4+ cells in adult IQI GF mice colonized with 3-mix, 5mix-A, 5-mix-B, 5-mix-C or 17-mix as listed in tTable 4. Circles indicate individual animals. Experiments wasere performed more than twice with similar results. Error bars indicate SD. **P<0.01, *P<0.05, ns, not significant, as calculated by Student's t-test.
    • [Fig. 18]
      Fig. 18 shows a representative plot of the accumulation of Foxp3+CD4+ cells in adult SPF mice repeatedly inoculated with 17-mix(SPF+17mix; n=5) or control (SPF+cont; n=6). **P<0.01, as calculated by Student's t-test.
    • [Fig. 19]
      Fig. S19 shows the effects of inoculation with 17-mix on an OVA model of diarrhea, as measured by a qualitative diarrhea score. *P<0.05, as calculated by Student's t-test.
    • [Fig. 20]
      Fig. 20 shows the survival of adult mice inoculated with a mixture of 17 bacterial strains listed in Table 4 (17-mix) following exposure to trinitrobenzene sulfonic acid (TNBS), an agent used in experimental models of colitis.
    • [Fig. 21]
      Fig. 21 shows the relative abundance of each of the 17-mix strains in the human fecal microbiota of ulcerative colitis and healthy subjects. The publically available reads of 15 healthy and 20 ulcerative colitis subjects in the MetaHIT database were aligned to the genome of the 17 strains. The mean numbers of mapped reads in healthy and UC groups for each of the 17 strain genomes are shown. Error bars represent SEM. *P<0.05, as calculated by the Student's t-test.
    Brief Description of Tables
    • Table 1 shows the numbers of detected reads and the closest relatives for each OTU obtained from classification of sequences (3400 reads for each sample) resulting from 16srRNA coding gene amplification and PCR metasequencing of bacterial DNA extracted from the cecal contents of mouse #A1, #C4, #F8, #G2, #H3, #13, #J3 and #K3 (classification on the basis of sequence similarity, >97% identity to sequences in nucleic acid databases using BLAST)
    • Table 2 shows, for each of seventeen bacterial strains isolated from the cecal contents of mouse #F8, #G2, #11 and #K3 using BL agar or EG agar plates, the closest relative in known species, the maximum similarity with the closest relative, its classification in the Clostridiaceae cluster, origin of mouse ID, and culture medium for isolation.
    • Table 3 shows, for each of 31 bacterial strains isolated from the caecal contents of mouse #F8, #G2, #11 and #K3 using BL agar or EG agar plates, the closest relative in known species, the maximum similarity with the closest relative, the database used for BLAST search, and similarity between strains.
    • Table 4 shows 16S rDNA analysis for each of 31 strains that were isolated. Bacterial DNA was isolated from each of the 31 strains and the 16S rDNA of the isolates was amplified by colony-PCR. Each amplified DNA was purified, sequenced, and aligned using the ClustalW software program. Based on the sequence of 16S rDNA for each strain, their closest species, % similarity with the closest species, and the similarity to other strains are shown. Strains that were included in the 23-mix, 17-mix, 5-mixA, 5-mixB, 5-mixC, and 3-mix are marked in the right hand column.
    DETAILED DESCRIPTION <Composition Having Effect of Inducing Proliferation or Accumulation of Regulatory T cells>
  • Described herein is a composition that induces proliferation, accumulation of regulatory T cells or both proliferation and accumulation of regulatory T cells. The composition comprises, as an active ingredient, one or more of the following: a (at least one, one or more) organism selected from the group consisting of: Clostridium saccharogumia, Clostridium ramosum JCM1298, Clostridium ramosum, Flavonifractor plautii, Pseudoflavonifractor capillosus ATCC 29799, Clostridium hathewayi, Clostridium saccharolyticum WM1, Bacteroides sp. MANG, Clostridium saccharolyticum, Clostridium scindens, Lachnospiraceae bacterium 5_1_57FAA, Lachnospiraceae bacterium 6_1_63FAA, Clostridium sp. 14616, Clostridium bolteae ATCC BAA-613, cf. Clostridium sp. MLG055, Erysipelotrichaceae bacterium 2_2_44A, Clostridium indolis, Anaerostipes caccae, Clostridium bolteae, Lachnospiraceae bacterium DJF_VP30, Lachnospiraceae bacterium 3_1_57FAA_CT1, Anaerotruncus colihominis, Anaerotruncus colihominis DSM 17241, Ruminococcus sp. ID8, Lachnospiraceae bacterium 2_1_46FAA, Clostridium lavalense, Clostridium asparagiforme DSM 15981, Clostridium symbiosum, Clostridium symbiosum WAL-14163, Eubacterium contortum, Clostridium sp. D5, Oscillospiraceae bacterium NML 061048, Oscillibacter valericigenes, Lachnospiraceae bacterium A4, Clostridium sp. 316002/08, and Clostridiales bacterium 1_7_47FAA, Blautia cocoides, Anaerostipes caccae DSM 14662, a culture supernatant of one or more of the bacteria, a component of culture medium in which a (at least one, one or more) bacterium described herein has grown, a physiologically active substance derived from a (at least one; one or more) bacterium described herein; and a (at least one; one or more) bacterium containing DNA comprising a nucleotide sequence having at least 97% homology to the nucleotide sequence of DNA of any of the bacterial species described herein, such as those listed above. Bacteria described herein were isolated from human fecal samples using the methods outlined in Examples 19 to 28.
  • The term "regulatory T cells" refers to T cells that suppress an abnormal or excessive immune response and play a role in immune tolerance. The regulatory T cells are typically transcription factor Foxp3-positive CD4-positive T cells. The regulatory T cells described herein also include transcription factor Foxp3-negative regulatory T cells that are IL-10-producing CD4-positive T cells.
  • The term "induces proliferation or accumulation of regulatory T cells" refers to an effect of inducing the differentiation of immature T cells into regulatory T cells, which differentiation leads to the proliferation and/or the accumulation of regulatory T cells. Further, the meaning of "induces proliferation or accumulation of regulatory T cells" includes in-vivo effects, in vitro effects, and ex vivo effects. All of the following effects are included: an effect of inducing in vivo proliferation or accumulation of regulatory T cells through administration or ingestion of the aforementioned bacteria belonging to the Clostridia class, a culture supernatant of the bacteria or supernatant component(s), or a physiologically active substance derived from the bacteria; an effect of inducing proliferation or accumulation of cultured regulatory T cells by causing the aforementioned bacteria belonging to the Clostridia class, a culture supernatant of the bacteria or supernatant component(s), or a physiologically active substance derived from the bacteria to act on the cultured regulatory T cells; and an effect of inducing proliferation or accumulation of regulatory T cells which are collected from a living organism and which are intended to be subsequently introduced into a living organism, such as the organism from which they were obtained or another organism, by causing the aforementioned bacteria belonging to the Clostridia class, a culture supernatant of the bacteria or supernatant component(s), or the physiologically active substance derived from the bacteria to act on the regulatory T cells. The effect of inducing proliferation or accumulation of regulatory T cells can be evaluated, for example, as follows. Specifically, the aforementioned bacteria belonging to the Clostridia class, a culture supernatant of the bacteria or supernatant component(s), or a physiologically active substance derived from the bacteria is orally administered to an experimental animal, such as a germ-free mouse, then CD4-positive cells in the colon are isolated, and the ratio of regulatory T cells contained in the CD4-positive cells is measured by flow cytometry (refer to Example 7).
  • The regulatory T cells whose proliferation or accumulation is induced by the composition of the present invention are preferably transcription factor Foxp3-positive regulatory T cells or IL-10-producing regulatory T cells.
  • In the present disclosure, "human-derived bacteria" means bacterial species that have been isolated from a fecal sample or from a gastrointestinal biopsy obtained from a human individual or whose ancestors were isolated from a fecal sample or from a gastrointestinal biopsy obtained from a human (e.g., are progeny of bacteria obtained from a fecal sample or a gastrointestinal biopsy). For example, the bacterial species may have been previously isolated from a fecal sample or from a gastrointestinal biopsy obtained from a human and cultured for a sufficient time to generate progeny. The progeny can then be further cultured or frozen. The human-derived bacteria are naturally occurring commensals that populate the gastrointestinal tract of human individuals, preferably healthy human individuals.
  • In the present disclosure, the term "Clostridia class" (as in "compositions containing bacteria belonging to the Clostridia class") refers to a class of Gram+, obligate anaerobic bacteria belonging to the Firmicutes phylum that have the ability to form spores. It is important to note that while currently most bacteria in this class are included in the Clostridiales order, this categorization is still partly based on old methods and is likely to be redefined in the future based on new advances in sequencing technologies that are enabling sequencing of the full genomes of bacteria in this class. Table 2 provides a summary of the categorization of 17 abundant species belonging to the Clostridia class which have been identified by the inventors as strong Treg-inducers and cultured in vitro. All of these species fall, under current categorization rules, in the Clostridiaceae family, and belong to clusters IV, XIVa, XVI, and XVIII.
  • The composition described herein may include one strain alone (only one strain) of any of the aforementioned bacterial species, but two or more strains of the bacteria can be used together. For example, one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen or seventeen of the strains listed in Table 2 or Table 4, in any combination, can be used together to affect regulatory T cells. In some cases, the 23, 17, 5, or 3 species mixes listed in Table 4 can be used together (and administered in one or several compositions) to affect regulatory T cells. In some cases, the following strains can be combined (the composition comprises): strain 1 (OTU136, closest species: Clostridium saccharogumia, Clostridium ramosum JCM1298), strain 3 (OTU221, closest species: Flavonifractor plautii, Pseudoflavonifractor capillosus ATTC 29799), strain 4 (OTU9, closest species: Clostridium hathewayi, Clostridium saccharolyticum WM1), strain 5 (OTU296, closest species: Clostridium scindens, Lachnospiraceae bacterium 5_1_57FAA), strain 6 (OTU21, closest species: Blautia coccoides, Lachnospiraceae bacterium 6_1_63FAA), strain 7 (OUT 166, closest species: Clostridium sp., Clostridium bolteae ATCC BAA-613), strain 8 (OTU73, closest species: cf. Clostridium sp. MLG055, Erysipelotrichaceae bacterium 2_2_44A), strain 9 (OTU174, closest species: Clostridium indolis, Anaerostipes caccae DSM 14662), strain 10 (OTU166, closest species: Clostridium bolteae, Clostridiu bolteae ATCC BAA-613), strain 12 (OTU55, closest species: Lachnospiraceae bacterium DJF_VP30, Lachnospiraceae bacterium 3_1_57FAA_CT1), strain 13 (OTU337, closest species: Anaerotruncus colihominis, Anaerotruncus colihominis DSM 17241), strain 14 (OTU314, closest species: Ruminococcus sp. ID8, Lachnospiraceae bacterium 2_1_46FAA), strain 15 (OTU195, closest species: Clostridium lavalense, Clostridium asparagiforme DSM 15981), strain 16 (OTU306, closest species: Clostridium symbiosum, Clostridium symbiosum WAL-14163), strain 18 (OTU46, closest species: Clostridium ramosum, Clostridium ramosum), strain 21 (OTU87, closest species: Eubacterium contortum, Clostridium sp. D5), strain 23 (OTU152, closest species: Lachnospiraceae bacterium DJF_VP30, Lachnospiraceae bacterium 3_1_57FAA_CT1), strain 24 (OTU253, closest species: Oscillospiraceae bacterium NML 061048, Oscillibacter valericigenes), strain 25 (OTU259, closest species: Eubacterium contortum, Clostridium sp. D5), strain 26 (OTU281, closest species: Clostridium scindens, Lachnospiraceae bacterium 5_1_57FAA), strain 27 (OTU288, closest species: Lachnospiraceae bacteriumA4, Lachnospiraceae bacterium 3_1_57FAA_CT1), strain 28 (OTU344, closest species: Clostridium sp. 316002/08, Clostridiales bacterium 1_7_47FAA), and strain 29 (OTU359, closest species: Lachnospiraceae bacteriumA4, Lachnospiraceae bacterium 3_1_57FAA_CT1) as described in Table 4.
  • In some cases, the following strains can be combined (the composition comprises: strain 1 (OTU136, closest species: Clostridium saccharogumia, Clostridium ramosum JCM1298), strain 3 (OTU221, closest species: Flavonifractor plautii, Pseudoflavonifractor capillosus ATTC 29799), strain 4 (OTU9, closest species: Clostridium hathewayi, Clostridium saccharolyticum WM1), strain 6 (OTU21, closest species: Blautia coccoides, Lachnospiraceae bacterium 6_1_63FAA), strain 7 (OUT 166, closest species: Clostridium sp., Clostridium bolteae ATCC BAA-613), strain 8 (OTU73, closest species: cf. Clostridium sp. MLG055, Erysipelotrichaceae bacterium 2_2_44A), strain 9 (OTU174, closest species: Clostridium indolis, Anaerostipes caccae DSM 14662), strain 13 (OTU337, closest species: Anaerotruncus colihominis, Anaerotruncus colihominis DSM 17241), strain 14 (OTU314, closest species: Ruminococcus sp. ID8, Lachnospiraceae bacterium 2_1_46FAA), strain 15 (OTU195, closest species: Clostridium lavalense, Clostridium asparagiforme DSM 15981), strain 16 (OTU306, closest species: Clostridium symbiosum, Clostridium symbiosum WAL-14163), strain 18 (OTU46, closest species: Clostridium ramosum, Clostridium ramosum), strain 21 (OTU87, closest species: Eubacterium contortum, Clostridium sp. D5), strain 26 (OTU281, closest species: Clostridium scindens, Lachnospiraceae bacterium 5_1_57FAA), strain 27 (OTU288, closest species: Lachnospiraceae bacteriumA4, Lachnospiraceae bacterium 3_1_57FAA_CT1), strain 28 (OTU344, closest species: Clostridium sp. 316002/08, Clostridiales bacterium 1_7_47FAA), and strain 29 (OTU359, closest species: Lachnospiraceae bacteriumA4, Lachnospiraceae bacterium 3_1_57FAA_CT1) as described in Table 4.
  • In some cases, the following strains can be combined (the composition comprises): strain 1 (OTU136, closest species: Clostridium saccharogumia, Clostridium ramosum JCM1298), strain 4 (OTU9, closest species: Clostridium hathewayi, Clostridium saccharolyticum WM1), strain 16 (OTU306, closest species: Clostridium symbiosum, Clostridium symbiosum WAL-14163), strain 27 (OTU288, closest species: Lachnospiraceae bacteriumA4, Lachnospiraceae bacterium 3_1_57FAA_CT1), and strain 29 (OTU359, closest species: Lachnospiraceae bacteriumA4, Lachnospiraceae bacterium 3_1_57FAA_CT1) as described in Table 4. In some cases, the following strains can be combined: strain 6 (OTU21, closest species: Blautia coccoides, Lachnospiraceae bacterium 6_1_63FAA), strain 8 (OTU73, closest species: cf. Clostridium sp. MLG055, Erysipelotrichaceae bacterium 2_2_44A), strain 13 (OTU337, closest species: Anaerotruncus colihominis, Anaerotruncus colihominis DSM 17241), strain 14 (OTU314, closest species: Ruminococcus sp. ID8, Lachnospiraceae bacterium 2_1_46FAA), and strain 26 (OTU281, closest species: Clostridium scindens, Lachnospiraceae bacterium 5_1_57FAA) as described in Table 4. In some cases, the following strains can be combined: strain 3 (OTU221, closest species: Flavonifractor plautii, Pseudoflavonifractor capillosus ATTC 29799), strain 7 (OUT 166, closest species: Clostridium sp., Clostridium bolteae ATCC BAA-613), strain 9 (OTU174, closest species: Clostridium indolis, Anaerostipes caccae DSM 14662), strain 15 (OTU195, closest species: Clostridium lavalense, Clostridium asparagiforme DSM 15981), and strain 28 (OTU344, closest species: Clostridium sp. 316002/08, Clostridiales bacterium 1_7_47FAA) as described in Table 4 In some cases, the following strains can be combined: strain 1 (OTU136, closest species: Clostridium saccharogumia, Clostridium ramosum JCM1298), strain 2 (OTU46, closest species: Flavonifractor plautii, Pseudoflavonifractor capillosus ATCC 29799) and strain 3 (OTU221, closest species: Flavonifractor plautii, Pseudoflavonifractor capillosus ATTC 29799) as described in Table 4.
  • The use of multiple strains of the aforementioned species of bacteria, preferably belonging to the Clostridium cluster XIVa or the cluster IV in combination can bring about an excellent effect on regulatory T cells. In addition to the bacteria belonging to clusters XIVa and IV, Clostridium ramosum, Clostridium saccharogumia (belonging to cluster XVIII) and cf. Clostridium sp. MLG055 (belonging to cluster XVI) can also be used. If more than one strain of bacteria is used (e.g., one or more strain belonging to cluster XIVa, one or more strain belonging to cluster IV, one or more strain belonging to clusters XVIII or XVI or a combination of any of the foregoing), the number and ratio of strains used can vary widely. The number and ratio to be used can be determined based on a variety of factors (e.g., the desired effect, such as induction or inhibition of proliferation or accumulation of regulatory T cells; the disease or condition to be treated, prevented or reduced in severity; the age or gender of the recipient; the typical amounts of the strains in healthy humans).
  • The strains can be present in a single composition, in which case they can be consumed or ingested together (in a single composition), or can be present in more than one composition (e.g., each can be in a separate composition), in which case they can be consumed individually or the compositions can be combined and the resulting combination (combined compositions) consumed or ingested. Any number or combination of the strains that proves effective (e.g., any number from one to 22, such as 1 to 20, 1 to 15, 1 to 10, 1 to 5, 1 to 3, 1 to 2, and any number therebetween or one to 23, such as 1 to 23, 3 to 23, 5 to 23, 1 to 20, 1 to 17, 3 to 17, 5 to 17, 1 to 15, 1 to 10, 1 to 5, 3 to 5, 1 to 3, 1 to 2, and any number therebetween) can be administered.
  • In certain cases, a combination of some or all of the 22 or 23 (e.g., the 23 strains in Exampe 32 and Table 4) strains described in the present disclosure is used. For example, at least one, two or more, three, three or more, four, four or more, five, five or more, six, six or more or any other number of the 22 or 23 described strains, including 22 or 23 strains, can be used. In some cases, the specific combinations of 3, 5, 17, or 23 strains described in Table 4 can be used (the composition comprises combinations of 3, 5, 17 or 23 strains described in Table 4). They can be used in combination with one another and in combination with strains not described in the cited reference.
  • Cells of bacteria belonging to the Clostridia class, such as these specifically described herein, can be used in spore form or in vegetative form. From the viewpoint of stability to high temperature and pressure conditions, extended shelf life, ease of handling, resistance to antibiotics, and lack of need for a cold chain storage and distribution, the bacteria may be preferably in the form of spore. From the viewpoint of abiding by the directives of certain manufacturing organizations that do not tolerate spore contamination in their facilities, the bacteria may alternatively be produced (and later administered) in the form of vegetative cells.
  • The term the "physiologically active substance derived from bacteria belonging to the Clostridia class" of the present disclosure includes substances contained in the bacteria, secretion products of the bacteria, and metabolites of the bacteria. Such a physiologically active substance can be identified by purifying an active component from the bacteria, a culture supernatant thereof, or intestinal tract contents in the intestinal tract of a mouse in which only bacteria belonging to the Clostridia class are colonized by an already known purification method.
  • "Chloroform treatment" of a fecal sample obtained from a human is a method that isolates the bacteria in the fecal sample that have the ability to form spores, and is not particularly limited, as long as the spore-forming fraction is obtained by treating feces of a human with chloroform (for example, 3% chloroform), and has the effect of inducing proliferation or accumulation of regulatory T cells, including mammalian regulatory T cells such as murine regulatory T cells and human regulatory T cells.
  • When the aforementioned "bacteria belonging to the Clostridia class" are cultured in a medium, substances contained in the bacteria, secretion products and metabolites produced by the bacteria are released from the bacteria. The meaning of the active ingredient "culture supernatant of the bacteria" in the composition of the present disclosure includes such substances, secretion products, and metabolites. The culture supernatant is not particularly limited, as long as the culture supernatant has the effect of inducing proliferation or accumulation of regulatory T cells. Examples of the culture supernatant include a protein fraction of the culture supernatant, a polysaccharide fraction of the culture supernatant, a lipid fraction of the culture supernatant, and a low-molecular weight metabolite fraction of the culture supernatant.
  • The bacterial composition may be administered in the form of a pharmaceutical composition, a dietary supplement, or a food or beverage (which may also be an animal feed), or may be used as a reagent for an animal model experiment. The pharmaceutical composition, the dietary supplement, the food or beverage, and the reagent induce proliferation or accumulation of regulatory T cells. An example presented herein revealed that regulatory T cells (Treg cells) induced by bacteria or the like belonging to the Clostridia class suppressed the proliferation of effector T-cells. The composition of the present disclosure can be used suitably as a composition having an immunosuppressive effect. The immunosuppressive effect can be evaluated, for example, as follows. Regulatory T cells isolated from an experimental animal, such as a mouse, to which the composition of the present disclosure is orally administered are caused to act on effector T-cells (CD4+ CD25- cells) isolated from the spleen, and the proliferation ability thereof is measured by using the intake amount of [3H]-thymidine as an index (refer to Example 14).
  • The bacterial composition described herein can be used, for example, as a pharmaceutical composition for preventing or treating (reducing, partially or completely, the adverse effects of) an autoimmune disease. such as chronic inflammatory bowel disease, systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, or Hashimoto's disease; an allergic disease, such as a food allergy, pollenosis, or asthma; an infectious disease, such as an infection with Clostridium difficile; an inflammatory disease such as a TNF-mediated inflammatory disease (e.g., an inflammatory disease of the gastrointestinal tract, such as pouchitis, a cardiovascular inflammatory condition, such as atherosclerosis, or an inflammatory lung disease, such as chronic obstructive pulmonary disease); a pharmaceutical composition for suppressing rejection in organ transplantation or other situations in which tissue rejection might occur; a supplement, food, or beverage for improving immune functions; or a reagent for suppressing the proliferation or function of effector T-cells.
  • More specific examples of target diseases for which the composition is useful for treatment (reducing adverse effects or prevention) include autoimmune diseases, allergic diseases, infectious diseases, and rejection in organ transplantations, such as inflammatory bowel disease (IBD), ulcerative colitis, Crohn's disease, sprue, autoimmune arthritis, rheumatoid arthritis, Type I diabetes, multiple sclerosis, graft vs. host disease following bone marrow transplantation, osteoarthritis, juvenile chronic arthritis, Lyme arthritis, psoriatic arthritis, reactive arthritis, spondy loarthropathy, systemic lupus erythematosus, insulin dependent diabetes mellitus, thyroiditis, asthma, psoriasis, dermatitis scleroderma, atopic dermatitis, graft versus host disease, acute or chronic immune disease associated with organ transplantation, sarcoidosis, atherosclerosis, disseminated intravascular coagulation, Kawasaki's disease, Grave's disease, nephrotic syndrome, chronic fatigue syndrome, Wegener's granulomatosis, Henoch-Schoenlejn purpurea, microscopic vasculitis of the kidneys, chronic active hepatitis, uveitis, septic shock, toxic shock syndrome, sepsis syndrome, cachexia, acquired immunodeficiency syndrome, acute transverse myelitis, Huntington's chorea, Parkinson's disease, Alzheimer's disease, stroke, primary biliary cirrhosis, hemolytic anemia, polyglandular deficiency type I syndrome and polyglandular deficiency type II syndrome, Schmidt's syndrome, adult (acute) respiratory distress syndrome, alopecia, alopecia areata, seronegative arthopathy, arthropathy, Reiter's disease, psoriatic arthropathy, chlamydia, yersinia and salmonella associated arthropathy, spondyloarhopathy, atheromatous disease/arteriosclerosis, allergic colitis, atopic allergy, food allergies such as peanut allergy, tree nut allergy, egg allergy, milk allergy, soy allergy, wheat allergy, seafood allergy, shellfish allergy, or sesame seed allergy, autoimmune bullous disease, pemphigus vulgaris, pemphigus foliaceus, pemphigoid, linear IgA disease, autoimmune haemolytic anaemia, Coombs positive haemolytic anaemia, acquired pernicious anaemia, juvenile pernicious anaemia, myalgic encephalitis/Royal Free Disease, chronic mucocutaneous candidiasis, giant cell arteritis, primary sclerosing hepatitis, cryptogenic autoimmune hepatitis, Acquired Immunodeficiency Disease Syndrome, Acquired Immunodeficiency Related Diseases, Hepatitis C, common varied immunodeficiency (common variable hypogammaglobulinaemia), dilated cardiomyopathy, fibrotic lung disease, cryptogenic fibrosing alveolitis, postinflammatory interstitial lung disease, interstitial pneumonitis, connective tissue disease associated interstitial lung disease, mixed connective tissue disease associated lung disease, systemic sclerosis associated interstitial lung disease, rheumatoid arthritis associated interstitial lung disease, systemic lupus erythematosus associated lung disease, dermatomyositis/polymyositis associated lung disease, Sjogren's disease associated lung disease, ankylosing spondy litis associated lung disease, vasculitic diffuse lung disease, haemosiderosis associated lung disease, drug-induced interstitial lung disease, radiation fibrosis, bronchiolitis obliterans, chronic eosinophilic pneumonia, lymphocytic infiltrative lung disease, postinfectious interstitial lung disease, gouty arthritis, autoimmune hepatitis, type-1 autoimmune hepatitis (classical autoimmune or lupoid hepatitis), type-2 autoimmune hepatitis (anti-LKM antibody hepatitis), autoimmune mediated hypoglycemia, type B insulin resistance with acanthosis nigricans, hypoparathyroidism, acute immune disease associated with organ transplantation, chronic immune disease associated with organ transplantation, osteoarthrosis, primary sclerosing cholangitis, idiopathic leucopenia, autoimmune neutropenia, renal disease NOS, glomerulonephritides, microscopic vasulitis of the kidneys, discoid lupus, erythematosus, male infertility idiopathic or NOS, sperm autoimmunity, multiple sclerosis (all subtypes), insulindependent diabetes mellitus, sympathetic ophthalmia, pulmonary hypertension secondary to connective tissue disease, Goodpasture's syndrome, pulmonary manifestation of polyarteritis nodosa, acute rheumatio fever, rheumatoid spondylitis, Still's disease, systemic sclerosis, Takayasu's disease/arteritis, autoimmune thrombocytopenia, idiopathic thrombocytopenia, autoimmune thyroid disease, hyperthyroidism, goitrous autoimmune hypothyroidism (Hashimoto's disease), atrophic autoimmune hypothyroidism, primary myxoedema, phacogenic uveitis, primary vasculitis, vitiligo, allergic rhinitis (pollen allergies), anaphylaxis, pet allergies, latex allergies, drug allergies, allergic rhinoconjuctivitis, eosinophilic esophagitis, hypereosinophilic syndrome, eosinophilic gastroenteritis cutaneous lupus erythematosus, eosinophilic esophagitis, hypereosinophilic syndrome, and eosinophilic gastroenteritis, and diarrhea.
  • Additional examples of target diseases for which the composition is useful for treatment include colon cancer, cystic fibrosis, celiac disease, Type 2 diabetes, and autism-related immunopathologies. These diseases are characterized by a reduction of Clostridium Clusters IV and XIV in the gastrointestinal microbiota.
  • Compositions described herein can also be used as a pharmaceutical composition for preventing or treating infectious diseases in an individual whose resistance to the infectious diseases is impaired, for example because of damage due to excessive inflammation caused by the immunity or due to an alteration of the patient's microbiome. Examples of infectious pathogens that impair maintenance or recovery of homeostasis of a host, and which eventually bring about such immunopathological tissue damage include Salmonella, Shigella, Clostridium difficile, Mycobacterium (which cause the disease tuberculosis), protozoa (which cause malaria), filarial nematodes (which cause the disease filariasis), Schistosoma (which cause schistosomiasis), Toxoplasma (which cause the disease toxoplasmosis), Leishmania (which cause the disease leishmaniasis), HCV and HBV (which cause the disease hepatitis C and hepatitis B), and herpes simplex viruses (which cause the disease herpes).
  • Pharmaceutical preparations can be formulated from the bacterial compositions described by drug formulation methods known to those of skill in the art. For example, the composition can be used orally or parenterally in the form of capsules, tablets, pills, sachets, liquids, powders, granules, fine granules, film-coated preparations, pellets, troches, sublingual preparations, chewables, buccal preparations, pastes, syrups, suspensions, elixirs, emulsions, liniments, ointments, plasters, cataplasms, transdermal absorption systems, lotions, inhalations, aerosols, injections, suppositories, and the like.
  • For formulating these preparations, the bacterial compositions can be used in appropriate combination with carriers that are pharmacologically acceptable or acceptable for ingestion, such as in a food or beverage, including one or more of the following: sterile water, physiological saline, vegetable oil, solvent, a base material, an emulsifier, a suspending agent, a surfactant, a stabilizer, a flavoring agent, an aromatic, an excipient, a vehicle, a preservative, a binder, a diluent, a tonicity adjusting agent, a soothing agent, a bulking agent, a disintegrating agent, a buffer agent, a coating agent, a lubricant, a colorant, a sweetener, a thickening agent, a flavor corrigent, a solubilizer, and other additives.
  • A pharmaceutical preparation or formulation and particularly a pharmaceutical preparation for oral administration, comprises an additional component that enables efficient delivery of the bacterial composition of the present disclosure to the colon, in order to more efficiently induce proliferation or accumulation of regulatory T cells in the colon. A variety of pharmaceutical preparations that enable the delivery of the bacterial composition to the colon can be used. Examples thereof include pH sensitive compositions, more specifically, buffered sachet formulations or enteric polymers that release their contents when the pH becomes alkaline after the enteric polymers pass through the stomach. When a pH sensitive composition is used for formulating the pharmaceutical preparation, the pH sensitive composition is preferably a polymer whose pH threshold of the decomposition of the composition is between about 6.8 and about 7.5. Such a numeric value range is a range in which the pH shifts toward the alkaline side at a distal portion of the stomach, and hence is a suitable range for use in the delivery to the colon.
  • A pharmaceutical preparation useful for delivery of the bacterial composition to the colon is one that ensures the delivery to the colon by delaying the release of the contents (e.g., the bacterial composition) by approximately 3 to 5 hours, which corresponds to the small intestinal transit time. In one case of a pharmaceutical preparation for delayed release, a hydrogel is used as a shell. The hydrogel is hydrated and swells upon contact with gastrointestinal fluid, with the result that the contents are effectively released (released predominantly in the colon). Delayed release dosage units include drug-containing compositions having a material which coats or selectively coats a drug or active ingredient to be administered. Examples of such a selective coating material include in vivo degradable polymers, gradually hydrolyzable polymers, gradually water-soluble polymers, and/or enzyme degradable polymers. A wide variety of coating materials for efficiently delaying the release is available and includes, for example, cellulose-based polymers such as hydroxypropyl cellulose, acrylic acid polymers and copolymers such as methacrylic acid polymers and copolymers, and vinyl polymers and copolymers such as polyvinylpyrrolidone.
  • Examples of the composition enabling the delivery to the colon further include bioadhesive compositions which specifically adhere to the colonic mucosal membrane (for example, a polymer described in the specification of US Patent No. 6.368.586 ) and compositions into which a protease inhibitor is incorporated for protecting particularly a biopharmaceutical preparation in the gastrointestinal tracts from decomposition due to an activity of a protease.
  • An example of a system enabling the delivery to the colon is a system of delivering a composition to the colon by pressure change in such a way that the contents are released by utilizing pressure change caused by generation of gas in bacterial fermentation at a distal portion of the stomach. Such a system is not particularly limited, and a more specific example thereof is a capsule which has contents dispersed in a suppository base and which is coated with a hydrophobic polymer (for example, ethyl cellulose).
  • Another example of the system enabling the delivery to the colon is a system of delivering a composition to the colon, the system being specifically decomposed by an enzyme (for example, a carbohydrate hydrolase or a carbohydrate reductase) present in the colon. Such a system is not particularly limited, and more specific examples thereof include systems which use food components such as non-starch polysaccharides, amylose, xanthan gum, and azopolymers.
  • When used as a pharmaceutical preparation, the bacterial composition may be used in combination with an already known pharmaceutical composition for use in immunosuppression. In some cases, the pharmaceutical preparation can comprise both the bacterial composition and the already known pharmaceutical composition. Such a known pharmaceutical composition is not particularly limited, and may be at least one therapeutic composition selected from the group consisting of corticosteroids, mesalazine, mesalamine, sulfasalazine, sulfasalazine derivatives, immunosuppressive drugs, cyclosporin A, mercaptopurine, azathiopurine, prednisone, methotrexate, antihistamines, glucocorticoids, epinephrine, theophylline, cromolyn sodium, anti-leukotrienes, anti-cholinergic drugs for rhinitis, anti-cholinergic decongestants, mast-cell stabilizers, monoclonal anti-IgE antibodies, vaccines (preferably vaccines used for vaccination where the amount of an allergen is gradually increased), anti-TNF inhibitors such as infliximab, adalimumab, certolizumab pegol, golimumab, or etanercept, and combinations thereof. It is preferable to use these therapeutic compositions in combination with the bacterial composition described herein. The bacterial composition can also be used as an adjuvant to improve the efficacy of a vaccine formulation such as a vaccine for the prophylaxis or treatment of an autoimmune disease or an allergic disease.
  • The bacterial composition can be used as a food or beverage, such as a health food or beverage, a food or beverage for infants, a food or beverage for pregnant women, athletes, senior citizens or other specified group, a functional food, a beverage, a food or beverage for specified health use, a dietary supplement, a food or beverage for patients, or an animal feed. Specific examples of the foods and beverages include various beverages such as juices, refreshing beverages, tea beverages, drink preparations, jelly beverages, and functional beverages; alcoholic beverages such as beers; carbohydrate-containing foods such as rice food products, noodles, breads, and pastas; paste products such as fish hams, sausages, paste products of seafood; retort pouch products such as curries, food dressed with a thick starchy sauces, and Chinese soups; soups; dairy products such as milk, dairy beverages, ice creams, cheeses, and yogurts; fermented products such as fermented soybean pastes, yogurts, fermented beverages, and pickles; bean products; various confectionery products such as Western confectionery products including biscuits, cookies, and the like, Japanese confectionery products including steamed bean-jam buns, soft adzuki-bean jellies, and the like, candies, chewing gums, gummies, cold desserts including jellies, cream caramels, and frozen desserts; instant foods such as instant soups and instant soy-bean soups; microwavable foods; and the like. Further, the examples also include health foods and beverages prepared in the forms of powders, granules, tablets, capsules, liquids, pastes, and jellies. The composition of the present disclosure can be used for animals, including humans. The animals, other than humans, are not particularly limited, and the composition can be used for various livestock, poultry, pets, experimental animals, and the like. Specific examples of the animals include pigs, cattle, horses, sheep, goats, chickens, wild ducks, ostriches, domestic ducks, dogs, cats, rabbits, hamsters, mice, rats, monkeys, and the like, but the animals are not limited thereto.
  • Without wishing to be bound by theory, individuals in whom bacteria belonging to the group Firmicutes (the group to which the Clostridium clusters IV and XIVa belong) are relatively abundant gain more body weight than individuals in whom bacteria belonging to the group Bacteroidetes are relatively abundant is large. The bacterial composition is capable of conditioning absorption of nutrients and improving feed efficiency. From such a viewpoint, the bacterial composition can be used for promoting body weight gain, or for a high efficiency animal feed. Diseases and conditions that would benefit from body weight gain include, e.g., starvation, cancer, AIDS, gastrointestinal disorders (e.g., celiac disease, peptic ulcer, inflammatory bowel disease (Crohns' disease and ulcerative colitis), pancreatitis, gastritis, diarrhea), hyperthyroidism, infection, renal disease, cardiac disease, pulmonary disease, connective tissue disease, weight loss caused by medications, anorexia, Addison's disease, dementia, depression, hypercalcemia, Parkinson's disease and tuberculosis.
  • The addition of the bacterial composition to an antibiotic-free animal feed makes it possible to increase the body weight of an animal that ingests the animal feed to a level equal to or higher than that achieved by animal ingesting antibiotic-containing animal feeds, and also makes it possible to reduce pathogenic bacteria in the stomach to a level equal to those in animals consuming typical antibiotic-containing animal feeds. The bacterial composition can be used as a component of an animal feed that does not need the addition of antibiotics.
  • In addition, unlike conventional bacteria (Lactobacillus and Bifidobacteria) in commercial use, which are not easy to incorporate into the livestock production, the present bacterial composition in spore form can be pelletized, sprayed, or easily mixed with an animal feed and can also be added to drinking water.
  • Animal feed comprising the bacterial composition can be fed to a wide variety of types of animals and animals of a varying ages and can be fed at regular intervals or for a certain period (for example, at birth, during weaning, or when the animal is relocated or shipped).
  • The bacterial composition can be used to promote weight gain and enhance energy absorption in humans and nonhumans (e.g., farm or other food animals).
  • The bacterial active components of the bacterial composition can be manufactured using fermentation techniques well known in the art. In one case, the active ingredients are manufactured using anaerobic fermentors, which can support the rapid growth of bacterial species belonging to the Clostridia class. The anaerobic fermentors may be, for example, stirred tank reactors or disposable wave bioreactors. Culture media such as BL media and EG media, or similar versions of these media devoid of animal components can be used to support the growth of the bacterial species. The bacterial product can be purified and concentrated from the fermentation broth by traditional techniques, such as centrifugation and filtration, and can optionally be dried and lyophilized by techniques well known in the art.
  • A food or beverage comprising a bacterial composition described herein can be manufactured by manufacturing techniques well known in the technical field. One or more components (for example, a nutrient) which are effective for the improvement of an immune function by an immunosuppressive effect may be added to the food or beverage. In addition, the food or beverage may be combined with another component or another functional food exhibiting a function other than the function of the improvement of an immune function to thereby serve as a multi-functional food or beverage.
  • Moreover, the bacterial composition can be incorporated into foods requiring a processing step which may destroy ordinary probiotic strains. Specifically, most commercially usable probiotic strains cannot be incorporated into foods that need to be processed, for example, by heat treatment, long term storage, freezing, mechanical stress, or high-pressure treatment (for example, extrusion forming or roll forming). On the other hand, because of the advantageous nature of forming spores, the bacterial composition described herein can be easily incorporated into such processed foods. For example, the bacterial composition in the form of spores can survive even in a dried food, and can remain living even after being ingested. The bacterial composition can withstand low-temperature sterilization processes, typically processes carried out at a temperature from about 70 °C to about 100 °C, both inclusive. The bacterial composition can be incorporated into dairy products that require a pasteurization step. Furthermore, the bacterial composition can withstand long-term storage of many years; high-temperature processing such as baking and boiling; low-temperature processing such as freezing and cold storage; and high-pressure treatments such as extrusion forming and roll forming.
  • Many types of foods that need to be processed under such harsh conditions include foods which need to be processed in a microwave oven to be edible (for example, oatmeal), foods which need to be baked to be edible (for example, a muffin), foods which need to be subjected to a sterilization high-temperature treatment for a short period of time to be edible (for example, milk), and foods which need to be heated to be drinkable (for example, hot tea).
  • The amount of the bacterial composition to be administered or ingested can be determined empirically, taking into consideration such factors as the age, body weight, gender, symptoms, health conditions, of an individual who will receive it, as well as the kind of bacterial composition (a pharmaceutical product, a food or beverage) to be administered or ingested. For example, the amount per administration or ingestion is generally 0.01 mg/kg body weight to 100 mg/kg body weight, and, in specific cases, 1 mg/kg body weight to 10 mg/kg body weight. Also described herein is a method for suppressing the immunity (reducing the immune response) of a subject, the method being characterized in that the bacteria belonging to the Clostridia class or the physiologically active substance derived from the bacteria is administered to or ingested by the subject as described above.
  • The bacterial composition may be administered to an individual once, or it may be administered more than once. If the composition is administered more than once, it can be administered on a regular basis (for example, once a day, once every two days, once a week, once every two weeks, once a month, once every 6 months, or once a year) or on an as needed or irregular basis. The appropriate frequency of administration (which may depend on host genetics, age, gender, and health or disease status of the subject, among other factors) may be determined empirically. For example, a patient can be administered one dose of the composition, and the levels of the bacterial strains of the composition in fecal samples obtained from the patient can be measured at different times (for example after 1 day, after 2 days, after 1 week, after 2 weeks, after 1 month). When the levels of the bacteria fall to, for example, one half of their maximum value, a second dose can be administered, and so on.
  • A product comprising the bacterial composition (a pharmaceutical product, a food or beverage, or a reagent) or a manual thereof may be accompanied by document or statement explaining that the product can be used to suppress the immunity (including a statement that the product has an immunosuppressive effect and a statement that the product has an effect of suppressing the proliferation or function of effector T-cells). Here, the "provision to the product or the manual thereof with the note" means that the document or statement is provided to a main body, a container, a package, or the like of the product, or the note is provided to a manual, a package insert, a leaflet, or other printed matters, which disclose information on the product.
    • <Method for Inducing Proliferation or Accumulation of Regulatory T Cells>
  • As described above, and as shown in Examples, administration of the bacterial composition to an individual makes it possible to induce proliferation or accumulation of regulatory T cells in the individual. This provides a method of inducing proliferation or accumulation of regulatory T cells in an individual, the method comprising: administering, to the individual, at least one substance selected from the group consisting of: (a) Clostridium saccharogumia, Clostridium ramosum JCM1298, Clostridium ramosum, Flavonifractor plautii, Pseudoflavonifractor capillosus ATCC 29799, Clostridium hathewayi, Clostridium saccharolyticum WM1, Bacteroides sp. MANG, Clostridium saccharolyticum, Clostridium scindens, Lachnospiraceae bacterium 5_1_57FAA, Lachnospiraceae bacterium 6_1_63FAA, Clostridium sp. 14616, Clostridium bolteae ATCC BAA-613, cf. Clostridium sp. MLG055, Erysipelotrichaceae bacterium 2_2_44A, Clostridium indolis, Anaerostipes caccae, Clostridium bolteae, Lachnospiraceae bacterium DJF_VP30, Lachnospiraceae bacterium 3_1_57FAA_CT1, Anaerotruncus colihominis, Anaerotruncus colihominis DSM 17241, Ruminococcus sp. ID8, Lachnospiraceae bacterium 2_1_46FAA, Clostridium lavalense, Clostridium asparagiforme DSM 15981, Clostridium symbiosum, Clostridium symbiosum WAL-14163, Eubacterium contortum, Clostridium sp. D5, Oscillospiraceae bacterium NML 061048, Oscillibacter valericigenes, Lachnospiraceae bacterium A4, Clostridium sp. 316002/08, and Clostridiales bacterium 1_7_47FAA, Blautia cocoides, Anaerostipes caccae DSM 14662; (b) a culture supernatant of at least one (a, one or more) of the bacteria described/listed herein; (c) a physiologically active substance derived from a (one or more, at least one) bacterium described/listed herein; or a combination of any two or three of (a), (b) and (c). The bacterial composition is administered (provided) to the individual in sufficient quantity to produce the desired effect of inducing proliferation, accumulation or both proliferation and accumulation of regulatory T cells. It may be administered to an individual in need of treatment, reduction in the severity of or prevention of at least one disease selected from an autoimmune disease, an inflammatory disease, an allergic disease, and an infectious disease.
  • Note that, the "individual" or "subject" may be in a healthy state or a diseased state.
    The method may further comprise the optional step of administering at least one (a, one or more) antibiotic preceding, or in combination with, the bacterial composition. The antibiotic administered can be, for example, one which facilitates recolonization of the gut by Gram-positive bacteria of the Clostridia class, such as an antibiotic that reduces Gram-negative bacteria. Examples of such antibiotics include aminoglycoside antibiotics (amikacin, gentamicin, kanamycin, neomycin, netilmicin, tobramycin, and paromomycin), cephalosporin antibiotics (cefaclor, cefamandole, cefoxitin, cefprozil, cefuroxime, cefixime, cefdinir, cefditoren, cefoperazone, cefotaxime, ceftazidime, ceftibuten, ceftizoxime, ceftriaxone, and cefoxotin), sulfonamides, ampicillin, and streptomycin.
  • Moreover, a prebiotic composition such as almond skin, inulin, oligofructose, raffinose, lactulose, pectin, hemicellulose (such as xyloglucan and alpha-glucans), amylopectin, and resistant starch which are not decomposed in the upper gastrointestinal tract and promote the growth of intestinal microbes in the intestinal tract, as well as growth factors such as acetyl-Co A, biotin, beet molasses, and yeast extracts, preferentially contributes to the proliferation of the bacterial species in the composition belonging to the Clostridia class. A method of inducing proliferation and/or accumulation of regulatory T cells in an individual can comprise administering, to the individual, at least one substance selected from the above in combination with the bacterial composition. Also contemplated herein is a composition comprising the bacterial composition and a prebiotic [00] composition.
  • The above-described antibiotic, and the above-described prebiotic composition or growth factor may be used in combination. Moreover, a therapeutic composition may be administered to an individual together with at least one substance selected from the group consisting of the bacterial composition, an antibiotic, and a prebiotic composition or growth factor.
  • A therapeutic composition can be, for example, one therapeutic composition selected from the group consisting of corticosteroids, mesalazine, mesalamine, sulfasalazine, sulfasalazine derivatives, immunosuppressive drugs, cyclosporin A, mercaptopurine, azathiopurine, prednisone, methotrexate, antihistamines, glucocorticoids, epinephrine, theophylline, cromolyn sodium, anti-leukotrienes, anti-cholinergic drugs for rhinitis, anti-cholinergic decongestants, mast-cell stabilizers, monoclonal anti-IgE antibodies, vaccines (preferably, vaccines used for vaccination where the amount of an allergen is gradually increased), anti-TNF inhibitors such as infliximab, adalimumab, certolizumab pegol, golimumab, or etanercept, and combinations thereof. These therapeutic compositions can be administered prior to, in combination with or following administration of the bacterial composition and optionally, also in combination with an antibiotic, a prebiotic composition, a growth factor or any combination of an antibiotic, a prebiotic composition and a growth factor.
  • There is no particular limitation imposed on the combined use of the therapeutic composition with at least one substance selected from the group consisting of the bacterial composition, the "antibiotic", and the "prebiotic composition or growth factor". For example, the "one substance" and the therapeutic composition are administered orally or parenterally to an individual simultaneously or sequentially/individually at any appropriate time.
  • Whether administration of the bacterial composition induces the proliferation and/or accumulation of regulatory T cells can be determined by using, as an index, increase or reinforcement of at least one of the following: the number of regulatory T cells, the ratio of regulatory T cells in the T cell group of the colon, a function of regulatory T cells, or expression of a marker of regulatory T cells. A specific approach is measurement counts or percentage of Foxp3-expressing Tregs in a patient sample, such as a biopsy or a blood sample, promotion (enhancement) of IL-10 expression, promotion (enhancement) of CTLA4 expression, promotion (enhancement) of IDO expression, suppression of IL-4 expression, or colonization of an individual with the bacterial composition administered as the index of the induction of proliferation or accumulation of regulatory T cells.
  • Methods for detecting such expression include northern blotting, RT-PCR, and dot blotting for detection of gene expression at the transcription level; ELISA, radioimmunoassays, immunoblotting, immunoprecipitation, and flow cytometry for detection of gene expression at the translation level.
  • Samples that may be used for measuring such an index include tissues and fluids obtained from an individual, such as blood, obtained in a biopsy, and a fecal sample.
    • <Method for Predicting Response of an Individual to the Bacteria Composition by Monitoring the Individual's Response to Treatment with the Composition>
  • Also described is a method in which an amount (e.g. count) or the percentage of at least one bacterial species selected from the group consisting of: Clostridium saccharogumia, Clostridium ramosum JCM1298, Clostridium ramosum, Flavonifractor plautii, Pseudoflavonifractor capillosus ATCC 29799, Clostridium hathewayi, Clostridium saccharolyticum WM1, Bacteroides sp. MANG, Clostridium saccharolyticum, Clostridium scindens, Lachnospiraceae bacterium 5_1_57FAA, Lachnospiraceae bacterium 6_1_63FAA, Clostridium sp. 14616, Clostridium bolteae ATCC BAA-613, cf. Clostridium sp. MLG055, Erysipelotrichaceae bacterium 2_2_44A, Clostridium indolis, Anaerostipes caccae, Clostridium bolteae, Lachnospiraceae bacterium DJF_VP30, Lachnospiraceae bacterium 3_1_57FAA_CT1, Anaerotruncus colihominis, Anaerotruncus colihominis DSM 17241, Ruminococcus sp. ID8, Lachnospiraceae bacterium 2_1_46FAA, Clostridium lavalense, Clostridium asparagiforme DSM 15981, Clostridium symbiosum, Clostridium symbiosum WAL-14163, Eubacterium contortum, Clostridium sp. D5, Oscillospiraceae bacterium NML 061048, Oscillibacter valericigenes, Lachnospiraceae bacterium A4, Clostridium sp. 316002/08, and Clostridiales bacterium 1_7_47FAA, Blautia cocoides, Anaerostipes caccae DSM 14662 in a patient's sample (e.g. a colonic biopsy or a fecal sample) is determined. When the percentage or the count of the bacteria selected from the list above is lower in an individual than a base line value obtained by performing a similar determination on a healthy individual (e.g., an individual who does not have/has not been identified as having a disease or condition for which the bacterial composition is a potential treatment such as an auto-immune disease, an allergic condition, cancer, organ rejection), it is determined that the individual is likely to be responsive to the bacterial composition. This determination can be used, for example, by a clinician to determine whether an individual or a patient is likely to benefit from treatment with the bacterial composition, or to select an individual or a patient for inclusion in a clinical trial. The clinician can then administer the bacterial composition to the individual or patient based on the determination that the individual or patient is likely to benefit from treatment. This determination can also be used as a method to monitor an individual's response to treatment with the bacterial compositions described, wherein a higher value of the determination after treatment with the bacterial composition (compared to a determination before treatment) indicates that the individual has responded favorably to treatment (e.g. is a positive indicator of successful colonization and enhanced immunosuppression in the individual). Optionally, the prognosis and monitoring methods described here may further comprise the step of measuring in the individual's samples the percentages or absolute counts of other commensal species belonging to Clostridium Clusters IV and XIVa that are not present in the bacterial composition, wherein lower than baseline values before treatment indicate a higher likelihood of a positive response to treatment, and wherein an increased value after treatment indicates that the individual has responded favorably to treatment. In the prognosis and monitoring methods described here, a variety of known methods can be used for determining the composition of the microbiota. For example, 16S rRNA sequencing can be used
    • <Vaccine Adjuvant Composition and Method for Treating or Preventing Infectious Disease or Autoimmune Disease by Using the Vaccine Composition>
  • As described above, and as shown in the Examples, the induction of Treg cells in the colon by bacteria belonging to the Clostridia class has an important role in local and systemic immune responses. The bacterial composition can also be used as an adjuvant to improve the efficacy of a vaccine formulation. In one case, the bacterial composition can be used as an adjuvant to a vaccine for the prophylaxis or treatment of an autoimmune disease or an allergic disease (for example, as an adjuvant for a vaccination protocol where the amount of an allergen is gradually increased).
    • Example of autoimmune diseases and allergic diseases include those described as the "specific examples of target diseases" in <Composition Having Effect of Inducing Proliferation or Accumulation of Regulatory T cells>.
  • As described herein, the bacterial composition can also be administered to an individual who is also receiving antibiotic treatment. The present inventors have demonstrated that antibiotics that act against Gram+ bacteria, such as vancomycin or metronidazole, can effectively eliminate or greatly reduce bacterial species belonging to the Clostridia class from the gastrointestinal tract of mammals and subsequently decrease the levels of regulatory T cells (Example 5, Fig. 30). Without wishing to be bound by theory, the key role of bacteria belonging to the Clostridia class in preserving immune tolerance strongly indicates that their absence or reduced levels can play a key role in autoimmune diseases characterized by failures of immune tolerance. Accordingly, individuals undergoing courses of antibiotics against Gram+ bacteria (for example, individuals being treated for infections with pathogens such as C. difficile and Giardia), who are at a high risk of experiencing a loss of the bacteria belonging to the Clostridia class and thus experience immune tolerance deficits, can be preventively "repopulated" through use of the bacterial composition. The bacterial composition described herein can be administered before, simultaneously with, or after the antibiotic treatment, but preferably it is administered simultaneously or after the antibiotic treatment. The bacterial composition described herein is preferably administered in spore form, to improve its resistance to residual antibiotics. Antibiotics against Gram-positive bacteria include, but are not limited to, vancomycin, metronidazole, linezolid, ramoplanin, fidaxomicin, cephalosporin antibiotics (cephalexin, cefuroxime, cefadroxil, cefazolin, cephalothin, cefaclor, cefamandole, cefoxitin, cefprozil, and ceftobiprole); fluoroquinolone antibiotics (cipro, Levaquin, floxin, tequin, avelox, and norflox); tetracycline antibiotics (tetracycline, minocycline, oxytetracycline, and doxycycline); penicillin antibiotics (amoxicillin, ampicillin, penicillin V, dicloxacillin, carbenicillin, vancomycin, and methicillin); and carbapenem antibiotics (ertapenem, doripenem, imipenem/cilastatin, and meropenem).
    • <Methods to Select Treg-inducing Organisms>
  • Also described is a method of obtaining bacteria capable of inducing Tregs, comprising (1) isolating the bacterial spore-forming fraction from a fecal or biopsy sample obtained from a mammal, preferably a human (e.g. by chloroform treatment or by heat treatment), (2) optionally, orally administering the spore-forming fraction to a non-human mammal, preferably a germ-free non-human mammal; (3) optionally, obtaining a fecal sample from the non-human mammal, diluting the fecal sample (for example diluting it by volume by a factor of 10, 100, 1,000, or 10,000), thereby producing a diluted fecal sample, and orally administering the diluted sample to a second germ-free non-human mammal, wherein optional step (3) can be repeated more than one time, (4) plating serial dilutions, under aerobic condition or strictly anaerobic conditions, of either the spore-forming fraction obtained in (1) or a sample of intestinal contents of the non-human mammal of (3), and (5) picking a single colony from the culture plate. The colony can be further assessed for the ability of bacteria to induce proliferation of regulatory T cells and/or accumulation of regulatory T cells using known methods, such as those described in the examples.
  • The following examples assist in the understanding of the invention and are not intended to be limiting in any way.
  • Note that mice used in Examples were prepared or produced as follows. In the following description, mice may be referred to as "SPF" or "GF". These "SPF" and "GF" indicate that the mice were maintained in the absence of specific pathogenic bacteria (specific pathogen-free, SPF), and that the mice were maintained under Germ-Free (GF) conditions, respectively.
    • <Mice>
  • C57BL/6, Balb/c, and IQI mice maintained under SPF or GF conditions were purchased from Sankyo Labo Service Corporation, Inc. (Japan), JAPAN SLC, INC. (Japan), CLEA Japan, Inc. (Japan), or The Jackson Laboratory (USA). GF mice and gnotobiotic mice were bred and maintained within the gnotobiotic facility of The University of Tokyo, Yakult Central Institute for Microbiological Research, or Sankyo Labo Service Corporation, Inc. Myd88 -/-, Rip2 -/-, and Card9 -/- mice were produced as described in NPL 1 to 3, and backcrossed for 8 generations or more, so that a C57BL/6 genetic background was achieved. Foxp3eGFP mice were purchased from the Jackson Laboratory.
    • <Il10 venus mice>
  • To form a bicistronic locus encoding both 1110 and Venus under control of an 1110 promoter, a targeting construct was first created. Specifically, a cassette (IRES-Venus-SV40 polyA signal cassette, refer to Non-Patent Document 4) which was made of an internal ribosome entry site (IRES), a yellow fluorescent protein (Venus), and a SV40 polyA signal (SV40 polyA) and which was arranged next to a neomycin-resistant gene (neo), was inserted between a stop codon and a polyA signal (Exon 5) of a 1110 gene. Next, the obtained targeting construct was used to cause homologous recombination with the 1110 gene region in the genome of mice. Thus, Il10 venus mice having an Il10 venus alleles were produced (refer to Fig. 1). Note that in Fig. 1 "tk" represents a gene coding thymidine kinase, "neo" represents the neomycin-resistant gene, and "BamHl" represents a cleavage site by the restriction enzyme BamH1.
  • Genomic DNAs were extracted from the Il10 venus mice, treated with BamHl, and Southern blotted by use of a probe shown in Fig. 1. Fig. 2 shows the obtained results. Wild-type and Il10 venus alleles were detected as bands having sizes of 19 kb and 5.5 kb, respectively. Hence, as is apparent from the results obtained, the homologous recombination occurred in the genome of the Il10 venus mice.
  • Further, CD4+ Venus- cells or CD4+ Venus+ cells in the colonic lamina propria of the Il10 venus mice were sorted by use of a FACSAria. Then, real-time RT-PCR was carried out on an ABI 7300 system by a method to be described later, to determine the amount of IL-10 mRNA expressed. It was found that, since the development of the IL-10 mRNA was detected only in the CD4+Venus+ cells, the expression of IL-10 mRNA in the Il10 venus mice was correctly reflected in the expression of Venus. Note that the germ-free states of such Il10 venus mice were established in Central Institute for Experimental Animals (Kawasaki, Japan). The Il10 venus mice in the germ-free states were maintained in vinyl isolators in Sankyo Labo Service Corporation, Inc. (Tokyo, Japan), and used in the following Examples.
  • Experiments and analyses in Examples were carried out as follows.
    • <Method for Colonization of Mice with Murine Bacteria and Analysis Thereof>
  • According to the description in NPL 5 and 6, mice in which SFB or Clostridium were colonized were produced. Cecal contents or feces of the obtained gnotobiotic mice were dissolved in sterile water or an anaerobic dilution solution. The dissolved cecal contents or feces as they were or after a chloroform treatment were orally administered to GF mice. Three strains of the Lactobacillus and 16 strains of the Bacteroides were cultured separately from each other in a BL or EG agar medium in an anaerobic manner. The cultured bacteria were harvested, suspended in an anaerobic TS broth, and orally administrated forcibly to GF mice. The state of the colonization of the bacteria in the mice was assessed by microscopic observation conducted on a smear preparation of fecal pellets.
    • <Isolation of Intestinal Lamina Propria Lymphocytes and Flow Cytometry>
  • The small intestine and colon were collected and opened longitudinally. The cecum was also isolated and cecal content was directly frozen at -80°C or suspended in 2 ml PBS, then added 40% glycerol (final concentration 20%), snap-frozen in liquid nitrogen and stored at -80 °C until use. The colon and small intestine were washed in PBS to remove all luminal contents and shaken in Hanks' balanced salt solution (HBSS) containing 5 mM EDTA for 20 min at 37 °C. After removing epithelial cells, muscle layers and fat tissue using tweezers, the lamina propria layers were cut into small pieces and incubated with RPMI1640 containing 4% fetal bovine serum, 1 mg/ ml collagenase D, 0.5 mg/ml dispase and 40 micro gram/ml DNase I (all Roche Diagnostics) for 1 h at 37 °C in a shaking water bath. The digested tissues were washed with HBSS containing 5 mM EDTA, resuspended in 5 ml of 40% Percoll (GE Healthcare) and overlaid on 2.5 ml of 80% Percoll in a 15-ml Falcon tube. Percoll gradient separation was performed by centrifugation at 800 g for 20 min at 25 °C. The lamina propria lymphocytes were collected from the interface of Percoll gradient and suspended in ice-cold PBS. For analysis of regulatory T cells, isolated lymphocytes were labeled with the LIVE/DEAD fixable violet dead cell stain kit (Invitrogen) to exclude dead cells in the analysis. The cells were washed with staining buffer containing PBS, 2% FBS, 2 mM EDTA and 0.09% NaN3 and stained surface CD4 with PECy7-labeled anti-CD4 Ab (RM4-5, BD Biosciences). Intracellular staining of Foxp3 and Helios was performed using the Alexa700-labeled anti-Foxp3 Ab (FJK-16s, eBioscience), Alexa647-labeled anti-Helios (22F6, eBioscience) and Foxp3 Staining Buffer Set (eBioscience). For analysis of Th1 and Th17 cells, isolated lymphocytes were stimulated for 4 hours with 50 ng/ml phorbol 12-myristate 13-acetate (PMA, Sigma) and 1 micro gram/ml ionomycin (Sigma) in the presence of GolgiStop (BD Biosciences). After incubation for 4 hours, cells were washed in PBS, labeled with the LIVE/DEAD fixable violet dead cell stain kit and stained surface CD4 with PECy7-labeled anti-CD4 Ab. Cells were washed, fixed in Cytofix/Cytoperm, permeabilized with Perm/Wash buffer (BD Biosciences), and stained with the APC-labeled anti-IL-17 Ab (eBio17B7, eBioscience) and FITC-labeled anti-IFN- gamma Ab (XMG1.2, BD Biosciences). The Ab stained cells were analyzed with a LSR Fortessa (BD Biosciences), and data were analyzed using Flow Jo software (Treestar).
    • <Real-Time RT-PCR>
  • From an RNA prepared by using RNeasy Mini Kit (Qiagen), a cDNA was synthesized by use of a MMV reverse transcriptase (Promega KK). The cDNA obtained was analyzed by real-time RT-PCR using Power SYBR Green PCR Master Mix (Applied Biosystems) and ABI 7300 real time PCR system (Applied Biosystems),or real-time RT-PCR using SYBR Premix Ex Taq (TAKARA) and Light Cycler 480. For each sample, a value obtained was normalized for the amount of GAPDH. A primer set was designed by using Primer Express Version 3.0 (Applied Biosystems), and those exhibiting a 90% or higher sequence identity at an initial evaluation were selected. The primer set used was as follows:
    • Foxp3
    • 5'-GGCAATAGTTCCTTCCCAGAGTT-3' (SEQ ID NO: 1)
    • 5'-GGGTCGCATATTGTGGTACTTG-3' (SEQ ID NO: 2)
    CTLA4
    • 5'-CCTTTTGTAGCCCTGCTCACTCT-3' (SEQ ID NO: 3)
    • 5'-GGGTCACCTGTATGGCTTCAG-3' (SEQ ID NO: 4)
    GITR
    • 5'-TCAGTGCAAGATCTGCAAGCA-3' (SEQ ID NO: 5)
    • 5'-ACACCGGAAGCCAAACACA-3' (SEQ ID NO: 6)
    IL-10
    • 5'-GATTTTAATAAGCTCCAAGACCAAGGT-3' (SEQ ID NO: 7)
    • 5'-CTTCTATGCAGTTGATGAAGATGTCAA-3' (SEQ ID NO: 8)
    GAPDH
    • 5'-CCTCGTCCCGTAGACAAAATG-3' (SEQ ID NO: 9)
    • 5'-TCTCCACTTTGCCACTGCAA-3' (SEQ ID NO: 10)
    Mmp2
    • 5'-GGACATTGTCTTTGATGGCA-3' (SEQ ID NO: 11)
    • 5'-CTTGTCACGTGGTGTCACTG-3' (SEQ ID NO: 12)
    Mmp9
    • 5'-TCTCTGGACGTCAAATGTGG-3' (SEQ ID NO: 13)
    • 5'-GCTGAACAGCAGAGCCTTC-3' (SEQ ID NO: 14)
    Mmp13
    • 5'-AGGTCTGGATCACTCCAAGG-3' (SEQ ID NO: 15)
    • 5'-TCGCCTGGACCATAAAGAA-3' (SEQ ID NO: 16)
    Idol
    • 5'-AGAGGATGCGTGACTTTGTG-3' (SEQ ID NO: 17)
    • 5'-ATACAGCAGACCTTCTGGCA-3' (SEQ ID NO: 18).
    <Preparation and Culturing of Large Intestinal Epithelial Cells (IECs)>
  • First, the colon was collected, cut open longitudinally, and rinsed with PBS. Subsequently, the colon was treated with 1mM dithiothreitol (DTT) at 37 °C for 30 minutes on a shaker, and then vortexed for one minute to disrupt the epithelial integrity. The released intestinal epithelial cells (IECs) were collected, and suspended in 5 ml of 20% percoll. The suspension was overlayered on 2.5 ml of 80% percoll in a 15-ml Falcon tube. Then, the tube was centrifuged at 25 °C and 780 g for 20 minutes to conduct cell separation by percoll density gradient centrifugation. Cells at the interface were collected, and used as colonic IECs (purity: 90% or higher, viability: 95%). The IECs obtained collected were suspended in RPMI containing 10% FBS, and 1 x 105 cells of the IECs were cultured in a 24-well plate for 24 hours. Thereafter, the culture supernatant was collected, and measured for active TGF- beta 1 level by ELISA (Promega).
  • Meanwhile, for culturing T cells in vitro, 1.5 x 105 MACS-purified splenic CD4+ T cells were cultured in each well of a round-bottomed 96-well plate, together with a 50% conditioned medium in which IECs isolated from GF mice or Clostridium-colonized mice were cultured, and with 25 ng/ml of hIL-2 (Peprotech), in the presence or absence of 25 micro gram/ml of an anti-TGF- beta antibody (R&D). Note that 10 micro gram/ml of an anti-CD3 antibody and an anti-CD28 antibody (BD Bioscience) were bound to the round-bottomed plate. After a 5-day culture, the CD4+T cells were collected, and subjected to a real-time PCR.
    • <Colitis Experimental Model>
  • A fecal suspension from Clostridium-colonized mice was orally administered to C57BL/6 mice (2-week old), which were grown in a conventional environment for six weeks.
  • For preparing a DSS-induced colitis model, 2% (wt/vol) DSS (reagent grade, DSS salt, molecular weight = 36 to 50 kD, manufactured by MP Biomedicals), together with drinking water, was given to the mice for six days.
  • Meanwhile, for preparing an oxazolone-induced colitis model, the mice were presensitized by transdermally applying, onto the mice, 150 micro liter of a 3% oxazolone (4-ethoxymethylene-2-phenyl-2-oxazolin-5-one, Sigma-Aldrich)/100% ethanol solution. Five days after that, 150 micro liter of a 1% oxazolone/50% ethanol solution was intrarectally administered again to the presensitized mice under a light anesthesia. Note that the intrarectal administration was conducted by using a 3.5F catheter.
  • Each mouse was analyzed daily for body weight, occult blood, bleeding visible with the naked eyes (gross blood), and the hardness of stool. Moreover, the body weight loss percentage, intestinal bleeding (no bleeding, occult blood (hemoccult+), or bleeding visible with the naked eyes), and the hardness of stool (normal stool, loose stool, or diarrhea) were evaluated numerically, and the disease activity index (DAI) was calculated in accordance with the description in "S. Wirtz, C. Neufert, B. Weigmann, M. F. Neurath, )."
    • <OVA Specific IgE Reaction>
  • BALB/c SPF mice were inoculated with a fecal suspension from Clostridium-colonized mice (2-week old), and grown in a conventional environment. Then, 1 micro gram of OVA (grade V, Sigma) and 2 mg of alum (Thermo Scientific), 0.2 ml in total, were intraperitoneally injected to the mice (at their ages of 4 weeks and 6 weeks). Sera were collected every week from the mice at the root of their tail, and OVA-specific IgE was measured by ELISA (Chondrex). Then, at their ages of 8 weeks, splenic cells were collected, inoculated in a 96-well plate at 1 x 106 cells per well, and stimulated with OVA (100 micro gram/ml) for three days. Thereafter, the culture supernatant was collected, and measured for IL-4 and IL-10 levels by ELISA (R&D).
    • <Statistical Analysis>
  • The difference between control and experimental groups was evaluated by the Student's t-test.
    • <Chloroform Treatment and Oral Inoculation with Fecal Samples Into GF Mice>
  • Human stool (2g) from a healthy volunteer (Japanese, male, 29y old) was suspended with 20ml phosphate-buffered saline (PBS) and passed through a 70 micro meter cell strainer to eliminate clumps and debris. Then fecal suspension was mixed with or without chloroform (final concentration 3%), and incubated in a shaking water bath for 60 min. The fecal suspensions without chloroform treatment were orally inoculated into germ-free (GF) mice (250 micro liter/mouse). After evaporation of chloroform by bubbling with N2 gas for 30 min, the aliquots containing chloroform-resistant (spore-forming) fraction of human intestinal bacteria were inoculated into IQI GF mice. Each group of ex-GF mice was separately kept in a vinyl isolator for 3 or 4 weeks.
    • <Co-housing Experiment>
  • To evaluate whether Treg-inducing human bacteria can be transmitted horizontally, IQI GF mice were co-housed for 4 weeks with ex-GF mice colonized with chloroform-treated human feces (Example 21 mice) in a vinyl isolator (6 mice, designated as mouse #D1 to #D6
    • <Inoculation with Diluted Cecal Contents Into GF Mice>
  • The frozen cecal content from ex-GF mice inoculated with chloroform-treated human feces (#C 4) was suspended in 10 times volume (w/v) of PBS, passed through a 70 micro meter cell strainer and treated 3% chloroform. Then the suspension was diluted 2000 (for 4 mice, designated as mouse #E1 to #E4) or 20000 (for 8 mice, designated as mouse #F1 to #F8) -fold with PBS and orally inoculated into GF IQI mice (2.5x105 or 2.5x104 cells/250 micro liter/mouse). After 4 weeks, lymphocytes were collected from colon and small intestine and analyzed for Foxp3+ Treg cell proportion and their Helios expression. Cecal contents were frozen and stored at -80 °C until use.
    • <Re-colonization Experiments>
  • The frozen cecal content from ex-GF mice inoculated with 20000-fold dilution (#F3, 7 and 8) was suspended in 10 times volume (w/v) of PBS, passed through a 70 micro meter cell strainer and treated 3% chloroform. The suspensions were orally inoculated into GF IQI mice (5, 4 or 4 mice; designated as mouse #G1 to #G5, #H1 to #H4 or #11 to #14, respectively). After 4 weeks, colon and small intestine were collected and analyzed for Foxp3+ Treg cell proportion and their Helios expression. Cecal contents were suspended in 20% glycerol solution, snap-frozen in liquid nitrogen and stored at - 80 °C.
    • <Cultured Bacteria-Colonization Experiments>
  • The glycerol stock of cecal content from #G2 mouse was diluted with PBS and seeded onto BL agar plate. After 48 hours, all bacterial colonies were collected by scraping the plates with a plate scraper and inoculated into GF IQI mice (4 mice, designated as mouse #K1 to #K 4). Six bacterial strains were isolated from the freeze stock of cecal content from #F8 mouse using BL agar plate. These isolated strains were inoculated into GF IQI mice (4 mice, designated as mouse #J1 to #J4). (Details of the culture method are described below.)
    • <16S rRNA Gene Quantitative PCR Analysis
  • Using a QIAamp DNA Stool mini kit (QIAGEN), bacterial genomic DNA was isolated from the human stool from a healthy volunteer as described above (human stool), cecal contents from GF mice gavaged with chloroform-treated human stool (cecal content of B-4 mouse) or feces from SPF ICR mouse (feces of SPF mouse). The isolated DNA was used as template for quantitative PCR. The amplification program consisted of one cycle at 95°C for 1 min, followed by 50 cycles at 95°C for 10 s and 60 °C for 30 s. Quantitative PCR analysis was carried out using a LightCycler 480 (Roche). Relative quantity was calculated by the delta Ct method and normalized to the amount of total bacteria. The following primer sets were used: total bacteria, 5'-GGTGAATACGTTCCCGG-3'(SEQ ID NO.: 45) and 5'-TACGGCTACCTTGTTACGACTT-3'(SEQ ID NO.: 46); Clostridium cluster XIVa (Clostridium coccoides subgroup), 5'-AAATGACGGTACCTGACTAA-3' (SEQ ID NO.: 47) and 5'-CTTTGAGTTTCATTCTTGCGAA-3'(SEQ ID NO.: 48); Clostridium cluster IV (Clostridium leptum) 5'-CCTTCCGTGCCGSAGTTA-3'(SEQ ID NO.: 49) and 5'-GAATTA AACCACATACTCCACTGCTT-3'(SEQ ID NO.: 50); Bacteroides, 5'-GAGAGGAAGGTCCCCCAC-3'(SEQ ID NO.: 51) and 5'-CGCTACTTGGCTGGTTCAG-3'(SEQ ID NO.: 52); Bifidobacterium, 5'-CGGGTGAGTAATGCGTGACC-3' (SEQ ID NO.: 53) and 5'-TGATAGGACGCGACCCCA-3'(SEQ ID NO.: 54). Note that mice gavaged with chloroform-treated human stool exhibited high levels of spore-forming bacteria, such as Clostridium clusters XIVa and IV, and a severe decrease of non-spore-forming bacteria, such as Bacteroides and Bifidobacterium, compared with the human stool before chloroform treatment.
    • <Isolation of DNA from Cecal Contents for 16S rRNA Gene Metasequence Analysis>
  • The cecal contents of A1-1, A2-4, B-4, E-3, E-7, E-8, F-2, G-3, H-3,1-3 and J-3 were collected by centrifugation at 5000 x g for 10 min at 4 °C, suspended in 10 ml of Tris-EDTA containing 10 mM Tris-HCl and 1 mM EDTA (pH 8), and then used for DNA isolation. Lysozyme (SIGMA, 15 mg/ml) was added to the cell suspension. After incubation at 37 °C for 1 h with gentle mixing, a purified achromopeptidase (Wako) was added (final 2000 unit/ ml) and incubated at 37 °C for 30 min. Then, sodium dodecyl sulfate (final 1%) was added to the cell suspension and mixed well. Subsequently, proteinase K (Merck) was added (final 1mg/ml) to the suspension and the mixture was incubated at 55 °C for 1 h. High-molecular-weight DNA was isolated and purified by phenol/chloroform extraction, ethanol, and finally polyethyleneglycol precipitation.
    • <16S rRNA Gene Metasequence>
  • An aliquot of the DNA was used for PCR amplification and sequencing of bacterial 16S rRNA genes. ∼330bp amplicons, spanning variable region 1-2 (V1-2) of the gene were generated by using (i) modified primer 8F (5'-CCATCTCATCCCTGCGTGTCTCCGACTCAG+ Barcode+agrgtttgatymtggctcag-3' (SEQ ID NO.: 55)) which consists of 454 adaptor sequence (underlined), a sample specific, error correcting barcode (10 bases, bold) and the universal bacterial primer 8F and
    • (ii) modified primer 338R
  • (5'-CCTATCCCCTGTGTGCCTTGGCAGTCTCAG+tgctgcctcccgtaggagt-3'(SEQ ID NO.: 56)) which contains 454 adaptor sequence (underlined) and the bacterial primer 338R. Polymerase chain reactions were performed for each fecal DNA sample: each 50- micro L reaction contained 40 ng of DNA, 5 micro liter of 10 X Ex Taq buffer (TAKARA), 5 micro liter of 2.5 mM dNTP mixture, 0.2 micro liter Ex Taq and 0.2 micro M of each primer. PCR conditions consisted of an initial denaturation step performed at 96 °C for 2 min, followed by 20 cycles of denaturation (96 °C, 30 s), annealing (55 °C, 45 s) and amplification (72 °C, 1 min) and final amplification step performed at 72 °C for 10 min. Amplicons generated from each sample were subsequently purified using AMPur XP (Beckman Coulter). The amount of DNA was quantified using Quant-iT Picogreen dsDNA Assay Kit (Invitrogen) and TBS-380mini Fluorometer (Turner Biosystems). The amplified DNA were used as template for 454 GS Junior (Roche) pyrosequencing. The sequences were performed using GS Junior Titanium emPCR Kit-Lib-L, GS Junior Titanium Sequencing Kit and GS Junior Titanium PicoTiterPlate Kit (all Roche) according to the manufacturer's manuals (GS Junior Titanium Series, emPCR Amplification Method Manual - Lib-L and Sequencing Method Manual). Resulting sequences (3400 reads were produced for each sample) were classified into OTU on the basis of sequence similarity (>97% identity). Representative sequences from each OTU were compared with sequences in nucleic acid databases (Ribosomal Database Project) using BLAST to determine the closest relatives. Then, OTUs were classified into species on the basis of the closest relatives. All data of close relatives and the number of reads are shown in Table. 1.
    • <Isolation of Bacterial Strains>
  • Bacterial strains were isolated from the cecal contents of #F8, #G2, #11 and #K3 by plating serial dilutions of the cecal samples under aerobic condition or strictly anaerobic conditions (80% N2 10% H2 10% CO2) onto BL agar (Eiken Chemical) or EG agar plates containing medium with the following components (quantities expressed per liter): Meat extract 500 ml; Proteose peptone No.3 (10.0 g, Difco); Yeast Extract (5.0 g, Difco); Na2HPO4 (4.0 g); D(+)-Glucose (1.5 g); Soluble Starch (0.5 g); L-cystine (0.2 g), L-cysteine-HCl-H2O (0.5g); Tween80 (0.5 g); Bacto Agar (16.0 g, Difco); defibrinated horse blood (50 ml). After culture at 37°C for 2 or 4 days, each single colony was picked up and cultured for additional 2 or 4 days at 37 °C by ABCM broth or EG agar plate. The isolated strains were collected into EG stock medium (10% DMSO) and stored at -80°C. For suspension of isolated strains to re-inoculate mice, TS medium (27.5g of trypticase soy broth w/o dextrose, 0.84 g of Na2CO3, 0.5 g of L-cysteine-HCl-H2O, 1000 ml of distilled water, pH adjusted to 7.2 +/- 0.2 with NaOH, then autoclaved for 15 minutes at 115 degrees Celsius). To identify the isolated strains, 16SrRNA coding gene sequences were performed. The 16S rRNA genes were amplified by colony-PCR using KOD FX (TOYOBO), 16S rRNA gene-specific primer pairs: 8F (5'-AGAGTTTGATCMTGGCTCAG-3'(SEQ ID NO.: 57)) and 519R (5'-ATTACCGCGGCKGCTG-3'(SEQ ID NO.: 58)) for C. indolis, C. bolteae, Bacteroides sp. MANG, L. bacterium DJF_VP30, A.colihominis, Ruminococcus sp. ID8, C. lavalense, C. symbiosum and E. contortum or 1513R (5'-ACGGCTACCTTGTTACGACTT-3'(SEQ ID NO.: 59)) for C. saccharogumia, C. ramosum, F. plautii, C. hathewayi, C. scindens, Clostridium sp. 2335, Clostridium sp. 14616 and cf Clostridium sp. MLG055 and GeneAmp PCR System9700 (Applied Biosystems). The amplification program consisted of one cycle at 98°C for 2 min, followed by 40 cycles at 98°C for 10 s, 57°C for 30s and 68°C for 40 s. Each amplified DNA was purified from the reaction mixture using Illustra GFX PCR DNA and Gel Band Purification Kit (GE Healthcare). Sequence analysis was performed using BigDye Terminator V3.1 Cycle Sequencing Kit (Applied Biosystems) and Applied Biosystems 3730xl DNA analyzer (Applied Biosystems). The resulting sequences were compared with sequences in nucleic acid databases using BLAST to determine the closest relatives. The closest relatives and % identity of all isolated strains, information for genus-species of the closest relatives, Clostridium cluster, ID of mouse from which was derived, maximum similarity and culture medium of isolated strains were summarized in Table 2.
    • Example 1
  • Example 1: First, it was investigated whether or not accumulation of regulatory T cells (Treg cells) in the colonic lamina propria was dependent on commensal bacteria. Specifically, lymphocytes were isolated from peripheral lymph nodes (pLN) of Balb/c mice bred in the absence of specific pathogenic bacteria (SPF) or from lamina propria of the colon or the small intestine (SI) of the mice. The CD4 and Foxp3 were stained by antibodies. Then, the ratio of Foxp3+ cells in CD4+lymphocytes was analyzed by flow cytometry. The results showed that Foxp3+ Treg cells were present at a high frequency in the lamina propria of the gastrointestinal tracts, especially in the colonic lamina propria, of the mice kept under the environment free from specific pathogenic microorganisms (SPF). In addition, it was also found that the number of the Foxp3+ Treg cells in the colonic lamina propria gradually increased up to three months after their birth, whereas the number of the Foxp3+Treg cells in the peripheral lymph nodes was basically constant from the time of two weeks after their birth.
    • Example 2
  • Example 2: Next, it was investigated whether or not the temporal accumulation of the Treg cells in the colon as found in Example 1 had a relationship with the colonization of intestinal commensal microbiota. Specifically, the expression of CD4 and the expression of Foxp3 in lymphocytes isolated from the small intestine, the colon, and the peripheral lymph nodes of mice bred under a germ-free (GF) or SPF environment (8 weeks old: Balb/c mice, IQI mice, and C57BL/6 mice) were analyzed. Similar results were obtained in three or more independent experiments. In addition, lamina propria lymphocytes were collected from SPF mice and GF mice (Balb/c mice or C57BL/6 mice). CD4 and Foxp3 were stained with antibodies. Then, the lamina propria lymphocytes were analyzed by FACS. Further, lymphocytes were isolated from the lamina propria of the colon, the lamina propria of the small intestine (SI), Peyer's patches (PPs), and mesenteric lymph nodes (MLNs) of mice (SPF C57BL/6 mice) to which antibiotics were orally administered with water for eight weeks. CD4 and Foxp3 were stained with antibodies. Then, the lymphocytes were analyzed by FACS. Similar results (the ratio of the Foxp3+ cells in the CD4+ cells of an individual mouse) were obtained in two or more independent experiments. Note that the following antibiotics were used in combination in accordance with the description in the following document:
    • ampicillin (A; 500 mg/L, Sigma)
    • vancomycin (V; 500 mg/L, NACALAI TESQUE, INC.)
    • metronidazole (M; 1g/L, NACALAI TESQUE, INC.)
    • neomycin (N; 1g/L, NACALAI TESQUE, INC.)
    • Rakoff-Nahoum, J. Paglino, F. Eslami-Varzaneh, S. Edberg, R. Medzhitov, Cell 118, 229 ()
    • Fagarasan et al., Science 298, 1424 ()
  • As is apparent from the results the frequencies and the absolute numbers of Foxp3+ CD4+ cells in the small intestine and the peripheral lymph nodes of the GF mice were equal to or greater than those of the SPF mice. In addition, the numbers of the Treg cells in the small intestinal lamina propria, Peyer's patches, and mesenteric lymph nodes of the SPF mice to which the antibiotics were orally administered for eight weeks were equal to or greater than those of the SPF mice that had not received antibiotics. Meanwhile, the number of the Foxp3+ CD4+ cells in the colonic lamina propria of the GF mice was decreased significantly in comparison with that of the SPF mice. This decrease was commonly observed among mice of different genetic backgrounds (Balb/c, IQI, and C57BL/6), as well as among mice bred in different animal facilities. In addition, it was also shown that the number of Treg cells in the colonic lamina propria of the SPF C57BL/6 mice to which the antibiotics were administered was decreased significantly.
    • Example 3
  • Example 3: Next, it was directly checked whether or not the decrease in the number of the Treg cells in the colonic lamina propria of the GF mice shown in Example 2 was attributed to the absence of microbiota. Specifically, a fecal suspension of B6 SPF mice purchased from The Jackson Laboratory was orally administered to GF-IQI mice (conventionalization). Three weeks after the administration, lymphocytes were isolated from the colonic lamina propria, and the expression of Foxp3 in CD4+ lymphocytes was analyzed. The results showed that the number of Treg cells in the small intestinal lamina propria did not change. However, the number of the Treg cells in the colonic lamina propria increased significantly. Hence, it was shown that host-microbial interaction played an important role in the accumulation of Foxp3+ Treg cells in the colonic lamina propria, while the accumulation of the Treg cells in the small intestinal lamina propria had a different mechanism.
    • Example 4
  • Example 4: Next, the relationship between the gut-associated lymphoid tissues of mice and the number of Foxp3+ cells in the colonic lamina propria of the mice was investigated in accordance with the method described in M. N. Kweon et al., ). Specifically, 100 micro gram of an extracellular domain recombinant protein (a fusion protein (LT beta R-Ig) between a lymphotoxin beta receptor (LT beta R) and a Fc region of human IgG1, refer to Honda et al., J Exp Med 193, 621 ()) was injected intraperitoneally into pregnant C57BL/6 mice 14 days after conception. The LT beta R-Ig was again injected intraperitoneally into fetuses obtained from such mice, so that mice from which isolated lymphoid follicles (ILFs), Peyer's patches (PPs), and colonic-patches (CPs) were completely removed were produced. Then, the ratios of Foxp3+ cells in CD4+ cells in the colonic lamina propria of the mice treated with the LT beta R-Ig, and mice treated with rat IgG (control) were analyzed by FACS. The results show that the ratio of the Foxp3+ cells in the colonic lamina propria of the mice deficient in isolated lymphoid follicles, Peyer's patches, and the colonic-patches (the mice treated with the LT beta R-Ig) rather increased. Accordingly, it was suggested that the decrease in the number of the Treg cells in the colonic lamina propria of the GF mice and the mice treated with the antibiotics was caused because the transmission of specific signals which promotes the accumulation of Treg cells in the colonic lamina propria and which is caused by the intestinal microbes did not occur, rather than simply because of a secondary effect of disorganized gut-associated lymphoid tissues.
    • Example 5
  • Example 5: To investigate whether or not a specific intestinal flora induced the accumulation of colonic Treg cells, vancomycin as an antibiotic against Gram-positive bacteria or polymyxin B as an antibiotic against Gram-negative bacteria was administered to SPF mice (from 4 weeks of age) for four weeks, and analyzed for the ratio of Foxp3+ cells in the CD4+ cell group ([%] Foxp3+ in CD4).
  • The results show that the number of Treg cells in the colon of the mice to which vancomycin was administered was markedly decreased in comparison with that of the control. In contrast, no influence was observed on the number of Treg cells of the mice to which polymyxin B was administered. Those facts suggested that Gram-positive commensal bacteria played a major role in accumulation of Treg cells.
    • Example 6
  • Example 6: A recent report has suggested that spore-forming bacteria play an important role in intestinal T cells response (see V. Gaboriau-Routhiau et al., Immunity 31, 677 ()). In this respect, fecal microorganisms (spore-forming fraction) resistant to 3% chloroform were orally administered to GF mice, which were then analyzed for the ratio of Foxp3+ cells in the CD4+ cell group ([%] Foxp3+ in CD4).
  • Three weeks after the administration of the chloroform-treated feces, the number of Treg cells in the administered mice was markedly increased to the same level as those of the SPF mice and the GF mice to which the untreated feces was forcibly administered.
  • Accordingly, considering the results shown in Example 5 in combination, it was revealed that the specific components of the indigenous microbiota were highly likely to belong to the Gram-positive group, and that the spore-forming fraction played an important role in the induction of Treg cells.
    • Example 7
  • Example 7: Next, the species of the intestinal microbiota which induced the accumulation of Treg cells in the colon as suggested in Examples 4 to 6 were identified. Specifically, segmented filamentous bacteria (SFB), 16 strains of the Bacteroides spp. (Bactero. (6 strains of B. vulgatus, 7 of the B. acidifaciens group 1, and 3 of the B. acidifaciens group 2)), 3 strains of the Lactobacillus (Lacto. (L. acidophilus, L. fermentum, and L. murinum)), and 46 strains of Clostridium spp. (Clost., refer to "Itoh, K., and Mitsuoka, T. Characterization of clostridia isolated from faeces of limited flora mice and their effect on caecal size when associated with germ-free mice. Lab. Animals 19: 111-118 (1985))"), or microbiota collected from mice (SPF) bred under a conventional environment was orally administered to GF-Balb/c mice or GF-IQI mice. The mice were maintained in vinyl isolators for three weeks. Then, CD4 cells were isolated from the colon and the small intestine of these mice. The numbers of Treg cells in the colon and the small intestine were analyzed by flow cytometry.
  • The bacteria belonging to the genus Clostridium are classified by sequencing of 16S rRNA gene, as follows. Specifically, the 16S rRNA genes of the bacteria were amplified by PCR using 16S rRNA gene-specific primer pairs:
    • 5'-AGAGTTTGATCMTGGCTCAG-3' (SEQ ID NO: 60) and
    • 5'-ATTACCGCGGCKGCTG-3' (SEQ ID NO: 61) (see T. Aebischer et al., Vaccination prevents Helicobacter pylori-induced alterations of the gastric flora in mice. FEMS Immunol. Med. Microbiol. 46,221-229(2006)). The 1.5-kb PCR product was then introduced into pCR-Blunt Vector. The inserts were sequenced and aligned using the ClustalW software program. The resulting sequences of 16S rRNA genes derived from strain 1-41 of 46 strains of Clostridium spp. were shown in SEQ ID NO: 21-61. A phylogenetic tree was constructed by the neighbor-joining method with the resulting sequences of the 41 strains of Clostridium and those of known bacteria obtained from Genbank database using Mega software.
  • The results showed no effect on the number of the Treg cells in the colon was observed in the GF mice in which the segmented filamentous bacteria (SFB) were colonized. Moreover, mice in which the cocktail of three strains of Lactobacillus was colonized gave similar results. On the other hand, it was shown that the accumulation of Foxp3+ cells in the colonic lamina propria was strongly induced in the mice in which 46 strains of Clostridium spp. were colonized. Importantly, such accumulation was promoted irrespective of the genetic backgrounds of the mice, and led to the increase in number similar to that in the SPF mice although intestinal microbiota of only a single genus were colonized. It was also shown that the colonization of the Clostridium did not change the number of Treg cells in the small intestinal lamina propria. Note that, when the 16 strains of Bactericides spp. were colonized, the number of Treg cells in the colon was increased significantly. However, the extent of the increase varied depending on the genetic background of the mice in which the bacteria were colonized.
    • Example 8
  • Example 8: Next, CD4 expression, Foxp3 expression, and Helios expression in LP lymphocytes of the thymuses and the colons of SPF mice, GF mice, Lactobacillus-colonized mice, and Clostridium-colonized mice were analyzed by flow cytometry.
  • The results show that most Foxp3+ cells found in the SPF mice or the Clostridium-colonized mice did not express Helios. Note that Helios is a transcription factor known to be expressed in thymic-derived natural Treg cells (see A. M. Thornton et al., J Immunol 184, 3433 ()). Accordingly, it was suggested that most of the Treg cells in the SPF mice and the Clostridium-colonized mice were Treg cells induced in peripheral portions (so-called iTreg cells).
    • Example 9
  • Example 9: Next, it was investigated whether or not the colonization of the Clostridium or the like had an influence on other T cells. Specifically, SFB, 16 strains of Bacteroides spp. (Bactero.), 46 strains of Clostridium spp. (Clost.), or microbiota collected from mice bred under a conventional environment (SPF) was colonized in GF IQI mice. Three weeks later, lymphocytes in the colonic lamina propria were isolated from these mice, and stimulated with PMA (50 ng/ml) and ionomycin (1 micro gram/ml) for four hours in the presence of Golgistop (BD Bioscience). After the stimulation was given, intracellular cytokines were stained by using an anti-IL-17 PE antibody (TC11-18H10) and an anti-IFN-g FITC antibody (BD Bioscience) in accordance with the manual of a cytofix/cytoperm kit (BD Bioscience). Then, the ratio of IFN- gamma+ cells or IL-17+ cells in CD4+ leucocytes was analyzed by flow cytometry. The results show that the colonization of the Clostridium did not have any influence on Th1 cells (CD4+ IFN- gamma+ cells) in the colon, and caused only a slight increase of Th17 cells (CD4+IL-17+ cells). Accordingly, it was suggested that the genus Clostridium was a genus of bacteria which specifically induced Treg cells.
    • Example 10
  • Example 10: It has been reported that 46 strains of Clostridium spp. exert an influence on the accumulation of CD8+intestinal tract intraepithelial lymphocytes (IELs) in the colon. Accordingly, it is conceivable that Clostridium regulates the immune system in various aspects, and that Clostridium exhibits a marked ability to induce and maintain Treg cells especially in the colon, as described above. In addition, a kind of cytokines, transforming growth factor- beta (TGF- beta), is known to play an important role in regulation of Treg cell generation.
  • In this respect, it was examined whether or not the colonization of Clostridium provided a colonic environment rich in TGF- beta. Specifically, first, the whole colons of GF mice, Clostridium-colonized mice, and Lactobacillus-colonized mice were cultured for 24 hours, and the culture supernatants thereof were measured for the concentration of active TGF- beta (TGF- beta 1) by ELISA (the number of mice analyzed was four per group).
  • The results show that the amount of TGF- beta produced in the colons of the Clostridium-colonized mice was significantly greater than that in colons of the GF mice and the Lactobacillus-colonized mice.
  • Next, intestinal epithelial cells (IECs) of GF mice and Clostridium-colonized mice were cultured for 24 hours, and the culture supernatants thereof were measured for the concentration of active TGF- beta (TGF- beta 1) by ELISA (the number of mice analyzed was four per group).
  • The results show that TGF- beta was detected in the culture supernatant of the IECs isolated from the Clostridium-colonized mice, whereas no TGF- beta was detected in the culture supernatant of the IECs isolated from the GF mice.
  • Next, as described above, splenic CD4+ T cells were cultured for five days together with a 50% conditioned medium in which IECs isolated from the GF mice or the Clostridium-colonized mice were cultured, and with the anti-CD3 antibody, in the presence or absence of an anti-TGF- beta antibody. Then, the T cells were collected, and analyzed for expression of Foxp3 by real-time RT-PCR.
  • The results show that when the culture supernatant of the IECs derived from the Clostridium-colonized mice was added to the splenic CD4+ T cells, differentiation into Foxp3-expressing cells was accelerated. Meanwhile, differentiation into Treg cells was inhibited by the anti-TGF- beta antibody.
  • The expression of MMP2, MMP9, and MMP13, which are thought to contribute to the activation of latent TGF- beta was investigated. The expression of indoleamine 2,3-dioxygenase (IDO), which is thought to be involved in the induction of Treg cells, was also investigated. Specifically, 46 bacterial strains of the genus Clostridium (Clost.), or three bacterial strains of the genus Lactobacillus (Lacto.) were orally administered to C57BL/6 germ-free mice. Three weeks after administration, IECs were collected, and analyzed for relative mRNA expression levels of MMP2, MMP9, MMP13, and IDO genes by real-time RT-PCR (the number of mice analyzed was three per group).
  • For the relationship between the activation of latent TGF- beta and the above-describe MMP, see D'Angelo et al., J. Biol. Chem. 276, 11347-11353, 2001; Heidinger et al., Biol. Chem. 387, 69-78, 2006; Yu et al., Genes Dev. i4, 163-176, 2000. For the relationship between IDO and the induction of Treg cells, see G. Matteoli et al., Gut 59, 595 (May, 2010).
  • The results show in agreement with the production of TGF- beta described above, that transcription products of the genes encoding MMP2, MMP9, and MMP13 were expressed at higher levels in the IECs derived from the Clostridium-colonized mice than in those in the GF mice and in the Lactobacillus-colonized mice.
  • Moreover, IDO was expressed only in the Clostridium-colonized mice. Accordingly, it was revealed that the Clostridium activated the IECs, and led to the production of TGF- beta and other Treg cell-inducing molecules in the colon.
    • Example 11
  • Example 11: Next, it was investigated whether or not the Treg cell accumulation induced by the colonization of the Clostridium was dependent on signal transmission by pathogen-associated molecular pattern recognition receptors. Specifically, the numbers of Treg cells in the colonic lamina propria of each SPF mice of Myd88 -/- (deficient in Myd88 (signaling adaptor for Toll-like receptor)), Rip2 -/- (deficient in Rip2 (NOD receptor adaptor)), and Card9 -/- (deficient in Card9 (essential signal transmission factor for Dectin-1 signal transmission)) were examined. In addition, Clostridium spp. were caused to be colonized in the Myd88 -/-GF mice, and the change in the number of Treg cells was investigated. The results show that the number of Treg cells of each kind of the SPF mice deficient in the associated factors of the pathogen-associated molecular pattern recognition receptors did not change relative to that of wild-type mice of the same litter, which served as a control. In addition, it was found that when Clostridium spp. were colonized in GF mice deficient in Myd88, the accumulation of Treg cells in the colonic lamina propria was induced. Accordingly, it has been suggested that the mechanism of inducing the accumulation of Treg cells in the colonic lamina propria relies not on activation of recognition pathway for major pathogen-associated molecular patterns as is caused by most bacteria, but on specific commensal bacterial species.
    • Example 12
  • Example 12: Intestinal tract Foxp3+Treg cells are known to exert some immunosuppressive functions through IL-10 production (refer to NPL 9). Meanwhile, animals having CD4+Foxp3+ cells from which IL-10 is specifically removed are known to develop inflammatory bowel disease (refer to NPL 18). In this respect, first, the expression of IL-10 in lymphocytes of various tissues was examined. Specifically, lymphocytes were isolated from various tissues of SPF Il10 venus mice, and the expression of CD4 and the expression of Venus were analyzed by flow cytometry.
  • Lymphocytes in the colonic lamina propria were isolated from Il10 venus mice, and the expression of T cell receptor beta chain (TCR beta) on the surfaces of the cells was detected by FACS.
  • Lymphocytes in the colonic lamina propria were isolated from Il10 venus mice. The lymphocytes were stimulated with PMA (50 ng/ml) and ionomycin (1 micro gram/ml) for four hours in the presence of Golgistop (BD Bioscience). Then, after the stimulation was given, intracellular cytokines were stained by using an anti-IL-17 PE antibody, an anti-IL-4 APC antibody (11B11), and an anti-IFN-g FITC antibody (BD Bioscience) in accordance with the manual of a cytofix/cytoperm kit (BD Bioscience).
  • In addition, Foxp3+ CD4+ cells and Foxp3- CD4+ cells were isolated from the spleen (Spl) of Foxp3eGFP reporter mice, and Venus+ cells were isolated from the colonic lamina propria and the small intestine (SI) lamina propria of Il10 venus mice. The obtained cells were analyzed in terms of expression of predetermined genes. The gene expression was analyzed by real-time RT-PCR using a Power SYBR Green PCR Master Mix (Applied Biosystems) and an ABI 7300 real time PCR system (Applied Biosystems). Here, the value for each cell was normalized for the amount of GAPDH.
  • The results show that almost no Venus+ cells (IL-10-producing cells) were detected in the cervical lymph nodes (peripheral lymph nodes), thymus, peripheral blood, lung, and liver of mice kept under the SPF conditions. Meanwhile, in the spleen, Peyer's patches, and mesenteric lymph nodes thereof, Venus+ cells were slightly detected. On the other hand, many Venus+ cells were found in the lymphocytes in the small intestine lamina propria and colonic lamina propria. In addition, most of the Venus+ cells in the intestines were positive for CD4, and also positive for T cell receptor beta chain (TCR beta). It was found that the Venus+ CD4+ T cells expressed Foxp3 and other Treg cell-associated factors such as a cytotoxic T-Lymphocyte antigen (CTLA-4) and a glucocorticoid-induced TNFR-associated protein (GITR), although the Venus+ CD4+ T cells showed none of the phenotypes of Th2 (IL-4-producing) and Th17 (IL-17-producing). It was shown that the expression level of CTLA-4 in the intestinal Venus+ cells was higher than that in the splenic GFP+ Treg cells isolated from the Foxp3eGFP reporter mice.
    • Example 13
  • Example 13: Venus+ cells can be classified into at least two subsets, namely, Venus+ Foxp3+ double positive (DP) Treg cells and Venus+ Foxp3- Treg cells on the basis of intracellular Foxp3 expression. Cells of the latter subset correspond to type 1 regulatory T cells (Trl) (refer to NPL 8 and 9). In this respect, the Venus+ cells (IL-10-producing cells) observed in Example 8 were investigated in terms of the expression of Foxp3. Specifically, the expression of CD4, Foxp3, and Venus in the lamina propria of the colon and the lamina propria of the small intestine of Il10 venus mice kept under GF or SPF conditions was analyzed by FACS, and the numbers of Venus+ cells in the intestinal tract lamina propria were compared between SPF and GF Il10 venus mice.
  • In addition, the intracellular expression of Venus and Foxp3 in CD4 cells in various tissues of SPF Il10 venus mice was analyzed by flow cytometry.
  • In order to investigate whether or not the presence of commensal bacteria had any influence on the expression of IL-10 in regulatory cells in the gastrointestinal tracts, germ-free (GF) Il10 venus mice were prepared. Then, predetermined species of bacteria were caused to be colonized in the obtained GF Il10 venus mice. Three weeks after the species of bacteria were colonized, a CD4+ cell group (V+F-, Venus+ Foxp3-cells; V+F+, Venus+Foxp3+cells; and V-F+, Venus-Foxp3+cells) in which Foxp3 and/or Venus were expressed in the colon and the small intestine was analyzed by flow cytometry.
  • In order to check whether or not the presence of commensal bacteria had any influence on the expression of IL-10 in regulatory cells in the gastrointestinal tracts, antibiotics were orally given with water to five or six Il10 venus mice per group for 10 weeks. The following antibiotics were used in combination.
    ampicillin (A; 500 mg/L Sigma)
    vancomycin (V; 500 mg/L NACALAI TESQUE, INC.)
    metronidazole (M; 1 g/L NACALAI TESQUE, INC.)
    neomycin (N; 1 g/L NACALAI TESQUE, INC.)
  • Then, CD4 and Foxp3 of lymphocytes in the lamina propria of the colon, the lamina propria of the small intestine (SI), mesenteric lymph nodes (MLN), and Peyer's patches (PPs) were stained with antibodies, and analyzed by FACS. The results were obtained from two or more independent experiments which gave similar results.
  • The results show that the small intestinal lamina propria was rich in Venus+ Foxp3- cells, namely, Trl-like cells, and that the Venus+Foxp3+DP Treg cells were present at a high frequency in the colon of the SPF mice. In contrast, although sufficient numbers of Foxp3+ cells were observed also in other tissues, the expression of Venus was not observed in almost all of the cells.
  • In addition, it was shown that all regulatory T cell fractions of Venus+ Foxp3-, Venus + Foxp3+, and Venus- Foxp3+ in the colon significantly decreased under the GF conditions. Moreover, similar decrease in Venus+ cells was observed also in the SPF Il10 Venus mice treated with the antibiotics.
  • The colonization of Clostridium spp. strongly induced all regulatory T cell fractions of Venus+ Foxp3-, Venus+ Foxp3+, and Venus- Foxp3+ in the colon, and the degrees of the induction thereof were equal to those in the SPF mice. In addition, it was found that the colonization of the three strains of Lactobacillus or the colonization of SFB had an extremely small influence on the number of Venus+ and/or Foxp3+ cells in the colon. Moreover, the colonization of 16 strains of Bacteroides spp. also induced Venus+ cells, but the influence of the colonization was specific to Venus+ Foxp3- Tr1-like cells. On the other hand, it was found that none of the bacterial species tested exerted any significant influence on the number of IL-10-producing cells in the small intestinal lamina propria (refer to Fig. 26).
  • Hence, it was shown that the genus Clostridium colonized in the colon or a physiologically active substance derived from the bacteria provided a signal for inducing the accumulation of IL-10+ regulatory T cells in the colonic lamina propria or the expression of IL-10 in T cells. It was shown that the number of Venus+ cells in the small intestine was not significantly influenced by the situation where no commensal bacteria were present or commensal bacteria were decreased, and that IL-10+ regulatory cells (Trl-like cells) accumulated in the small intestinal lamina propria independently of commensal bacteria.
    • Example 14
  • Example 14: It was investigated whether or not Venus+ cells induced by the genus Clostridium had an immunosuppressive function similar to that of Venus+ cells in the colon of SPF mice. Specifically, CD4+ CD25- cells (effector T cells, Teff cells) isolated from the spleen were seeded in a flat-bottomed 96-well plate at 2 x 104/well, and cultured for three days together with 2 x 104 splenic CD11c+ cells (antigen-representing cells) subjected to 30 Gy radiation irradiation treatment, 0.5 micro gram/ml of an anti-CD3 antibody, and a lot of Treg cells. In addition, for the last six hours, the CD4+ CD25- cells were cultured, with [3H]-thymidine (1 micro Ci/well) was added thereto. Note that, Treg cells used in Example 14 were CD4+GFP+T cells isolated from the spleen of Foxp3eGFP reporter mice, or CD4+ Venus+ T cells in the colonic lamina propria of GF Il10 venus mice in which Clostridium spp. were colonized or SPF Il10 venus mice. Then, proliferation of the cells was determined based on the uptake amount of [3 H]-thymidine, and represented by a count per minute (cpm) value.
  • The results show that Venus+ CD4+ cells of the mice in which the genus Clostridium was colonized suppressed in vitro proliferation of CD25- CD4+ activated T cells. The suppression activity was slightly inferior to that of GFP+ cells isolated from the Foxp3 eGFP reporter mice, but equal to that of Venus+ cells isolated from the SPF Il10 Venus mice. Accordingly, it has been shown that the genus Clostridium induces IL-10-expressing T cells having sufficient immunosuppressive activities, and thereby plays a critical role in maintaining immune homeostasis in the colon.
    • Example 15
  • Example 15: Next, the influence of the colonization of a large number of Clostridium on the local immune response and the resultant proliferation of Treg cells were investigated.
    • <Dextran Sulfate Sodium (DSS)-Induced Colitis Model>
  • First, the DSS-induced colitis model was prepared as described above, and the influence on the model mice of the inoculation of the Clostridium and the proliferation of Treg cells was investigated. Specifically, control mice and Clostridium-inoculated mice were treated with 2% DSS, then observed and measured for six days for body weight loss, the hardness of stool, and bleeding, and then were evaluated numerically. In addition, on day 6, the colons were collected, dissected, and analyzed histologically by HE staining.
  • The results show that the symptoms of the colitis such as body weight loss and rectal bleeding were significantly suppressed in the mice having a large number of Clostridium (hereinafter also referred to as "Clostridium-abundant mice") in comparison with the control mice (C57BL/6 mice grown in a conventional environment for six weeks and not inoculated with the fecal suspension). All the features typical for colonic inflammation, such as shortening of the colon, edema, and hemorrhage, were observed markedly in the control mice in comparison with the Clostridium-abundant mice. Moreover, histological features such as mucosal erosion, edema, cellular infiltration, and crypt loss were less severe in the DSS-treated Clostridium-abundant mice than in the control mice.
    • <Oxazolone-Induced Colitis Model>
  • Next, the oxazolone-induced colitis model was prepared as described above, and the influence on the model mice of the inoculation of Clostridium and the proliferation of Treg cells was investigated. Specifically, control mice and Clostridium-inoculated mice were sensitized with oxazolone, and subsequently the inside of the rectums thereof were treated with a 1% oxazolone/50% ethanol solution. Then, body weight loss was observed and measured. In addition, the colons were dissected, and analyzed histologically by HE staining.
  • The results show that the colitis proceeded along with persistent body weight loss in the control mice. Meanwhile, the body weight loss of the Clostridium-abundant mice was reduced. In addition, it was also revealed that portions having histological diseases such as mucosal erosion, edema, cellular infiltration , and hemorrhage were reduced in the colon of the Clostridium-abundant mice.
    • Example 16
  • Example 16: Next, the influence, on the systemic immune response (systemic IgE production), of the colonization of a large number of Clostridium and the resultant proliferation of Treg cells was investigated. Specifically, as described above, control mice and Clostridium-inoculated mice were immunized by administering alum-absorbed ovalbumin (OVA) twice at a 2-week interval. Then, sera were collected from these mice, and the OVA-specific IgE level thereof was investigated by ELISA. In addition, splenic cells were collected from the mice in each group, and IL-4 and IL-10 production by in-vitro OVA restimulation was investigated.
  • Results show that the IgE level was significantly lower in the Clostridium-abundant mice than in the control mice. Moreover, the IL-4 production by the OVA restimulation was reduced and the IL-10 production thereby was increased in the splenic cells of the Clostridium-abundant mice sensitized with OVA and alum, in comparison with those of the control mice.
  • Accordingly, in consideration of the results shown in Example 15 in combination, the induction of Treg cells by Clostridium in the colon plays an important role in local and systemic immune responses.
    • Example 17
  • Example 17: Next, GF Balb/c were colonized with three strains of Clostridium belonging to cluster IV(strains 22, 23 and 32 listed in Fig.49). Three weeks later, colonic Foxp3+Treg cells were analyzed by FACS. Results show that gnotobiotic mice colonized with three strains of Clostridium showed an intermediate pattern of Treg induction between GF mice and mice inoculated with all 46 strains.
    • Example 18
  • Example 18: Next, it was investigated whether or not a spore-forming (for example, a chloroform resistant) fraction of a fecal sample obtained from humans had the effect of inducing proliferation or accumulation of regulatory T cells similar to the spore-forming fraction of the fecal sample obtained from mice.
  • Human stool from a healthy volunteer (Japanese, male, 29years old) was suspended with phosphate-buffered saline (PBS), mixed with chloroform (final concentration 3%), and then incubated in a shaking water bath for 60 min. After evaporation of chloroform by bubbling with N2 gas, the aliquots containing chloroform-resistant (for example, spore-forming) fraction of human intestinal bacteria were orally inoculated into germ-free (GF) mice (IQI, 8 weeks old). The treated mice were kept in a vinyl isolator for 3 weeks. The colon was collected and opened longitudinally, washed to remove fecal content, and shaken in Hanks' balanced salt solution (HBSS) containing 5 mM EDTA for 20 min at 37 °C. After removing epithelial cells and fat tissue, the colon was cut into small pieces and incubated with RPMI1640 containing 4% fetal bovine serum, 1 mg/ml collagenase D, 0.5 mg/ml dispase and 40 micro gram/ml DNase I (all manufactured by Roche Diagnostics) for 1 hour at 37 °C in a shaking water bath. The digested tissue was washed with HBSS containing 5 mM EDTA, resuspended in 5 ml of 40% Percoll (manufactured by GE Healthcare) and overlaid on 2.5 ml of 80% Percoll in a 15-ml Falcon tube. Percoll gradient separation was performed by centrifugation at 780 g for 20 min at 25 °C. The interface cells were collected and suspended in staining buffer containing PBS, 2% FBS, 2 mM EDTA and 0.09% NaN3 and stained for surface CD4 with Phycoerythrin-labeled anti-CD4 Ab (RM4-5, manufactured by BD Biosciences). Intracellular staining of Foxp3 was performed using the Alexa647-labeled anti-Foxp3 Ab (FJK-16s, manufactured by eBioscience) and Foxp3 Staining Buffer Set (manufactured by eBioscience). The percentage of Foxp3 positive cells within the CD4 positive lymphocyte population was analyzed by flow cytometry. Results show that when the spore-forming (for example, the chloroform resistant) fraction of human intestinal bacteria was colonized in GF mice, the accumulation of Foxp3+ regulatory (Treg) cells in the colonic lamina propria of the mice was induced. Next, it was investigated what species of bacteria grew by gavaging with chloroform-treated human stool.
  • Specifically, using a QIAamp DNA Stool mini kit (manufactured by QIAGEN), bacterial genomic DNA was isolated from the human stool from a healthy volunteer as described above (human stool) or fecal pellets from GF mice gavaged with chloroform-treated human stool (GF+Chloro.). Quantitative PCR analysis was carried out using a LightCycler 480 (manufactured by Roche). Relative quantity was calculated by the delta Ct method and normalized to the amount of total bacteria, dilution, and weight of the sample. The following primer sets were used:
    • total bacteria
      • 5'-GGTGAATACGTTCCCGG-3' (SEQ ID NO: 62) and
      • 5'-TACGGCTACCTTGTTACGACTT-3' (SEQ ID NO: 63)
    • Clostridium cluster XIVa (Clostridium coccoides subgroup)
      • 5'-AAATGACGGTACCTGACTAA-3' (SEQ ID NO: 64) and
      • 5'-CTTTGAGTTTCATTCTTGCGAA-3' (SEQ ID NO: 65)
    • Clostridium cluster IV (Clostridium leptum)
      • 5'-GCACAAGCAGTGGAGT-3' (SEQ ID NO: 66) and
      • 5'-CTTCCTCCGTTTTGTCAA-3' (SEQ ID NO: 69)
    • Bacteroides
      • 5'-GAGAGGAAGGTCCCCCAC-3' (SEQ ID NO: 67) and
      • 5'-CGCTACTTGGCTGGTTCAG-3' (SEQ ID NO: 68).
  • Results show that gavaged with chloroform-treated human stool had large amounts of spore-forming bacteria, such as Clostridium clusters XIVa and IV, and a severe decrease of non-spore-forming bacteria, such as Bacteroides, compared with the human stool before chloroform treatment.
    • Example 19
  • Example 19: Human stool (2g) from a healthy volunteer (Japanese, male, 29y old) was suspended with 20ml phosphate-buffered saline (PBS), mixed with or without chloroform (final concentration 3%), and incubated in a shaking water bath for 60 min. The chloroform was then evaporated by bubbling with N2 gas for 30 min. The suspensions of untreated human feces (designated as 'huUT') and chloroform-treated human feces (designated as 'huChloro') were orally inoculated into Germ-free (GF) mice (IQI, 8 week old) (250 micro liter/mouse). The suspension of huUT was inoculated into 4 GF mice, which were numbered from #A1 to #A4, and that of huChloro was inoculated into 4 GF mice numbered from #B1 to #B4. Such GF mice which were inoculated with suspensions of feces or the like are also referred to as "ex-GF mice" hereinafter. Each group of ex-GF mice was separately kept in a vinyl isolator to avoid further microbial contamination. After 3 weeks, the small intestinal and colonic lamina propria lymphocytes from each mouse were separately collected, and examined for the expressions of surface CD4 and intracellular Foxp3, Helios, IL-17 and IFN- gamma by flow cytometry. For intracellular IL-17 and IFN- gamma staining, isolated lymphocytes were stimulated in vitro with PMA and ionomycin for 4 hours. Foxp3 is the transcription factor essential for the differentiation and function of Treg cells. Helios is a member of the Ikaros transcription factor family and Helios- Foxp3+ Treg cells have been suggested to be Treg cells induced in the periphery [so called induced Treg (iTreg) cells]. As shown in Figs. 1A-D, the percentages of Foxp3+ Treg cells within CD4+ T cells in the small intestinal and colonic lamina propria of both groups of ex-GF mice were increased, compared with those in GF mice. Marked increases were also observed for the percentage of Helios- cells among Foxp3+ Treg cells in small intestine and colon in both groups of ex-GF mice. Notably, besides Foxp3+ Treg cells, a significant accumulation of IL-17-expressing CD4+ cells (namely, Th17 cells) was observed in exGF+huUT mice, whereas it was only marginally observed in exGF+huChloro mice (Figs. IE, F). In both groups of mice, the percentages of IFN- gamma + cells in CD4+ cells were unchanged (Figs. IE, G).
    • Example 20
  • Example 20: To investigate whether dead bacteria also have an effect on the induction of Treg cells, the suspension of chloroform-treated human feces was autoclaved (121 °C for 20 min) and orally inoculated into GF mice (once a week for 4 weeks). After 4 weeks, mice were sacrificed, and the colonic lamina propria lymphocytes from each mouse were examined for the expression of CD4, Foxp3 and Helios by flow cytometry. As shown in Fig. 2, the inoculation of dead bacteria exhibited no effect on the numbers of Foxp3+ cells or Helios-Foxp3+ cells. These results do not rule out the possibility that the amount of dead bacteria inoculated was not sufficient, but suggest that live bacteria are required for the induction of Treg cells.
    • Example 21
  • Example 21: To confirm the induction of Treg cells by chloroform-resistant bacteria, another stool was obtained from the same person on a different day, treated with chloroform, and inoculated into IQI GF mice (7 mice, numbered from #C1 to C7). After 3-4 weeks, mice from #C1 to #C5 were sacrificed, and the small intestinal and colonic lamina propria lymphocytes from each mouse were separately collected, and examined for the expression of CD4 and Foxp3 by flow cytometry. Consistent with the findings in Example 19, colonization with chloroform-treated human feces significantly induced the accumulation of Foxp3+CD4+ Treg cells in colonic and small intestinal lamina propria (Fig. 3). These results further support the notion that chloroform-resistant spore-forming bacteria can induce differentiation, proliferation and/or recruitment of Treg cells in intestinal lamina propria.
    • Example 22
  • Example 22: To test whether Treg cell induction by chloroform-resistant spore-forming fraction of human intestinal bacteria is horizontally transmissible, IQI GF mice (6 mice, numbered from #D1 to #D6) were cohoused for 4 weeks with mice #C6 and #C7 in the same cage in a vinyl isolator. Lamina propria lymphocytes from colon and small intestine were isolated and examined for CD4 and Foxp3. Cohoused mice exhibited a significant increase in the percentage of Foxp3+ cells among CD4+ cells (Fig. 4). Therefore, Treg cell induction by human intestinal bacteria is horizontally transmissible. These results let us assume a role of prominent components of the intestinal microbiota, rather than minor components, for the induction of Treg cells.
    • Example 23
  • Example 23: The frozen stock of cecal content from mouse #C4 was thawed, suspended in 10 times its volume (w/v) of PBS, and passed through a 70 micro meter cell strainer. The suspension was then treated with 3% chloroform, diluted 2000- or 20000-fold with PBS, and orally inoculated into GF IQI mice (2.5x105 or 2.5x104 bacterial cells / 250 micro liter / head, respectively). The 2000-fold diluted sample was orally inoculated into 4 mice (designated as exGF+2000, numbered from #E1 to #E4), whereas 20000-fold diluted sample was inoculated into 8 mice (designated as exGF+20000, numbered from #F1 to #F8). After 3 weeks, the intestinal lamina propria lymphocytes were isolated and examined for CD4, Foxp3 and Helios. Both 2000- and 20000-fold diluted samples similarly induced a marked accumulation of Foxp3+CD4+ cells in the intestinal lamina propria (Fig. 5). Therefore, the dose of bacteria for oral inoculation can be minimized to less than 2.5x104 bacterial cells.
    • Example 24
  • Example 24: The frozen stock of cecal content from mouse #F3, #F7 or #F8 was suspended in 10 times its volume (w/v) of PBS, passed through a 70 micro meter cell strainer, and treated with 3% chloroform. Then, the fecal suspension from mouse #F3 was orally inoculated into 5 GF mice (numbered from #G1 to #G5), that from #F7 mouse into 4 GF mice (numbered from #H1 to #H4), and that from #F8 mouse into 4 GF mice (numbered from #11 to #14). After 4 weeks, lymphocytes from colonic and small intestinal lamina propria were isolated and examined for CD4, Foxp3 and Helios expression by flow cytometry. All #F, #G, and #H mice exhibited a significant increase in the percentage of Foxp3+ cells among CD4+ cells in the intestinal lamina propria compared with untreated GF mice (Fig. 6). Therefore, the Treg cell induction by human intestinal bacteria colonizing in exGF+20000 mice is also transmissible. Moreover, as shown in the later meta 16S rDNA sequencing data (Fig. 8), these mice commonly had bacteria having 16S rDNA sequence similarities with 16S rDNA sequence similarities with 20 species of known bacteria (C. aminophilum, H. saccgarovorans, E. fissicatena, H.filiformis, C. clostridioforme, C. indolis, C. bolteae, Bacteroides sp. MANG, L. bacterium DJF_VP30, Ruminococcus sp. ID8, C. lavalense, C. symbiosum, E. contortum, C. saccharogumia, C. ramosum, F. plautii, C. scindens, Clostridium sp. 2335, Clostridium sp. 14616 and cf Clostridium sp. MLG055).
    • Example 25
  • Example 25: A frozen stock of the cecal content from #F8 mouse was serially diluted with 0.85% NaCl under an aerobic condition and plated onto BL agar. After culture at 37 °C for 2 or 4 days, 50 single colonies were observed. Of the 50 colonies, 29 were picked up, cultured for additional 2 or 4 days at 37 °C by ABCM broth, and stored in EG stock medium (10% DMSO) at -80°C. The genomic DNA from each colony was isolated, and 16S rRNA coding gene sequence was analyzed. The sequence of 16S rRNA of each colony revealed that the 29 colonies observed were represented by three strains, each having 100 % similarity with Clostridium ramosum, 99.75 % with Clostridium saccharogumia, 100 % with Flavonifractor plautii, 99.17 % with Clostridium hathewayi, 99.23 % with Clostridium scindens, or 99.66 % with Clostridium sp. 2335. Within the 29 colonies that were selected from the original 50 colonies, only Clostridium saccharogumia, Clostridium ramosum, and Flavonifractor plautii were present (25, 3, and 1 colonies, respectively). These 3 isolated strains were propagated, mixed and inoculated into GF IQI mice (4 mice, numbered from #J1 to J4). After 3-4 weeks, the colonic lamina propria lymphocytes were collected, and examined for the expressions of CD4, Foxp3, and Helios by flow cytometry. Foxp3+ cells or Helios- cells were not induced or only weakly induced by the colonization of these strains of bacteria in the colon (Fig. 7). These results suggest that the combination of Clostridium saccharogumia and Clostridium ramosum (both within cluster XVIII) were insufficient to induce Treg cells in the colon of mice. The effects of Flavonifractor plautii were not clear, since the strain was only represented by 1 of the 29 colonies that were selected.
    • Example 26
  • Example 26: The frozen glycerol stock of cecal content from #G2 mouse was suspended with PBS, seeded onto BL agar plate, and incubated for 48 hours, similarly to the procedure done in Example 19. Different from Example 19, all bacteria on the plate were collected by scraping with a plate scraper, suspended in TS broth and inoculated into GF IQI mice (4 mice, numbering from #K1 to #K4). It should be noted that the bacterial suspension used in this experiment included bacteria that did not propagate but survived on the plate. After 4 weeks, lamina propria lymphocytes from colon and small intestine of K1∼K4 mice were isolated and examined for CD4, Foxp3 and Helios expression. All 4 mice exhibited a significant increase in the percentages of Foxp3+ cells among CD4+ cells (Figs. 9A, 9B) and Helios- cells among Foxp3+ Treg cells (Figs. 9A, 9C) in the intestinal lamina propria compared with untreated GF mice. Considering that the inoculation of mice with 6 strains of bacteria propagated on the BL agar plate failed to induce Treg cells, bacteria that did not propagate but survived on the plate might be responsible for the induction of Treg cells.
    • Example 27
  • Example 27: Bacterial DNA was extracted from the cecal contents of mouse #A1, #C4, #F8, #G2, #H3, #13, #J3 and #K3. Variable region 1-2 (V1-2) in bacterial 16S rRNA coding gene were amplified by PCR and used as template for metasequencing. Resulting sequences (3400 reads for each sample) were classified into operational taxonomic units (OTUs) on the basis of sequence similarity (>97 % identity). Representative sequences from each OTU were compared with sequences in nucleic acid databases using BLAST to determine their closest relatives in known species. The numbers of detected reads and the closest relatives for each OTU are shown in Table 1. The relative abundances of OTUs having the same closest relative in each cecal sample are shown in Fig. 8. In mouse #A1, 153 OTUs (their closest relatives were 93 species) were identified and half of them were related to Bacteroides species. In contrast, in mouse #C4, 113 OTUs were identified and most of them were related to species belonging to the family Clostridiaceae. In mouse #F8, #G2, #H3, #13, #J3 and #K3, 97-68 OTUs were identified. In these mice, in which Treg cell accumulation was observed in the intestine, the majority of bacteria consisted of bacteria having 16S rDNA sequence similarities with C. aminophilum, H. saccgarovorans, E. fissicatena, H.filiformis, C. clostridioforme, C. indolis, C. bolteae, Bacteroides sp. MANG, L. bacterium DJF_VP30, Ruminococcus sp. ID8, C. lavalense, C. symbiosum, E. contortum, C. saccharogumia, C. ramosum, F. plautii, C. scindens, Clostridium sp. 2335, Clostridium sp. 14616 and cf Clostridium sp. MLG055.
  • In mouse #J3, in which Treg accumulation was not observed, 3 OTUs were detected. Each has the 16S rDNA sequence similarity with C. saccharogumia, C. ramosum or F. plautii. These results suggest that the combination of these three species are insufficient to induce the intestinal Treg cells accumulation.
    • Example 28
  • Example 28: Bacterial strains were isolated from the cecal contents of mouse #F8, #G2, #11 and #K3 using BL agar or EG agar plates. Applicant picked-up 144 colonies from EG agar plates and 116 colonies from BL agar plates. BLAST search of 16S rRNA coding sequence of these clones revealed that they belonged to 17 species, and each had 93 - 100% similarities with C. indolis, C. bolteae, Bacteroides sp. MANG, L. bacterium DJF_VP30, A.colihominis, Ruminococcus sp. ID8, C. lavalense, C. symbiosum, E. contortum, C. saccharogumia, C. ramosum, F. plautii, C. hathewayi, C. scindens, Clostridium sp. 2335, Clostridium sp. 14616 and cf Clostridium sp. MLG055) (Table 2). They all belonged to Clostridium clusters IV, XIVa or XVIII (2 species of cluster IV, 12 of cluster XIVa, 1 of cluster XVI and 2 of cluster XVIII).
    • Example 29
  • Example 29: Of the colonies selected in Example 28, additional colonies were picked and isolated and these strains were cultured using EG and BL media. BLAST search of 16S rRNA coding sequence of these clones revealed that they belonged to a total of 31 species (including the species mentioned in Example 28), and each had 93 - 100% similarities with Clostridium saccharogumia, Clostridium ramosum JCM1298, Clostridium ramosum, Flavonifractor plautii, Pseudoflavonifractor capillosus ATCC 29799, Clostridium hathewayi, Clostridium saccharolyticum WM1, Bacteroides sp. MANG, Clostridium saccharolyticum, Clostridium scindens, Lachnospiraceae bacterium 5_1_57FAA, Lachnospiraceae bacterium 6_1_63FAA, Clostridium sp. 14616, Clostridium bolteae ATCC BAA-613, cf. Clostridium sp. MLG055, Erysipelotrichaceae bacterium 2_2_44A, Clostridium indolis, Anaerostipes caccae, Clostridium bolteae, Lachnospiraceae bacterium DJF_VP30, Lachnospiraceae bacterium 3_1_57FAA_CT1, Anaerotruncus colihominis, Anaerotruncus colihominis DSM 17241, Ruminococcus sp. ID8, Lachnospiraceae bacterium 2_1_46FAA, Clostridium lavalense, Clostridium asparagiforme DSM 15981, Clostridium symbiosum, Clostridium symbiosum WAL-14163, Eubacterium contortum, Clostridium sp. D5, Oscillospiraceae bacterium NML 061048, Oscillibacter valericigenes, Lachnospiraceae bacterium A4, Clostridium sp. 316002/08, and Clostridiales bacterium 1_7_47FAA, Blautia cocoides, Anaerostipes caccae DSM 14662 (Table 3). The stocks of bacterial strains were stored in 10% glycerol stock plus the media used to grow the cultures, and tubes were stored in a -80°C freezer.
    • Example 30
  • Example 30: To investigate whether the strains in Example 29 have the ability to induce Tregs in GF mice, 31 strains on Table 3 were mixed at equal amounts of media volume using TS media and inoculated into GF mice. A detailed analysis of the 16S rRNA sequences revealed that 8 of the 31 strains overlapped with other strains (see Table 3, indicated by an asterisk), resulting in 23 distinct bacterial strains. As shown in Figure 10, when orally administered to GF mice, the mixture of the 23 strains (23mix) induced very strong levels of Tregs (35-40% in the colon lamina propria, >10% in the small intestine; Figure 10). These Tregs observed with colonization by 23mix were mostly Helios-.
    • Example 31
  • Example 31: To investigate whether the abundant members of the intestinal microbiota in the chloroform-resistant fraction of human intestinal bacteria, rather than the minor members, drive the induction of Treg cells, adult GF mice were inoculated with diluted caecal samples from mice that had been inoculated with the chloroform-resistant fraction of human intestinal bacteria (+huChlo mice) as described in example 19. As shown in Figure 11, even when the huChlo mice cecal samples were diluted (diluted 2x104 and 2x105) to create +2x104 mice and 2x105 mice respectively, Tregs were induced in these adult GF mice.
    • Example 32
  • Example 32: To investigate whether the mix of 23 strains in Example 30 has the ability to induce Tregs in adult GF IQI mice more effectively than Faecalibacterium prausnitzii, a well-known human Clostridia strain characterized for enhancing regulatory cell functions, 23 strains in table 4 were mixed in equal amounts with media to make a cocktail, which was then administered to adult IQI GF mice. For comparison, Faecalibacterium prausnitzii was administered to another group of IQI GF mice. As shown in Figure 12, when orally administered to adult IQI GF mice, the mixture of the 23 strains (23-mix) induced higher levels of Tregs than Faecalibacterium prausnitzii. Faecalibacterium prausnitzii (+Faecali.) showed negligible levels of Treg induction.
    • Example 33
  • Example 33: To investigate whether the microbiota communities in the +2x104 mice, described in example 31, were stable, serial oral inoculation of adult GF mice was performed to create +2x104-re mice(secondary inoculation) and +2x104-re-re(tertiary inoculation). As shown in Figure 13 there was significant induction of Tregs in both the +2x104-re mice and the +2x104-re-re mice. To further eliminate nonessential components of the microbiota for Treg cell induction, the caecal content of +2x104 mice, described in example 31, was again diluted 2x104-fold and orally inoculated into another set of adult GF mice (+(2x104)2 mice). As shown in Figure 13, the +(2x104)2 mice exhibited a marked accumulation of Treg cells in the colon.
    • Example 34
  • Example 34: To assess the composition of the gut microbiota in +huUT (+hu), +huChlo, +2x104, +2x104-re and +(2x104)2, described in example 19, example 31, and example 33, bacterial DNA was extracted from the caecal contents of these adult mice. The variable region (V1-V2) of the bacterial 16S ribosomal DNA (rDNA) was amplified and metasequencing using a 454 sequencer was performed. The resulting sequences (3400 reads for each sample) were classified into operational taxonomic units (OTUs) based on sequence similarity (>96 % identity). Representative sequences from each OTU were compared with sequences deposited in publicly available 16S and genome databases using BLAST to determine their closest species. As shown in Figure 14, in +hu mice, OTUs belonging to Bacteroidetes accounted for about 50% of the caecal microbial community. In contrast, in most OTUs in +huChlo mouse were related to species belonging to Clostridia. In +2x104, +2x104-re and +(2x104)2 mice, the majority of bacteria consisted of bacteria having 16S rDNA sequence similarities with about 20 species of Clostridia belonging to cluster XIVa (also referred to as C. leptum group), IV, XVI, and XVIII, listed in Figure 14.
    • Example 35
  • Example 35: A meta analysis of 16S rDNA of caecal contents from mice inoculated with the 23 strains isolated in example 30 (+23-mix mice) confirmed the presence of 17 of the 23 strains listed in Figure 14 and Table 4. To determine whether these 17 strains could induce Treg cells, a mixture of these 17 strains was inoculated into adult GF mice (+17-mix mice), Each bacterial strain was cultured in 2mL EG liquid media and grown to confluence, and then these starter cultures were mixed into a 50mL tube (2mL x 17 strains=34mL). The bacteria were spun down into a pellet and resuspended in 10mL PBS. A 200uL aliquot, containing ∼1x106-1x107 of each strain, was used to inoculate the adult GF mice. As shown in Figure 15, when orally administered to adult IQI, BALB, and B6 mice, the mixture of 17 strains was able to induce Tregs in these three mouse models.
    • Example 36
  • Example 36: To investigate whether each of the 17 strains defined in example 35 could individually induce Tregs, adult GF mice were monocolonized with one of each of the 17 strains. As shown in Figure 16, adult GF mice monocolonized with a single strain exhibited low to intermediate levels of Treg. Importantly, no single strain induced Tregs to the same extent as the mix of 17 strains.
    • Example 37
  • Example 37: To investigate whether subsets of the 17 strains described in example 35 could induce Tregs, randomly selected combinations of 3-5 strains were made: 3-mix, 5mixA, 5-mix B, and 5-mix C, as shown in table 4, and used to inoculate adult GF mice. As shown in Figure 17, only the 5-species mixes induced significant increases in the frequency of Treg cells, the magnitude of which was intermediate compared with that observed in +17-mix mice.
    • Example 38
  • Example 38: To investigate the benefits of administration of the mix of the 17 strains described in example 35 (17-mix), adult SPF mice were orally inoculated with either 17-mix or control media and assessed for the induction of Foxp3+ Treg cells three weeks later. As shown in Figure 18, there was a significant increase in the frequency of colonic Foxp3+ Treg (CD4) cells after three weeks of treatment.
    • Example 39
  • Example 39: To evaluate the benefit of administration of 17-mix in an animal model of allergic diarrhea, adult SPF mice were orally inoculated with 17-mix or control media while being treated with ovalbumin (OVA), an inducer of allergic diarrhea. As shown in Figure 19, the occurrence and severity of diarrhea (diarrhea score) was significantly reduced in mice fed 17-mix relative to control mice.
    • Example 40
  • Example 40: To evaluate the benefit of administration of 17-mix in an animal model of colitis, . Adult SPF mice were orally inoculated with either 17-mix or control media while being treated with trinitrobenzene sulfonic acid (TNBS),a frequently used experimental inducer of colitis. As shown in Figure 20, SPF 17-mix mice demonstrated lower mortality than control mice on exposure to TNBS.
    • Example 41
  • Example 41: To evaluate the usefulness of the strains represented in 17-mix as a diagnostic and monitoring tool for ulcerative colitis, we examined the relative abundance of the 17 strains in healthy and ulcerative colitis (UC) human subjects using draft genomic sequences of the 17 strains and publicly available human faecal microbiome genomes
    generated through the European MetaHIT project. UC subjects (N=20) showed a a reduction of the 17 strains compared to healthy subjects (N=15), as shown in Figure 21.
    SEQ ID NOs.: OTU136; OTU46; OTU221; OTU9; OTU296; OTU21; OTU166; OTU73; OTU174; OTU14; OTU55; OTU337; OTU314; OTU195; OTU306; OTU87; OTU86; OTU152; OTU253; OTU259; OTU281; OTU288; OTU334; OTU359; OTU362; or OTU367are SEQ ID NOs. 19-44, respectively.
    • Industrial Applicability
  • As has been described above, the compositions and methods described herein make it possible to provide an excellent and well-characterized composition for inducing proliferation or accumulation of regulatory T cells (Treg cells) by utilizing certain human-derived bacteria belonging to the Clostridia class or a physiologically active substance or the like derived from the bacteria. Since the bacterial composition has immunosuppressive effects, the bacterial composition can be used, for example, to prevent or treat autoimmune diseases or allergic diseases, as well as to suppress immunological rejection in organ transplantation or the like. In addition, healthy individuals can easily and routinely ingest the bacterial composition, such as in food or beverage, (e.g., a health food), to improve their immune functions.
    Figure imgb0001
    Figure imgb0002
    Figure imgb0003
    Figure imgb0004
    • [Table 2]
  • Table. 2
    Strain The corresponding OTU The close relative Max similarity (%) Clostridiaceae Cluster Origin of mouse sample Cultured Media
    strain1 OTU136 Clostridium saccharogumia 99 XVIII #F8 BL
    strain2 OTU46 Clostridium ramosum 100 XVIII #F8, #G2, #J3 BL, EG
    strain3 OTU221 Flavonifractor plautii 100 IV #F8, #G2 BL
    strain4 OTU9 Clostridium hathewayi 99 XIVa #F8, #G2 BL
    strain5 OTU296 Clostridium scindens 99 XIVa #F8 BL
    strain6 OTU21 Clostridium sp. 2335 99 XIVa #F8, #G2 BL
    strain7 OTU166 Clostridium sp. 14616 99 XIVa #G2 BL
    OTU237
    strain8 OTU73 cf. Clostridium sp. MLG055 99 XVI #G2 BL
    strain9 OTU174 Clostridium indolis 99 XIVa #G2, #J3 EG
    strain
    10 OTU166 Clostridium sp. 14616 97 XIVa #I1 EG
    OTU181 Clostridium bolteae 98
    strain 11 OTU14 Bacteroides sp. MANG 99 XIVa #I1 EG
    strain
    12 OTU55 Lachnospiraceae bacterium DJF_VP30 96 XIVa #I1 EG
    strain
    13 OTU337 Anaerotruncus colihominis 99 IV #I1 EG
    strain14 OTU314 Ruminococcus sp. ID8 99 XIVa #11 EG
    strain15 OTU195 Clostridium lavalense 99 XIVa #11 EG
    strain16 OTU306 Clostridium symbiosum 99 XIVa #11 EG
    strain
    17 OTU87 Eubacterium contortum 99 XIVa #I1 EG
    • [Table 3-1]
  • Figure imgb0005
    Figure imgb0006
    • [Table 4]
  • Figure imgb0007
    Figure imgb0008
    Figure imgb0009
    Figure imgb0010
    Figure imgb0011
    Figure imgb0012
    Figure imgb0013
    Figure imgb0014
    Figure imgb0015
    Figure imgb0016
    Figure imgb0017
    Figure imgb0018
    Figure imgb0019
    Figure imgb0020
    Figure imgb0021
    Figure imgb0022
    Figure imgb0023
    Figure imgb0024
    Figure imgb0025
    Figure imgb0026
    Figure imgb0027
    Figure imgb0028
    Figure imgb0029
    Figure imgb0030
    Figure imgb0031
    Figure imgb0032
    Figure imgb0033
    Figure imgb0034
    Figure imgb0035
    Figure imgb0036
    Figure imgb0037
    Figure imgb0038
    Figure imgb0039
    Figure imgb0040
    Figure imgb0041
    Figure imgb0042
    Figure imgb0043
    Figure imgb0044
    Figure imgb0045
    Figure imgb0046
    Figure imgb0047
    Figure imgb0048
    Figure imgb0049
    Figure imgb0050
    Figure imgb0051
    Figure imgb0052
    Figure imgb0053
    Figure imgb0054
    Figure imgb0055
    Figure imgb0056
    Figure imgb0057
    Figure imgb0058
    Figure imgb0059
    Figure imgb0060
    Figure imgb0061
    Figure imgb0062
    Figure imgb0063
    Figure imgb0064
    Figure imgb0065
    Figure imgb0066
    Figure imgb0067
    Figure imgb0068
    Figure imgb0069
    Figure imgb0070
    Figure imgb0071
    Figure imgb0072
    Figure imgb0073
    Figure imgb0074
    Figure imgb0075
    Figure imgb0076
    Figure imgb0077
    Figure imgb0078
    Figure imgb0079
    Figure imgb0080
    Figure imgb0081
    Figure imgb0082
    Figure imgb0083
    Figure imgb0084
    Figure imgb0085
    Figure imgb0086
    Figure imgb0087
    Figure imgb0088
    Figure imgb0089
    Figure imgb0090
    Figure imgb0091
    Figure imgb0092
    Figure imgb0093
    Figure imgb0094
    Figure imgb0095
    Figure imgb0096
    Figure imgb0097
    Figure imgb0098
    Figure imgb0099
    Figure imgb0100
    Figure imgb0101
    Figure imgb0102
    Figure imgb0103
    Figure imgb0104
    Figure imgb0105
    Figure imgb0106
    Figure imgb0107
    Figure imgb0108
    Figure imgb0109
    Figure imgb0110
    Figure imgb0111
    Figure imgb0112
    Figure imgb0113

Claims (11)

  1. A composition which induces proliferation and/or accumulation of regulatory T cells, the composition consisting of a mixture of 17 bacterial strains corresponding to the operational taxonomic units (OTUs) identified below:
    Figure imgb0114
  2. The composition according to claim 1, wherein: (a) the regulatory T cells are transcription factor Foxp3-positive regulatory T cells, IL-10-producing regulatory T cells, or Helios-negative Foxp3-positive regulatory T cell; and/or (b) the composition has an immunosuppressive effect.
  3. The composition according to claim 1 or claim 2 further comprising a substance selected from the group consisting of almond skin, inulin, oligofructose, raffinose, lactulose, pectin, hemicellulose, amylopectin, acetyl-Co A, biotin, beet molasses, yeast extracts, resistant starch, corticosteroids, mesalazine, mesalamine, sulfasalazine, sulfasalazine derivatives, immunosuppressive drugs, cyclosporin A, mercaptopurine, azathiopurine, prednisone, methotrexate, antihistamines, glucocorticoids, epinephrine, theophylline, cromolyn sodium, anti-leukotrienes, anti-cholinergic drugs for rhinitis, anti-cholinergic decongestants, mast-cell stabilizers, monoclonal anti-IgE antibodies, vaccines, anti-TNF inhibitors, and combinations thereof.
  4. A pharmaceutical composition comprising the composition according to claim 1 or claim 2 and a pharmacologically acceptable carrier.
  5. The pharmaceutical composition of claim 4 wherein the pharmacologically acceptable carrier is selected from one or more of the following: sterile water, physiological saline, vegetable oil, solvent, a base material, an emulsifier, a suspending agent, a surfactant, a stabilizer, a flavoring agent, an aromatic, an excipient, a vehicle, a preservative, a binder, a diluent, a tonicity adjusting agent, a soothing agent, a bulking agent, a disintegrating agent, a buffer agent, a coating agent, a lubricant, a colorant, a sweetener, a thickening agent, a flavour corrigent and a solubilizer.
  6. The composition according to any one of claims 1-5 for use in therapy or prophylaxis.
  7. The composition according to any one of claims 1-5 for use in a method of inducing proliferation, accumulation or both proliferation and accumulation of regulatory T cells in an individual in need thereof.
  8. The composition according to any one of claims 1-5 for use in a method of treating, aiding in treating, reducing the severity of, or preventing an autoimmune disease in an individual in need thereof.
  9. The composition according to any one of claims 1-5 for use in a method of treating, aiding in treating, reducing the severity of, or preventing an inflammatory disease in an individual in need thereof.
  10. The composition according to any one of claims 1-5 for use in a method of treating, aiding in treating, reducing the severity of, or preventing an allergic disease in an individual in need thereof.
  11. The composition according to any one of claims 1-5 for use in a method of treating, aiding in treating, reducing the severity of, or preventing an infectious disease in an individual in need thereof.
EP12854485.5A 2011-12-01 2012-11-29 Human-derived bacteria that induce proliferation or accumulation of regulatory t cells Active EP2785828B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP21198256.6A EP3978598B1 (en) 2011-12-01 2012-11-29 Human-derived bacteria that induce proliferation or accumulation of regulatory t cells
EP19178787.8A EP3569690B1 (en) 2011-12-01 2012-11-29 Human-derived bacteria that induce proliferation or accumulation of regulatory t cells

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161565976P 2011-12-01 2011-12-01
US201261607360P 2012-03-06 2012-03-06
PCT/JP2012/007687 WO2013080561A1 (en) 2011-12-01 2012-11-29 Human-derived bacteria that induce proliferation or accumulation of regulatory t cells

Related Child Applications (3)

Application Number Title Priority Date Filing Date
EP21198256.6A Division EP3978598B1 (en) 2011-12-01 2012-11-29 Human-derived bacteria that induce proliferation or accumulation of regulatory t cells
EP19178787.8A Division EP3569690B1 (en) 2011-12-01 2012-11-29 Human-derived bacteria that induce proliferation or accumulation of regulatory t cells
EP19178787.8A Division-Into EP3569690B1 (en) 2011-12-01 2012-11-29 Human-derived bacteria that induce proliferation or accumulation of regulatory t cells

Publications (3)

Publication Number Publication Date
EP2785828A1 EP2785828A1 (en) 2014-10-08
EP2785828A4 EP2785828A4 (en) 2015-07-29
EP2785828B1 true EP2785828B1 (en) 2020-04-08

Family

ID=48535050

Family Applications (3)

Application Number Title Priority Date Filing Date
EP12854485.5A Active EP2785828B1 (en) 2011-12-01 2012-11-29 Human-derived bacteria that induce proliferation or accumulation of regulatory t cells
EP21198256.6A Active EP3978598B1 (en) 2011-12-01 2012-11-29 Human-derived bacteria that induce proliferation or accumulation of regulatory t cells
EP19178787.8A Active EP3569690B1 (en) 2011-12-01 2012-11-29 Human-derived bacteria that induce proliferation or accumulation of regulatory t cells

Family Applications After (2)

Application Number Title Priority Date Filing Date
EP21198256.6A Active EP3978598B1 (en) 2011-12-01 2012-11-29 Human-derived bacteria that induce proliferation or accumulation of regulatory t cells
EP19178787.8A Active EP3569690B1 (en) 2011-12-01 2012-11-29 Human-derived bacteria that induce proliferation or accumulation of regulatory t cells

Country Status (7)

Country Link
US (11) US10238694B2 (en)
EP (3) EP2785828B1 (en)
JP (6) JP6306507B2 (en)
CN (3) CN104160014A (en)
CA (1) CA2892588A1 (en)
HK (1) HK1204008A1 (en)
WO (1) WO2013080561A1 (en)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
WO2011151941A1 (en) 2010-06-04 2011-12-08 国立大学法人東京大学 Composition having activity of inducing proliferation or accumulation of regulatory t cell
AU2011286165B2 (en) 2010-08-04 2016-10-20 Thomas Julius Borody Compositions for fecal floral transplantation and methods for making and using them and devices for delivering them
ES2662412T3 (en) 2010-10-07 2018-04-06 California Institute Of Technology Probiotic therapies for autism
JP2014507481A (en) 2011-03-09 2014-03-27 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ Compositions and methods for colonic microbiota transplantation
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
CA2892588A1 (en) * 2011-12-01 2013-06-06 School Corporation, Azabu Veterinary Medicine Educational Institution Human-derived bacteria that induce proliferation or accumulation of regulatory t cells
BR112014021388A2 (en) 2012-02-29 2017-07-18 Ethicon Endo Surgery Inc microbiota compositions and methods related thereto
DK2830599T3 (en) 2012-03-29 2018-10-08 Therabiome Llc SITE-SPECIFIC GASTROINTESTINAL ORAL VACCINE FORMS WITH EFFECTS ON ILEUM AND APPENDIX
WO2013176774A1 (en) 2012-05-25 2013-11-28 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
CN104768560A (en) 2012-08-29 2015-07-08 加州理工学院 Diagnosis and treatment of autism spectrum disorder
PT3628161T (en) 2012-11-23 2023-05-15 Seres Therapeutics Inc Synergistic bacterial compositions and methods of production and use thereof
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
KR102222273B1 (en) 2013-02-04 2021-03-08 세레스 테라퓨틱스, 인코포레이티드 Compositions and methods
US10973861B2 (en) 2013-02-04 2021-04-13 Seres Therapeutics, Inc. Compositions and methods
US9907755B2 (en) 2013-03-14 2018-03-06 Therabiome, Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
JP2016519664A (en) 2013-03-15 2016-07-07 セレス セラピューティクス インコーポレイテッド Microbial composition and method based on network
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
JP6833514B2 (en) 2013-11-25 2021-02-24 セレス セラピューティクス インコーポレイテッド Synergistic bacterial composition and its production and use
EP3082431A4 (en) * 2013-12-16 2017-11-15 Seres Therapeutics, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
US10300137B2 (en) * 2014-04-10 2019-05-28 Riken Compositions and methods for induction of TH17 cells
US20150322176A1 (en) * 2014-04-16 2015-11-12 University Of Guelph Novel polysaccharide immunogens from clostridium bolteae isolated from autistic subjects and methods and uses thereof
AU2015264266A1 (en) 2014-05-19 2016-12-01 Memorial Sloan-Kettering Cancer Center Methods and compositions for reducing Clostridium difficile infection
JP6800846B2 (en) 2014-10-30 2020-12-16 カリフォルニア インスティチュート オブ テクノロジー Bacterial-containing compositions for improving behavior in the neurodevelopmental group, and methods for improving behavior in the neurodevelopmental group, including the use of bacteria.
EA201790811A1 (en) 2014-10-30 2017-11-30 Калифорния Инститьют Оф Текнолоджи COMPOSITIONS CONTAINING BACTERIA AND METHODS TO IMPROVE BEHAVIOR TYPES IN DISORDERS OF NEUROLOGICAL DEVELOPMENT
CN113730442A (en) 2014-10-31 2021-12-03 潘德勒姆治疗公司 Methods and compositions relating to microbial treatment and diagnosis of disorders
JP6777643B2 (en) * 2014-11-25 2020-10-28 メモリアル スローン ケタリング キャンサー センター Gut microbiota and GVHD
MA41020A (en) 2014-11-25 2017-10-03 Evelo Biosciences Inc PROBIOTIC AND PREBIOTIC COMPOSITIONS, AND THEIR METHODS OF USE FOR MODULATION OF THE MICROBIOME
JP6271093B1 (en) 2014-12-23 2018-01-31 フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ Immunoregulation
ES2668934T3 (en) 2014-12-23 2018-05-23 4D Pharma Research Limited Pirin polypeptide and immune modulation
US20170360853A1 (en) * 2015-01-07 2017-12-21 Ecole Polytechnique Federale De Lausanne (Epfl) Gastro-Intestinal Biomarkers for Diagnosis and Therapies of Proteinopathies
US9901603B2 (en) 2015-05-14 2018-02-27 Crestovo Holdings Llc Compositions for fecal floral transplantation and methods for making and using them and device for delivering them
NZ776366A (en) 2015-05-22 2023-02-24 Univ Minnesota Methods for treating autism spectrum disorder and associated symptoms
ES2753779T3 (en) * 2015-06-15 2020-04-14 4D Pharma Res Ltd Blautia stercosis and wexlerae for use in the treatment of inflammatory and autoimmune diseases
PL3307288T3 (en) 2015-06-15 2019-12-31 4D Pharma Research Limited Compositions comprising bacterial strains
MA41060B1 (en) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprising bacterial strains
MA41010B1 (en) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprising bacterial strains
DK3650033T3 (en) 2015-06-15 2022-04-11 4D Pharma Res Ltd COMPOSITIONS INCLUDING BACTERIA STRAINS
JP2018519295A (en) * 2015-06-22 2018-07-19 プレジデント アンド フェローズ オブ ハーバード カレッジ Induction of lamina propria regulatory T cells
US10851399B2 (en) 2015-06-25 2020-12-01 Native Microbials, Inc. Methods, apparatuses, and systems for microorganism strain analysis of complex heterogeneous communities, predicting and identifying functional relationships and interactions thereof, and selecting and synthesizing microbial ensembles based thereon
WO2017120495A1 (en) 2016-01-07 2017-07-13 Ascus Biosciences, Inc. Methods for improving milk production by administration of microbial consortia
MX2017016924A (en) 2015-06-25 2018-08-15 Ascus Biosciences Inc Methods, apparatuses, and systems for analyzing microorganism strains from complex heterogeneous communities, predicting and identifying functional relationships and interactions thereof, and selecting and synthesizing microbial ensembles based thereon.
US9938558B2 (en) 2015-06-25 2018-04-10 Ascus Biosciences, Inc. Methods, apparatuses, and systems for analyzing microorganism strains from complex heterogeneous communities, predicting and identifying functional relationships and interactions thereof, and selecting and synthesizing microbial ensembles based thereon
AU2016321348A1 (en) * 2015-09-09 2018-04-26 Psomagen, Inc. Method and system for microbiome-derived diagnostics and therapeutics for conditions associated with thyroid health issues
EP3370748B1 (en) 2015-11-03 2022-06-08 The Brigham and Women's Hospital, Inc. Therapeutic microbiota for the treatment and/or prevention of food allergy
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
CA3005781C (en) 2015-11-20 2019-01-22 4D Pharma Research Limited Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
JP6675752B2 (en) * 2016-02-23 2020-04-01 国立大学法人佐賀大学 Intestinal Blautia coccoides growth stimulant
ME03487B (en) 2016-03-04 2020-01-20 4D Pharma Plc Compositions comprising bacterial blautia strains for treating visceral hypersensitivity
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
WO2017160711A1 (en) 2016-03-14 2017-09-21 Holobiome, Inc. Modulation of the gut microbiome to treat mental disorders or diseases of the central nervous system
US11260083B2 (en) 2016-03-15 2022-03-01 The Regents Of The University Of Michigan Compositions and methods for treating and preventing graft versus host disease
WO2017212064A1 (en) 2016-06-10 2017-12-14 N.V. Nutricia Risk of allergy and nutrition to reduce that risk
US9999641B2 (en) 2016-06-14 2018-06-19 Vedanta Biosciences, Inc. Treatment of clostridium difficile infection
KR102554351B1 (en) * 2016-06-14 2023-07-13 베단타 바이오사이언시즈, 인크. Treatment of Clostridium difficile infection
US20170360848A1 (en) 2016-06-15 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
WO2017218956A1 (en) 2016-06-17 2017-12-21 New York University Methods and compositions for treating dysbiosis and gatrointestinal and inflammatory disorders
US10849936B2 (en) 2016-07-01 2020-12-01 Regents Of The University Of Minnesota Compositions and methods for C. difficile treatment
TW201821093A (en) 2016-07-13 2018-06-16 英商４Ｄ製藥有限公司 Compositions comprising bacterial strains
US20180036352A1 (en) 2016-08-03 2018-02-08 Crestovo Holdings Llc Methods for treating ulcerative colitis
US20180185421A1 (en) * 2016-08-29 2018-07-05 Tokyo Metropolitan Government Composition comprising fecal microbiota
WO2018064165A2 (en) 2016-09-27 2018-04-05 Board Of Regents, The University Of Texas System Methods for enhancing immune checkpoint blockade therapy by modulating the microbiome
US10092601B2 (en) 2016-10-11 2018-10-09 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
US11213549B2 (en) 2016-10-11 2022-01-04 Finch Therapeutics Holdings Llc Compositions and method for treating primary sclerosing cholangitis and related disorders
WO2018071537A1 (en) 2016-10-11 2018-04-19 Crestovo Holdings Llc Compositions and methods for treating multiple sclerosis and related disorders
US11447738B2 (en) * 2016-10-28 2022-09-20 Vedanta Biosciences, Inc. Methods and compositions for preserving bacteria
AU2017354716A1 (en) * 2016-11-01 2019-05-02 Keio University Bacteria inducing Th1 cells
EP3541400A2 (en) * 2016-11-18 2019-09-25 Sanford Burnham Prebys Medical Discovery Institute Gut microbiota and treatment of cancer
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
WO2018107365A1 (en) * 2016-12-13 2018-06-21 深圳华大基因研究院 Anaerostipes caccae and applications thereof
CA3122548A1 (en) * 2016-12-23 2018-06-28 Keio University Compositions and methods for the induction of cd8+ t-cells
AU2017386658A1 (en) 2016-12-28 2019-07-25 Native Microbials, Inc. Methods, apparatuses, and systems for analyzing complete microorganism strains in complex heterogeneous communities, determining functional relationships and interactions thereof, and identifying and synthesizing bioreactive modificators based thereon
AU2017388535A1 (en) 2016-12-28 2019-07-25 Native Microbials, Inc. Methods, apparatuses, and systems for microorganism strain analysis of complex heterogeneous communities with tracer analytics, determination of functional relationships and interactions thereof, and synthesis of microbial ensembles including dosed microbial ensembles and inoculative microbial ensembles
JP2020506968A (en) * 2017-02-07 2020-03-05 カリフォルニア インスティチュート オブ テクノロジー Regulation of gut microbiota in Huntington's disease and Rett syndrome
US10596206B1 (en) 2017-03-14 2020-03-24 Cornell University Probiotic compositions and methods of use
WO2018187272A1 (en) 2017-04-03 2018-10-11 Gusto Global, Llc Rational design of microbial-based biotherapeutics
WO2018187467A1 (en) 2017-04-05 2018-10-11 Crestovo Holdings Llc Compositions and methods for treating parkinson's disease (pd) and related disorders
US11040073B2 (en) 2017-04-05 2021-06-22 Finch Therapeutics Holdings Llc Compositions and methods for treating diverticulitis and related disorders
CA3057692A1 (en) 2017-04-28 2018-11-01 Ascus Biosciences, Inc. Methods for supporting grain intensive and/or energy intensive diets in ruminants by administration of a synthetic bioensemble of microbes or purified strains thereof
EP3624818A4 (en) * 2017-05-19 2021-04-14 Memorial Sloan-Kettering Cancer Center Methods and compositions for reducing listeria monocytogenes infection or colonization
ES2877726T3 (en) 2017-05-22 2021-11-17 4D Pharma Res Ltd Compositions comprising bacterial strains
MA41708A (en) 2017-05-24 2020-04-08 4D Pharma Res Ltd COMPOSITIONS CONTAINING BACTERIAL STRAINS
CN110996917A (en) 2017-05-26 2020-04-10 克雷斯顿沃控股公司 Lyophilized compositions comprising fecal microbe-based therapeutic agents and methods of making and using same
BR112019026677A2 (en) 2017-06-14 2020-06-30 4D Pharma Research Limited compositions comprising bacterial strains
HUE053488T2 (en) 2017-06-14 2021-06-28 4D Pharma Res Ltd Compositions comprising bacterial strains
EP3638271B1 (en) 2017-06-14 2020-10-14 4D Pharma Research Limited Compositions comprising bacterial strains
GB201709763D0 (en) * 2017-06-19 2017-08-02 Probi Ab Biological materials and methods
WO2019028402A1 (en) * 2017-08-04 2019-02-07 Second Genome, Inc. Roseburia hominis, eubacterium eligens, and combinations thereof as biotherapeutics
CN111328284A (en) 2017-08-07 2020-06-23 芬奇治疗公司 Compositions and methods for maintaining and restoring a healthy intestinal barrier
JP2020530493A (en) * 2017-08-07 2020-10-22 フィンチ セラピューティクス、インコーポレイテッド． Compositions and methods for eradicating antibiotic-resistant bacteria in the intestine
RU2020110462A (en) 2017-08-14 2021-09-16 Серес Терапеутикс, Инк. COMPOSITIONS AND METHODS FOR CHOLESTATIC DISEASE TREATMENT
TWI793151B (en) 2017-08-23 2023-02-21 瑞士商諾華公司 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
AU2018326705A1 (en) 2017-08-30 2020-03-05 Pendulum Therapeutics, Inc. Methods and compositions for treatment of microbiome-associated disorders
EP3476396A1 (en) * 2017-10-31 2019-05-01 Institut Gustave Roussy Bacterial and cell compositions for the treatment of colorectal cancer and methods for assessing a prognosis for patients having the same
WO2019094837A1 (en) * 2017-11-09 2019-05-16 Vedanta Biosciences, Inc. Compositions and methods for the treatment of allergy
US10507221B2 (en) 2017-11-09 2019-12-17 Vedanta Biosciences, Inc. Compositions and methods for the treatment of allergy
EP4410954A2 (en) 2017-12-11 2024-08-07 Vedanta Biosciences, Inc. Compositions and methods for suppressing pathogenic organisms
US20200368293A1 (en) * 2018-01-18 2020-11-26 Vedanta Biosciences, Inc. Compositions and methods for the treatment of cancer
CA3088505A1 (en) 2018-02-09 2019-08-15 Keio University Compositions and methods for the induction of cd8+ t-cells
EP3594321A1 (en) * 2018-07-10 2020-01-15 Université catholique de Louvain Dusodibacter, a novel bacterial genus of the gastroinstestinal microbiota and uses thereof
JOP20210001A1 (en) 2018-07-10 2021-01-05 Novartis Ag 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of ikaros family zinc finger 2 (ikzf2)-dependent diseases
AR116109A1 (en) 2018-07-10 2021-03-31 Novartis Ag DERIVATIVES OF 3- (5-AMINO-1-OXOISOINDOLIN-2-IL) PIPERIDINE-2,6-DIONA AND USES OF THE SAME
US11166990B2 (en) 2018-07-13 2021-11-09 Finch Therapeutics Holdings Llc Methods and compositions for treating ulcerative colitis
DE102018213030A1 (en) * 2018-08-03 2020-02-06 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Treatment of immune diseases through the antibody-mediated neutralization of specific intestinal bacteria
EP3836946A4 (en) * 2018-08-17 2022-05-04 Vedanta Biosciences, Inc. Methods of decreasing dysbiosis and restoring a microbiome
AU2019351017A1 (en) 2018-09-27 2021-04-29 Finch Therapeutics Holdings Llc. Compositions and methods for treating epilepsy and related disorders
JP7444459B2 (en) * 2018-10-04 2024-03-06 国立研究開発法人理化学研究所 Method for inducing IgA production targeting ILC2
JP2022510780A (en) * 2018-11-05 2022-01-28 ザ・ユニバーシティ・オブ・シカゴ Methods and compositions for treating infectious, autoimmune, and allergic diseases
WO2020234746A1 (en) 2019-05-18 2020-11-26 Janssen Biotech, Inc. Materials and methods for microbiome modulation
CA3147739A1 (en) * 2019-07-17 2021-01-21 University Of Utah Research Foundation Clostridia consortia compositions and methods of treating obesity, metabolic syndrome and irritable bowel disease
EP4013851A1 (en) 2019-08-16 2022-06-22 Janssen Biotech, Inc. Optimized culture media for clostridia bacteria
WO2021033043A1 (en) 2019-08-16 2021-02-25 Janssen Biotech, Inc. Optimized culture media for clostridia bacteria
EP4013850A1 (en) 2019-08-16 2022-06-22 Janssen Biotech, Inc. Optimized culture media for clostridia bacteria
JP2021045097A (en) * 2019-09-20 2021-03-25 腸内フローラ移植臨床研究株式会社 Method for diagnosing health status of intestinal flora and uses thereof
US20220409675A1 (en) * 2019-11-22 2022-12-29 Xbiome Inc. Compositions comprising bacterial species and methods related thereto
EP3895710A1 (en) 2020-04-15 2021-10-20 DSM IP Assets B.V. Food and/or feed compositions to manage immune homeostasis
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
WO2021234650A1 (en) * 2020-05-21 2021-11-25 Superbrewed Food, Inc. Method of treating or preventing an infection
US12011467B2 (en) 2021-05-18 2024-06-18 J. Craig Venter Institute, Inc. Bacterial formulation
CN116195742B (en) * 2021-11-30 2024-07-09 内蒙古伊利实业集团股份有限公司 Application of bifidobacterium lactis BL-99 in cartilage protection
WO2023100977A1 (en) * 2021-12-02 2023-06-08 地方独立行政法人神奈川県立産業技術総合研究所 Establishment of therapy and diagnosis for allergic diseases through control of immunoglobulin-binding protein

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011152566A2 (en) 2010-06-04 2011-12-08 The University Of Tokyo Composition for inducing proliferation or accumulation of regulatory t cells
WO2013080561A1 (en) 2011-12-01 2013-06-06 University Of Tokyo Human-derived bacteria that induce proliferation or accumulation of regulatory t cells

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3069074D1 (en) 1979-11-16 1984-10-04 Sterosynt Ltd 6-alpha-9-alpha-difluoro-16-beta-methyl-prednisolone-17,21 diesters and pharmaceutical compositions containing them
US5443826A (en) 1988-08-02 1995-08-22 Borody; Thomas J. Treatment of gastro-intestinal disorders with a fecal composition or a composition of bacteroides and E. Coli
US5599795A (en) 1994-08-19 1997-02-04 Mccann; Michael Method for treatment of idiopathic inflammatory bowel disease (IIBD)
US5700787A (en) 1994-09-02 1997-12-23 Brigham & Women's Hospital, Inc. Capsular polysaccharide immunomodulator
US6368586B1 (en) 1996-01-26 2002-04-09 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers
US6348452B1 (en) 1996-03-20 2002-02-19 The University Of New South Wales Alteration of microbial populations in the gastrointestinal tract
US6551632B2 (en) 1997-04-01 2003-04-22 Thomas Julius Borody Methods and compositions for treating inflammatory bowel disease
ID29150A (en) 1999-01-15 2001-08-02 Entpr Ireland Cs USE OF LACTOBACILLUS SALIVARIUS
JP2001112485A (en) 1999-10-19 2001-04-24 Yakult Honsha Co Ltd Primer for enterobacterium and detection using the same
FR2808689B1 (en) 2000-05-11 2004-09-03 Agronomique Inst Nat Rech USE OF HYDROGENOTROPHIC ACETOGENIC STRAINS FOR THE PREVENTION OR TREATMENT OF DIGESTIVE DISORDERS
US20040170617A1 (en) 2000-06-05 2004-09-02 Finegold Sydney M. Method of treating diseases associated with abnormal gastrointestinal flora
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
SV2003000753A (en) 2000-12-05 2003-06-16 Brigham & Womens Hospital USE OF ZWITTERIONIC POLYSACARIDS FOR THE SPECIFIC MODULATION OF IMMUNE PROGRESS
WO2002080963A1 (en) 2001-04-05 2002-10-17 Virginia Mason Research Center Methods of mhc class ii epitope mapping, detection of autoimmune t cells and antigens, and autoimmune treatment
PE20030283A1 (en) 2001-07-26 2003-05-01 Alimentary Health Ltd LACTOBACILLUS CASEI STRAINS
GB0307026D0 (en) 2003-03-27 2003-04-30 Rowett Res Inst Bacterial supplement
JP2006522135A (en) 2003-03-31 2006-09-28 ザ ブライアム アンド ウィミンズ ホスピタル インコーポレーテッド Zwitterionic immunomodulators for the treatment of asthma and allergies
WO2004104175A2 (en) 2003-05-14 2004-12-02 University Of Georgia Research Foundation, Inc. Probiotic bacteria and methods
JP2005124495A (en) 2003-10-24 2005-05-19 Yakult Honsha Co Ltd Primer for detecting human enterobacterium
US20070178072A1 (en) 2004-03-31 2007-08-02 Kirin Beer Kabushiki Kaisha Method for inducing differentiation of regulatory t cells usinggip-anchored protein agonist and pharmaceutical composition therefor ( as amended
US8092793B2 (en) 2004-12-15 2012-01-10 Qingdao East Sea Pharmaceuticals, Ltd. Treating inflammatory bowel disease with live bacteria
KR101260533B1 (en) 2005-03-03 2013-05-06 가부시키가이샤 메이지 Immune function modulating agents
CU23581A1 (en) 2005-10-28 2010-10-30 Ct Ingenieria Genetica Biotech ALFA AND C-FICOCIANINE INTERFERED FOR THE TREATMENT OF AUTOIMMUNE, ALLERGIC AND CANCER DISEASES
WO2007092451A2 (en) 2006-02-06 2007-08-16 The Brigham And Women's Hospital, Inc. Zwitterionic polysaccharides for promotion of immune system maturation and health
DE102006062250A1 (en) 2006-12-22 2008-06-26 Roland Saur-Brosch Use of a composition of minerals and / or vitamins and optionally acetogenic and / or butyrogenic bacteria for oral or rectal administration for the treatment and prevention of abdominal discomfort
EP1964570B1 (en) 2007-03-02 2012-11-21 Protectimmun GmbH Pharmaceutical compound to protect against allergies and inflammatory illnesses
EP1974743A1 (en) 2007-03-28 2008-10-01 Nestec S.A. Probiotics to Improve Gut Microbiota
CN101310730A (en) 2007-05-27 2008-11-26 青岛东海药业有限公司 Use of clostridium butyricum for preparing microbiological preparation for preventing and curing atrophic arthritis, ankylosing spondylitis
JP2009084215A (en) 2007-09-28 2009-04-23 Nippon Paper Chemicals Co Ltd Inflammatory bowel disease prophylactic or therapeutic agent
WO2009050486A2 (en) 2007-10-19 2009-04-23 The University Of Surrey Peptide manipulators of regulatory t cell activity
EP2217250A4 (en) 2007-11-09 2011-01-05 California Inst Of Techn Immunomodulating compounds and related compositions and methods
CN101496819A (en) 2008-01-31 2009-08-05 青岛东海药业有限公司 Eubacterium, Clostridium preparation and use thereof
KR100913405B1 (en) 2008-03-25 2009-08-21 광주과학기술원 Compositions for preventing or treating th2-mediated immune diseases
WO2009149149A1 (en) 2008-06-04 2009-12-10 Trustees Of Dartmouth College Prevention or treatment of immune-relevant disease by modification of microfloral populations
JP2010129134A (en) 2008-11-28 2010-06-10 Pulstec Industrial Co Ltd Hologram recording device and hologram reproducing device
ES2799891T3 (en) 2009-02-13 2020-12-22 Univ California Device, composition and method for tissue-based diagnosis
GB0903016D0 (en) 2009-02-23 2009-04-08 Univ Gent Method for alleviating intestinal problems and novel bacterial strains therefor
JP2012524910A (en) 2009-04-23 2012-10-18 カリフォルニア インスティチュート オブ テクノロジー Method and system for identifying immunomodulators
US20100311686A1 (en) 2009-06-03 2010-12-09 Kasper Lloyd H Nutraceutical composition and methods for preventing or treating multiple sclerosis
WO2011005756A1 (en) 2009-07-06 2011-01-13 Puretech Ventures, Llc Delivery of agents targeted to microbiota niches
WO2011022542A2 (en) 2009-08-19 2011-02-24 Puretech Ventures, Llc Administration of factors normally present in a microbial niche to improve health
US20120149584A1 (en) 2009-08-21 2012-06-14 Bernat Olle Methods of diagnosing and treating microbiome-associated disease using interaction network parameters
WO2011027956A2 (en) 2009-09-04 2011-03-10 주식회사이언메딕스 Extracellular vesicles derived from gram-positive bacteria, and disease model using same
WO2011046616A2 (en) * 2009-10-15 2011-04-21 New York University Methods for modulating bacterial infection
JP5600179B2 (en) 2009-11-11 2014-10-01 アリメンタリー、ヘルス、リミテッド Bifidobacteria strain
EP2556835B1 (en) * 2010-02-10 2015-08-05 Japan Eco-Science Co. Ltd. Mixture, dissolving solution and pharmaceutical agent each comprising thermophilic microorganism
EP2598155A2 (en) 2010-07-26 2013-06-05 Suomen Punainen Risti Veripalvelu Use of blood group status iii
US20120020941A1 (en) 2010-07-26 2012-01-26 Suomen Punainen Risti Veripalvelu Use of blood group status iii
ES2388662B1 (en) 2010-11-10 2014-04-11 Consejo Superior De Investigaciones Científicas (Csic) NEW DUGANELLA VINTAGES ISOLATED FROM THE WILD AND CULTIVATED OLIVE RIZOSPHERE AND ITS USE IN VIOLACEIN PRODUCTION.
US20120279149A1 (en) * 2011-05-04 2012-11-08 Sebastian George Quinn System and device for utilization of energy in buildings
WO2012170478A2 (en) * 2011-06-06 2012-12-13 The University Of North Carolina At Chapel Hill Methods and kits for detecting adenomas, colorectal cancer, and uses thereof
EP2744890A4 (en) 2011-09-14 2015-07-08 Univ Kingston Method for treatment of disorders of the gastrointestinal system
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
US8906668B2 (en) 2012-11-23 2014-12-09 Seres Health, Inc. Synergistic bacterial compositions and methods of production and use thereof
CA2896795A1 (en) 2012-11-26 2014-05-30 Thomas Julius Borody Compositions for the restoration of a fecal microbiota and methods for making and using them
KR102222273B1 (en) 2013-02-04 2021-03-08 세레스 테라퓨틱스, 인코포레이티드 Compositions and methods
WO2014153194A2 (en) 2013-03-14 2014-09-25 Seres Health, Inc. Methods for pathogen detection and enrichment from materials and compositions
US9907755B2 (en) 2013-03-14 2018-03-06 Therabiome, Llc Targeted gastrointestinal tract delivery of probiotic organisms and/or therapeutic agents
JP2016519664A (en) 2013-03-15 2016-07-07 セレス セラピューティクス インコーポレイテッド Microbial composition and method based on network
WO2015006355A2 (en) * 2013-07-09 2015-01-15 Puretech Ventures, Llc Compositions containing combinations of bioactive molecules derived from microbiota for treatment of disease
US10300137B2 (en) * 2014-04-10 2019-05-28 Riken Compositions and methods for induction of TH17 cells
WO2015198105A1 (en) 2014-06-27 2015-12-30 Telefonaktiebolaget L M Ericsson (Publ) System and method for supporting time-sensitive services in a communication network
JP6671360B2 (en) 2014-06-30 2020-03-25 サリックス ファーマスーティカルズ，インコーポレーテッド Method for re-treating irritable bowel syndrome (IBS)
MA41020A (en) 2014-11-25 2017-10-03 Evelo Biosciences Inc PROBIOTIC AND PREBIOTIC COMPOSITIONS, AND THEIR METHODS OF USE FOR MODULATION OF THE MICROBIOME
WO2016194427A1 (en) 2015-05-30 2016-12-08 日環科学株式会社 Probiotic or prebiotic, method for producing same, microbial preparation, health food, and medicine
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
US9642281B1 (en) * 2015-12-28 2017-05-02 Martas Precision Slide Co., Ltd. Buckle set for sliding rail of industrial rackmount chassis
WO2017160711A1 (en) * 2016-03-14 2017-09-21 Holobiome, Inc. Modulation of the gut microbiome to treat mental disorders or diseases of the central nervous system
US20170290889A1 (en) 2016-04-11 2017-10-12 New York University Methods and compositions for treating dysbiosis and gastrointestinal and inflammatory disorders
JP6792103B2 (en) 2016-06-01 2020-11-25 株式会社テックコーポレーション Fine bubble water supply system
US9999641B2 (en) 2016-06-14 2018-06-19 Vedanta Biosciences, Inc. Treatment of clostridium difficile infection
AU2017354716A1 (en) 2016-11-01 2019-05-02 Keio University Bacteria inducing Th1 cells
CA3122548A1 (en) * 2016-12-23 2018-06-28 Keio University Compositions and methods for the induction of cd8+ t-cells
JP2020530493A (en) 2017-08-07 2020-10-22 フィンチ セラピューティクス、インコーポレイテッド． Compositions and methods for eradicating antibiotic-resistant bacteria in the intestine
JP2019046634A (en) * 2017-08-31 2019-03-22 パナソニックＩｐマネジメント株式会社 Illumination system and controller
US10507221B2 (en) * 2017-11-09 2019-12-17 Vedanta Biosciences, Inc. Compositions and methods for the treatment of allergy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011152566A2 (en) 2010-06-04 2011-12-08 The University Of Tokyo Composition for inducing proliferation or accumulation of regulatory t cells
WO2013080561A1 (en) 2011-12-01 2013-06-06 University Of Tokyo Human-derived bacteria that induce proliferation or accumulation of regulatory t cells

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ATARASHI K, ET AL: "WS/PP-064-03 Regulation of colonic regulatory T cells by Clostridium species", XIVTH INTERNATIONAL CONGRESS OF IMMUNOLOGY, 25 August 2010 (2010-08-25), pages 132, XP055402353, [retrieved on 20170830]
DEY NEELENDU ET AL: "Association of gut microbiota with post-operative clinical course in Crohn's disease.", BMC GASTROENTEROLOGY 22 AUG 2013, vol. 13, 22 August 2013 (2013-08-22), pages 131, ISSN: 1471-230X *
GEVERS DIRK ET AL: "The Treatment-Naive Microbiome in New-Onset Crohn's Dis", CELL HOST & MICROBE, vol. 15, no. 3, 12 March 2014 (2014-03-12), pages 382 - 392, XP028629969, ISSN: 1931-3128, DOI: 10.1016/J.CHOM.2014.02.005 *
K. ATARASHI ET AL: "Induction of Colonic Regulatory T Cells by Indigenous Clostridium Species", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, vol. 331, no. 6015, 21 January 2011 (2011-01-21), pages 337 - 341, XP055005026, ISSN: 00368075, DOI: 10.1126/science.1198469
SHA SUMEI ET AL: "The biodiversity and composition of the dominant fecal microbiota in patients with inflammatory bowel disease", DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASES, ELSEVIER SCIENCE PUBLISHING CO., AMSTERDAM, NL, vol. 75, no. 3, 28 December 2012 (2012-12-28), pages 245 - 251, XP028976687, ISSN: 0732-8893, DOI: 10.1016/J.DIAGMICROBIO.2012.11.022 *

Also Published As

Publication number Publication date
EP3569690B1 (en) 2024-08-28
US20170209502A1 (en) 2017-07-27
CN108676774A (en) 2018-10-19
JP7097838B2 (en) 2022-07-08
US20240000858A1 (en) 2024-01-04
US20190030092A1 (en) 2019-01-31
JP2024129016A (en) 2024-09-26
WO2013080561A9 (en) 2013-08-08
JP7165218B2 (en) 2022-11-02
JP2018039833A (en) 2018-03-15
EP3569690A1 (en) 2019-11-20
US10624933B2 (en) 2020-04-21
JP2019134703A (en) 2019-08-15
WO2013080561A1 (en) 2013-06-06
JP6492151B2 (en) 2019-03-27
EP2785828A4 (en) 2015-07-29
US20190314426A1 (en) 2019-10-17
US20170216378A1 (en) 2017-08-03
JP2021078504A (en) 2021-05-27
EP2785828A1 (en) 2014-10-08
US10058578B2 (en) 2018-08-28
US20140341921A1 (en) 2014-11-20
US20210137998A1 (en) 2021-05-13
EP3978598B1 (en) 2024-08-28
JP7503273B2 (en) 2024-06-20
US20160193256A1 (en) 2016-07-07
EP3978598A1 (en) 2022-04-06
US20190046591A1 (en) 2019-02-14
CN108676774B (en) 2023-05-09
US20160193257A1 (en) 2016-07-07
US9649345B2 (en) 2017-05-16
CN116942833A (en) 2023-10-27
JP2023015099A (en) 2023-01-31
US10835559B2 (en) 2020-11-17
US10342832B2 (en) 2019-07-09
CN104160014A (en) 2014-11-19
US10238694B2 (en) 2019-03-26
JP2015500792A (en) 2015-01-08
US10052353B2 (en) 2018-08-21
CA2892588A1 (en) 2013-06-06
HK1204008A1 (en) 2015-11-06
JP6306507B2 (en) 2018-04-18
US10183045B2 (en) 2019-01-22
US9642881B2 (en) 2017-05-09
US11547732B2 (en) 2023-01-10
US20180243348A1 (en) 2018-08-30

Similar Documents

Publication Publication Date Title
US11547732B2 (en) Human-derived bacteria that induce proliferation or accumulation of regulatory T cells
US10092603B2 (en) Composition for inducing proliferation or accumulation of regulatory T cells

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20140701

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: HATTORI, MASAHIRA

Inventor name: ATARASHI, KOJI

Inventor name: HONDA, KENYA

Inventor name: MORITA, HIDETOSHI

Inventor name: TANOUE, TAKESHI

DAX Request for extension of the european patent (deleted)
RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 35/74 20150101ALI20150325BHEP

Ipc: C12N 1/20 20060101AFI20150325BHEP

Ipc: C12N 15/09 20060101ALI20150325BHEP

Ipc: A61P 37/02 20060101ALI20150325BHEP

Ipc: A61P 29/00 20060101ALI20150325BHEP

RA4 Supplementary search report drawn up and despatched (corrected)

Effective date: 20150701

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 1/20 20060101AFI20150625BHEP

Ipc: A61P 29/00 20060101ALI20150625BHEP

Ipc: C12N 15/09 20060101ALI20150625BHEP

Ipc: A61P 37/02 20060101ALI20150625BHEP

Ipc: A61K 35/74 20150101ALI20150625BHEP

17Q First examination report despatched

Effective date: 20160519

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTG Intention to grant announced

Effective date: 20191024

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE PATENT HAS BEEN GRANTED

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: AT

Ref legal event code: REF

Ref document number: 1254405

Country of ref document: AT

Kind code of ref document: T

Effective date: 20200415

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602012069199

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20200408

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200817

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200808

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200709

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200708

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200408

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200408

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200408

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200408

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 1254405

Country of ref document: AT

Kind code of ref document: T

Effective date: 20200408

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200708

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200408

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200408

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200408

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200408

REG Reference to a national code

Ref country code: DE

Ref legal event code: R026

Ref document number: 602012069199

Country of ref document: DE

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

PLAX Notice of opposition and request to file observation + time limit sent

Free format text: ORIGINAL CODE: EPIDOSNOBS2

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200408

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200408

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200408

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200408

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200408

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200408

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200408

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200408

26 Opposition filed

Opponent name: HGF IP LIMITED

Effective date: 20210111

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200408

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200408

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200408

PLBB Reply of patent proprietor to notice(s) of opposition received

Free format text: ORIGINAL CODE: EPIDOSNOBS3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200408

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201129

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20201130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201130

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201130

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201129

PLBD Termination of opposition procedure: decision despatched

Free format text: ORIGINAL CODE: EPIDOSNOPC1

PLBP Opposition withdrawn

Free format text: ORIGINAL CODE: 0009264

REG Reference to a national code

Ref country code: DE

Ref legal event code: R100

Ref document number: 602012069199

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200408

Ref country code: MT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200408

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200408

PLBM Termination of opposition procedure: date of legal effect published

Free format text: ORIGINAL CODE: 0009276

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20200408

27C Opposition proceedings terminated

Effective date: 20220320

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20201130

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230523

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20231127

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20231127

Year of fee payment: 12

Ref country code: DE

Payment date: 20231129

Year of fee payment: 12